

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL CKD study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-067386
Article Type:	Original research
Date Submitted by the Author:	12-Aug-2022
Complete List of Authors:	Tangri, Navdeep; University of Manitoba, Medicine Moriyama, Toshiki; Osaka University Schneider, Markus P.; Erlangen University Hospital Department of Medicine 4 Nephrology and Hypertension Virgitti, Jean Blaise; Cabinet Médical De Nicola, Luca ; Università degli Studi della Campania Luigi Vanvitelli, Arnold, Matt; AstraZeneca PLC, Real World Evidence Data & Analytics, BioPharmaceuticals Medical Barone, Salvatore; AstraZeneca US, Global Medical Affairs, BioPharmaceuticals Medical Peach, Emily; AstraZeneca PLC, Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical Wittbrodt, Eric; AstraZeneca US, Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical Chen, Hungta; AstraZeneca US, Medical/Payer Evidence Statistics, BioPharmaceuticals Medical Järbrink, Krister; AstraZeneca Sweden, Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical Kushner, Pamela; University of California Irvine Medical Center, Department of Family Medicine
Keywords:	NEPHROLOGY, EPIDEMIOLOGY, Chronic renal failure < NEPHROLOGY, Adult nephrology < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Prevalence of undiagnosed stage 3 chronic kidney disease in**
4
5
6 **France, Germany, Italy, Japan and the USA: results from the**
7
8
9 **multinational observational REVEAL-CKD study**
10
11

12 Navdeep Tangri,¹ Toshiki Moriyama,² Markus P Schneider,³ Jean Blaise J Virgitti,⁴ Luca De
13 Nicola,⁵ Matthew Arnold,⁶ Salvatore Barone,⁷ Emily J Peach,⁸ Eric Wittbrodt,⁹ Hungta
14 Chen,¹⁰ Krister Järbrink,¹¹ Pamela Kushner,¹²
15
16
17
18
19
20
21

22 ¹ Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
23

24 ² Osaka University, Suita, Osaka, Japan
25

26 ³ Department of Nephrology and Hypertension, University Hospital Erlangen, University of
27 Erlangen–Nuremberg, Erlangen, Germany
28

29 ⁴ Cabinet Médical, Orry-La-Ville, France
30

31 ⁵ Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit,
32 University of Campania Luigi Vanvitelli, Naples, Italy
33

34 ⁶ Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca,
35 Cambridge, UK
36

37 ⁷ Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg,
38 Maryland, USA
39

40 ⁸ Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical,
41 AstraZeneca, Cambridge, UK
42

43 ⁹ Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical,
44 AstraZeneca, Gaithersburg, Maryland, USA
45

46 ¹⁰ Medical/Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca,
47 Gaithersburg, Maryland, USA
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ¹¹ Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical,
4
5 AstraZeneca, Gothenburg, Sweden
6
7

8 ¹² Department of Family Medicine, University of California Irvine Medical Center, Orange,
9
10 California, USA
11
12
13
14

15 **Corresponding author:** Navdeep Tangri, MD, PhD, Seven Oaks General Hospital, 2LB19-
16
17 2300 McPhillips Street, Winnipeg, Manitoba, R2V 3M3, Canada (ntangri@sogh.mb.ca)
18
19

20 **Target journal:** *BMJ Open*
21
22

23 **Word count:** 3117/4000
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT (298/300 words)

Objectives: REVEAL-CKD aims to estimate the prevalence of, and factors associated with, undiagnosed stage 3 chronic kidney disease (CKD).

Design: Multinational, retrospective, observational study.

Setting: Data from six country-specific electronic medical records and/or insurance claims databases from five countries (France, Germany, Italy, Japan and the USA [two databases]).

Participants: Eligible participants (≥ 18 years old) had ≥ 2 consecutive estimated glomerular filtration rate (eGFR) measurements (calculated from serum creatinine values, sex and age) taken from 2015 onwards that were indicative of stage 3 CKD (≥ 30 and < 60 mL/min/1.73 m²). Undiagnosed cases lacked an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before, and up to 6 months after, the second qualifying eGFR measurement (study index).

Main outcome measures: The primary outcome was point prevalence of undiagnosed stage 3 CKD. Time to diagnosis was assessed using the Kaplan–Meier approach. Factors associated with lacking a CKD diagnosis and risk of diagnostic delay were assessed using logistic regression adjusted for baseline covariates.

Results: The prevalence of undiagnosed stage 3 CKD was 95.5% (19,120/20,012 patients) in France, 84.3% (22,557/26,767) in Germany, 77.0% (50,547/65,676) in Italy, 92.1% (83,693/90,902) in Japan, 61.6% (13,845/22,470) in the US Explorys LCED database and 64.3% (161,254/250,879) in the US TriNetX database. The prevalence of undiagnosed CKD tended to increase with age. Factors associated with increased likelihood of undiagnosed CKD were female sex (vs male, range of odds ratio across countries: 1.29–1.77), stage 3a CKD (vs 3b, 1.81–3.66), no medical history (vs a history) of diabetes (1.26–2.77) or hypertension (1.35–1.78).

1
2
3 **Conclusions:** There are substantial opportunities to improve stage 3 CKD diagnosis,
4 particularly in female patients and older patients. The low diagnosis rates in patients with
5 comorbidities that put them at risk of disease progression and complications is alarming.
6
7
8
9

10 **Trial registration:** NCT04847531
11
12
13
14

15 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

16

- 17 • REVEAL-CKD uses large, contemporary, country-specific databases to provide
18 robust estimates of the prevalence of undiagnosed stage 3 CKD.
19
- 20 • The study uses a strict, consistent and internationally recognised definition of stage 3
21 CKD to ensure accuracy when calculating the prevalence of diagnosed/undiagnosed
22 CKD.
23
- 24 • Data from the countries and databases examined may not be representative of other
25 countries with substantially different healthcare systems or CKD screening policies.
26
- 27 • There is a risk of misclassification of undiagnosed CKD if diagnoses were made in
28 environments that did not contribute to the databases used or if diagnosing physicians
29 did not use ICD-9/10 codes appropriately.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic kidney disease (CKD) is an established global public health concern.¹ CKD has a significant effect on patients, attributable to direct mortality and morbidity, as well as elevated risk of cardiovascular diseases.² The global prevalence of CKD is rising,³ owing to aging populations and increased prevalence of CKD-associated risk factors including type 2 diabetes (T2D) and hypertension.⁴

Early intervention and appropriate management of CKD is recommended in the internationally recognised Kidney Disease: Improving Global Outcomes (KDIGO) guidelines⁵ to help delay disease progression and reduce the incidence of complications. Furthermore, in 2019, KDIGO held a controversies conference on the topic of early identification and intervention in CKD. The consensus statement from this conference urged action, including the implementation of screening programs and interventions for high-risk individuals.⁶ Early-stage CKD is primarily asymptomatic,⁷ therefore CKD is primarily diagnosed at later disease stages and the initiation of effective interventions is delayed or missed.⁵ Previous studies have demonstrated low levels of diagnosis of early-stage CKD in Italy,⁸ Sweden⁹ and the USA.¹⁰⁻¹⁵ However, these previous studies have been limited to single countries or databases, or at-risk groups such as patients with T2D, and did not assess the prevalence of CKD diagnosis across various subgroups (eg, patients with or without comorbidities). There is a need for contemporary information on the prevalence of, and factors associated with, undiagnosed stage 3 CKD, as well as a need to understand factors associated with diagnostic delay in these patients.

REVEAL-CKD (NCT04847531) is a multinational, observational study designed to fill this evidence gap. REVEAL-CKD aims to quantify the prevalence of, and factors associated with, undiagnosed stage 3 CKD in large populations across several countries.¹⁶ Here, we present

1
2
3 data on the prevalence of, and factors associated with, undiagnosed stage 3 CKD in France,
4
5 Germany, Italy, Japan and the USA.
6
7

8 9 **METHODS**

10 11 12 **Study design**

13
14
15 The study design for REVEAL-CKD has been reported in detail elsewhere,¹⁶ and is
16
17 summarised below.
18
19

20
21 Data were extracted from established, verified relevant databases containing electronic
22
23 medical records and/or insurance claims in the countries of interest. Data for France were
24
25 extracted from The Health Improvement Network, a large database of anonymised, non-
26
27 extrapolated electronic medical records.¹⁷ Data for Germany were extracted from the German
28
29 Disease Analyzer, a database of anonymised longitudinal data on drug prescriptions,
30
31 diagnoses and medical and demographic data from a representative sample of practices
32
33 throughout Germany.¹⁸ Data for Italy were extracted from the IQVIA Longitudinal Patient
34
35 Database, a computerised network of over 900 family physicians, which includes anonymised
36
37 data on patient consultations and treatments.¹⁹ Data for Japan were extracted from Japan Real
38
39 World Data, an integrated database of medical information including both electronic medical
40
41 records and claims data.²⁰ Data for the USA were extracted from two separate databases:
42
43 Explorys Linked Claims and Electronic Medical Records Data (LCED), a database of
44
45 inpatient and outpatient medical records and claims data from commercially insured
46
47 individuals,²¹ and TriNetX, a database of integrated electronic medical records and claims
48
49 data from 35 healthcare organisations, which provides clinical patient data from both
50
51 inpatient and outpatient encounters.²²
52
53
54
55
56
57
58
59
60

1
2
3 Patients aged ≥ 18 years were included in the analyses if they had at least two consecutive
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patients aged ≥ 18 years were included in the analyses if they had at least two consecutive estimated glomerular filtration rate (eGFR) measurements that fell within the range indicative of stage 3 CKD (≥ 30 and < 60 mL/min/1.73 m²) and were recorded > 90 and ≤ 730 days apart (per KDIGO guideline recommendations), taken on or after 1 January 2015. All patients had at least 12 months of continuous presence in the database before the first qualifying eGFR measurement. Full inclusion and exclusion criteria are shown in **Supplementary table 1**. eGFR was calculated from serum creatinine values, sex and age, using the CKD Epidemiology Collaboration (CKD-EPI) equation.²³ In line with current trends among physicians^{24 25} and guidance from expert recommendations,²⁶ race modifiers were not used in the calculation of eGFR.

To account for potential delays in recording of diagnostic codes, undiagnosed CKD was defined as lacking an International Classification of Diseases (ICD) 9/10 diagnosis code corresponding to CKD (any stage), any time before and up to 6 months after index (date of second qualifying eGFR measurement). The ICD coding system varied by country depending on what was available in each database; the full list of ICD-9/10 codes used to determine diagnosed cases can be found in **Supplementary table 2**. A sensitivity analysis was performed to calculate the overall prevalence of undiagnosed stage 3 CKD using a broader definition of CKD adapted from Winkelmayr et al.²⁷ This sensitivity analysis included diagnostic codes for several additional manifestations of renal disease (**Supplementary table 3**).

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Statistical analysis

Overall prevalence of undiagnosed stage 3 CKD and patient demographic and clinical characteristics at index are presented descriptively. Odds ratios for factors associated with being undiagnosed any time before and up to 6 months after index were calculated using logistic regression analysis, adjusted for covariates at index. Hazard ratios for diagnostic delay among patients undiagnosed at index were calculated using Cox regression analysis, adjusted for covariates at index. The Kaplan–Meier method was used to estimate the time to diagnosis among patients undiagnosed at index.

RESULTS

This analysis of patients with stage 3 CKD included 20 012 patients from France, 90 902 patients from Germany, 65 676 patients from Italy, 26 767 patients from Japan, 22 470 patients from the LCED database in the USA, and 250 879 patients from the TriNetX database in the USA (**Figure 1**). Characteristics of these patients at index are shown in **Supplementary Table 4**. At index, median age was 71–80 years, median eGFR was 49–52 mL/min/1.73 m², 66.9%–77.7% of patients had CKD stage 3a (eGFR ≥45 and <60 mL/min/1.73 m²) and 22.3%–33.1% of patients had CKD stage 3b (eGFR ≥30 and <45 mL/min/1.73 m²). The overall prevalence of urinary albumin-creatinine ratio (UACR) testing was very low and ranged from 1.8% (US, TriNetX) to 5.5% (Japan).

Overall prevalence of undiagnosed stage 3 CKD

The proportion of patients with stage 3 CKD without a diagnosis at or within 6 months after index varied by database, and was 95.5% in France, 84.3% in Germany, 77.0% in Italy, 92.1% in Japan, 61.6% in the US LCED database and 64.3% in the US TriNetX database (**Figure 2A**). In the sensitivity analysis using a broader set of ICD-9/10 codes to identify

1
2
3 CKD diagnoses, the prevalence of undiagnosed CKD was 53.6%–89.9% (**Supplementary**
4 **Table 5**). The proportion of patients with undiagnosed CKD per calendar year at index is
5
6 shown in **Supplementary Figure 1**. Overall, there were no prevailing trends in the
7
8 proportion of patients with undiagnosed CKD per calendar year, except in Italy, where the
9
10 proportion of undiagnosed CKD tended to increase over time (68.2% undiagnosed in 2015 to
11
12 83.1% in 2020).
13
14
15
16
17

18 **Demographics and clinical characteristics of patients with diagnosed and undiagnosed** 19 **stage 3 CKD** 20 21

22
23 Characteristics for patients with diagnosed and undiagnosed stage 3 CKD at index are
24
25 presented in **Table 1**.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Overall patient characteristics at study index according to country, by CKD diagnosis status 6 months after index

Country	France		Germany		Italy		Japan		USA			
Database	THIN CegeDim		Disease Analyzer		LPD		Japan RWD		LCED		TriNetX	
	Undiagnosed n=19 120	Diagnosed* n=892	Undiagnosed n=22 557	Diagnosed* n=4210	Undiagnosed n=50 547	Diagnosed* n=15 129	Undiagnosed n=83 693	Diagnosed* n=7209	Undiagnosed n=13 845	Diagnosed* n=8625	Undiagnosed n=161 254	Diagnosed* n=89 625
Age, y, median (IQR)	80 (72–86)	77 (69–84)	79 (72–84)	79 (71–84)	80 (74–85)	80 (73–85)	76 (69–83)	77 (68–83)	74 (64–82)	74 (64–82)	71 (64–79)	70 (62–78)
Age groups, y												
<45	58 (0.3)	9 (1.0)	46 (0.2)	20 (0.5)	95 (0.2)	93 (0.6)	652 (0.8)	139 (1.9)	109 (0.8)	134 (1.6)	2426 (1.5)	3097 (3.5)
45–64	1551 (8.1)	126 (14.1)	1957 (8.7)	474 (11.3)	2724 (5.4)	1056 (7.0)	12 260 (14.6)	1026 (14.2)	3754 (27.1)	2237 (25.9)	38 302 (23.8)	25 424 (28.4)
65–74	4421 (23.1)	220 (24.7)	5088 (22.6)	944 (22.4)	10 976 (21.7)	3288 (21.7)	23 696 (28.3)	1931 (26.8)	3415 (24.7)	2177 (25.2)	57 891 (35.9)	29 989 (33.5)
≥75	13 090 (68.5)	537 (60.2)	15 466 (68.6)	2772 (65.8)	36 752 (72.7)	10 692 (70.7)	47 085 (56.3)	4113 (57.1)	6567 (47.4)	4077 (47.3)	62 635 (38.8)	31 115 (34.7)
Male, n (%)	8599 (45.0)	492 (55.2)	9173 (40.7)	2043 (48.5)	19 820 (39.2)	7908 (52.3)	43 658 (52.2)	4465 (61.9)	5438 (39.3)	4613 (53.5)	57 989 (36.0)	47 123 (52.6)
eGFR, mL/min/1.73 m², median (IQR)	52 (46–56)	45 (38–52)	52 (45–56)	49 (40–55)	51 (44–55)	45 (38–52)	53 (47–56)	45 (37–53)	53 (47–57)	47 (40–53)	53 (47–57)	47 (40–53)
CKD stage, n (%)												
CKD stage 3a	14 661 (76.7)	440 (49.3)	16 871 (74.8)	2621 (62.3)	36 460 (72.1)	7477 (49.4)	66 955 (80.0)	3713 (51.5)	11 348 (82.0)	4972 (57.6)	131 385 (81.5)	52 233 (58.3)
CKD stage 3b	4459 (23.3)	452 (50.7)	5686 (25.2)	1589 (37.7)	14 087 (27.9)	7652 (50.6)	16 738 (20.0)	3496 (48.5)	2497 (18.0)	3653 (42.4)	29 869 (18.5)	37 392 (41.7)
Baseline UACR available, n (%)	424 (2.2)	26 (2.9)	0 (0.0) [†]	0 (0.0) [†]	4 (<0.1) [‡]	5 (<0.1) [‡]	3851 (4.6)	1141 (15.8)	474 (3.4)	425 (4.9)	2455 (1.5)	2149 (2.4)
HDL, mmol/L, median (IQR)	1.37 (1.11–1.65)	1.32 (1.08–1.65)	1.34 (1.11–1.63)	1.29 (1.06–1.55)	1.32 (1.11–1.59)	1.27 (1.06–1.53)	1.40 (1.16–1.71)	1.32 (1.09–1.60)	1.24 (1.03–1.53)	1.16 (0.96–1.45)	1.24 (1.03–1.55)	1.14 (0.93–1.42)
Missing, n	6172	342	6904	1328	13 379	4134	33 243	2062	5673	4349	88 031	50 767
LDL, mmol/L, median (IQR)	2.89 (2.24–3.61)	2.81 (2.18–3.53)	2.87 (2.20–3.70)	2.70 (2.07–3.49)	2.74 (2.12–3.39)	2.53 (1.97–3.21)	2.77 (2.22–3.34)	2.53 (2.04–3.10)	2.46 (1.89–3.13)	2.25 (1.71–2.95)	2.43 (1.87–3.13)	2.22 (1.68–2.92)
Missing, n	6331	345	6026	1061	14 915	4560	31 643	1946	4988	3948	78 408	47 066
Comorbidities, n (%)												
Hypertension	11 737 (61.4)	675 (75.7)	10 969 (48.6)	2710 (64.4)	38 849 (76.9)	12 475 (82.5)	47 311 (56.5)	5711 (79.2)	11 863 (85.7)	8198 (95.0)	123 002 (76.3)	80 153 (89.4)
Type 2 diabetes	3311 (17.3)	221 (24.8)	5145 (22.8)	1790 (42.5)	15 785 (31.2) [§]	5515 (36.5) [§]	15 655 (18.7)	3334 (46.2)	4667 (33.7)	4621 (53.6)	49 299 (30.6)	46 142 (51.5)
Established CVD [¶]	1368 (7.2)	81 (9.1)	1467 (6.5)	437 (10.4)	5153 (10.2)	1784 (11.8)	23 248 (27.8)	2389 (33.1)	3337 (24.1)	2955 (34.3)	26 666 (16.5)	23 078 (25.7)
Heart failure	922 (4.8)	64 (7.2)	3318 (14.7)	1046 (24.8)	4248 (8.4)	2130 (14.1)	26 077 (31.2)	3986 (55.3)	2523 (18.2)	2791 (32.4)	22 422 (13.9)	24 580 (27.4)
Atrial fibrillation	2057 (10.8)	104 (11.7)	3351 (14.9)	866 (20.6)	8293 (16.4)	2812 (18.6)	10 765 (12.9)	1226 (17.0)	2409 (17.4)	2218 (25.7)	23 224 (14.4)	17 990 (20.1)
Medication use, n (%)												
ACE inhibitor	4363 (22.8)	271 (30.4)	8023 (35.6)	1612 (38.3)	19 141 (37.9)	5957 (39.4)	4027 (4.8)	474 (6.6)	5058 (36.5)	3725 (43.2)	33 532 (20.8)	24 274 (27.1)
ARB	6181 (32.3)	349 (39.1)	8855 (39.3)	1718 (40.8)	19 770 (39.1)	6428 (42.5)	18 959 (22.7)	2463 (34.2)	3605 (26.0)	2697 (31.3)	22 656 (14.0)	15 290 (17.1)
SGLT2 inhibitor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	287 (0.6)	66 (0.4)	1082 (1.3)	281 (3.9)	11 (0.1)	11 (0.1)	1171 (0.7)	978 (1.1)
GLD (any)	3300 (17.3)	189 (21.2)	6742 (29.9)	1577 (37.5)	13 108 (25.9)	4255 (28.1)	11 303 (13.5)	2128 (29.5)	5012 (36.2)	4388 (50.9)	29 690 (18.4)	30 569 (34.1)
Antiplatelets	5636 (29.5)	328 (36.8)	5451 (24.2)	1146 (27.2)	23 245 (46.0)	7906 (52.3)	16 690 (19.9)	2106 (29.2)	1274 (9.2)	1202 (13.9)	8256 (5.1)	8052 (9.0)
Loop diuretic	2747 (14.4)	177 (19.8)	8564 (38.0)	1944 (46.2)	15 719 (31.1)	6441 (42.6)	10 346 (12.4)	1633 (22.7)	2720 (19.6)	2843 (33.0)	21 136 (13.1)	22 334 (24.9)
Anticoagulants	2885 (15.1)	133 (14.9)	6838 (30.3)	1344 (31.9)	12 214 (24.2)	3983 (26.3)	12 886 (15.4)	1600 (22.2)	3434 (24.8)	2913 (33.8)	28 521 (17.7)	26 465 (29.5)

Percentages represent the proportion of diagnosed/undiagnosed patients in a specific group (eg, age) or with a specific variable (eg, medical history).

*Diagnosed cases include patients with a corresponding ICD-9/10 diagnosis code for CKD at or within 6 months of study index (date of second qualifying eGFR measurement).

[†]UACR testing data not available in the German Disease Analyzer database.

1
2
3 ‡Direct measurements of UACR were not available in the IQVIA Longitudinal Patient Database in Italy, however, UACR was calculated as urine albumin (mg/dL) divided
4 by urine creatinine (g/dL) if patients had records for both of these variables on the same day.

5 §Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

6 †Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischaemic attack, coronary artery bypass graft and percutaneous
7 coronary intervention.

8 ¶Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention
9 in patients from Italy.

10 ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular
11 filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LCED, Explorys Linked
12 Claims and Electronic Medical Records Data; LDL, low-density lipoprotein; LPD, Longitudinal Patient Database; RWD, Real World Data; SGLT2, sodium-glucose
13 cotransporter-2; THIN, The Health Improvement Network; UACR, urinary albumin-creatinine ratio
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3 Patients with undiagnosed CKD tended to have slightly higher eGFR values than those with
4 diagnosed CKD. A greater proportion of patients with stage 3a CKD were undiagnosed than
5 patients with stage 3b CKD. There were fewer comorbidities such as hypertension, T2D and
6 established cardiovascular disease in patients who were undiagnosed than in those who were
7 diagnosed. Similarly, the proportion of patients taking medicines such as glucose-lowering
8 drugs, loop diuretics, angiotensin-II converting enzyme inhibitors and angiotensin receptor
9 blockers tended to be lower in undiagnosed patients than in those who were diagnosed. In all
10 databases, a greater proportion of stage 3 CKD cases were undiagnosed in female patients
11 than in male patients (**Figure 2B**). Additionally, in all databases, patients aged less than 45
12 years had the lowest proportion of undiagnosed CKD; the prevalence of undiagnosed CKD
13 increased in older age groups in France, Germany, Italy and in the US TriNetX database
14 (**Supplementary Figure 2**).

31 **Factors associated with undiagnosed CKD**

32
33
34
35 The proportion of undiagnosed CKD tended to be higher in those without comorbidities at
36 study index versus those with such comorbidities (**Figure 3**). When adjusting for baseline
37 covariates, female patients (vs male patients), patients with CKD stage 3a (vs 3b) and patients
38 without a diagnosis of diabetes or hypertension (vs those with a diagnosis) were consistently
39 more likely to lack a CKD diagnosis before and up to 6 months after index (**Supplementary**
40 **Figure 3**).

49 **Time to CKD diagnosis**

50
51
52
53 Among patients who lacked a diagnosis for stage 3 CKD at or before study index, the median
54 (interquartile range [IQR]) follow-up duration was 2.22 (1.18–3.64) years in France, 0.61
55 (0.27–1.03) years in Germany, 3.64 (2.08–4.88) years in Italy, 1.96 (0.84–3.41) years in
56 Japan, 1.28 (0.53–2.34) years in the US LCED database and 1.19 (0.44–2.32) years in the US
57
58
59
60

1
2
3 TriNetX database. In patients undiagnosed at index, only a small proportion received a
4 diagnosis during follow-up: 686/19 293 patients (3.6%) in France, 1157/23 302 patients
5 (5.0%) in Germany, 8152/52 533 patients (15.5%) in Italy, 3855/84 603 patients (4.6%) in
6 Japan, 3987/15 376 patients (25.9%) in the US LCED database and 44 007/178 410 patients
7 (24.7%) in the US TriNetX database.
8
9
10
11
12
13

14
15
16 Among patients undiagnosed at index, diagnoses tended to accrue slowly over the whole
17 duration of follow-up (**Figure 4**). The proportion of patients with initial eGFR values
18 indicative of stage 3b CKD (≥ 30 and < 45 mL/min/1.73 m²) who received a diagnosis during
19 follow-up was consistently higher than patients with initial eGFR values indicative of stage
20 3a CKD (≥ 45 and < 60 mL/min/1.73 m²; **Figure 4**).
21
22
23
24
25
26
27

28 Among all patients undiagnosed at index (regardless of whether they received a diagnosis
29 during follow-up), median time to diagnosis was only calculable using the Kaplan–Meier
30 method for the US TriNetX database, because more than half of the patients in the other
31 databases remained undiagnosed at the end of the study period. In this database, the overall
32 median (IQR) time to diagnosis was 4.75 (4.68–4.82) years.
33
34
35
36
37
38
39

40 After adjusting for baseline covariates, in all countries, female patients (vs male patients) and
41 patients with stage 3a CKD at index (vs 3b) were more likely to be diagnosed later during
42 follow-up (**Supplementary Figure 4**). Although less pronounced, patients without a history
43 of comorbidities such as diabetes, heart failure or hypertension had a slightly elevated
44 likelihood of delayed diagnosis (vs patients with a history of these conditions). Older patients
45 also typically had a greater likelihood of delayed diagnosis than patients aged less than 45
46 years.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

REVEAL-CKD is a large, multinational, observational study that uses a consistent, strict definition for undiagnosed CKD based on internationally recognised guidelines. By extracting data from contemporary, country-specific databases, the study provides a robust estimate of the prevalence of undiagnosed CKD in countries across the globe. The results from this analysis of six databases from five countries (France, Germany, Italy, Japan and the USA) demonstrate severe shortcomings in the diagnosis of stage 3 CKD. Although there was some variability among countries, the consistently high proportions of undiagnosed stage 3 CKD despite clinical evidence of the disease are highly concerning, as are the low levels of UACR testing. Of note, except in Japan, the prevalence of UACR testing did not appear to be substantially higher even in patients with a diagnosis of stage 3 CKD. UACR testing, however, is necessary for assessing the risk of future progression to kidney failure.²⁸ Missing opportunities for early diagnosis, prognostic assessment and management leaves patients at greater risk of further disease progression and complications, including end-stage renal disease and cardiovascular events.^{6 29-31} Early interventions in CKD have been shown to improve outcomes by slowing CKD progression and reducing cardiovascular risk,^{6 32} and healthcare costs associated with the disease increase substantially as CKD stage advances.³³ It is therefore vital for clinicians to seize the opportunity to diagnose and manage the condition as early as possible to minimise the impact of the disease, both in terms of financial burden and effects on health-related quality of life.

It is reassuring that the patients who have comorbidities that are established risk factors for CKD, such as hypertension and T2D, had higher rates of diagnosis and tended to be diagnosed sooner than patients without these conditions. However, even in patients with these comorbidities, the prevalence of undiagnosed CKD remained high. In the US databases,

1
2
3 which had the lowest rates of undiagnosed CKD, approximately 50% of patients with
4 comorbidities in addition to CKD still lacked a CKD diagnosis. Alarming, this was the case
5 for patients with hypertension, T2D and established cardiovascular disease: groups in which
6 KDIGO recommends screening for CKD,⁶ owing to their elevated risks of CKD progression
7 and associated complications.³⁴⁻³⁶ Without an appropriate CKD diagnosis, opportunities may
8 also be missed to prescribe newer therapies such as sodium-glucose cotransporter-2 inhibitors
9 which have been shown to improve cardiorenal outcomes in patients with CKD.^{37 38}

10
11 We observed that the prevalence of undiagnosed CKD tended to rise with age, and older
12 patients tended to have a higher risk of increased diagnostic delay than younger patients. In
13 elderly patients, physicians may assume that eGFR values indicative of stage 3 CKD are
14 caused by age-related decline of kidney function.^{39 40} However, large population-based
15 studies indicate that even in older adults at lower risk for kidney failure, stage 3 CKD is
16 associated with an elevated risk of mortality, cardiovascular events and acute kidney injury.⁴¹
17 Accordingly, KDIGO guidelines support the use of a single threshold value to define CKD
18 across age subgroups consistent with criteria for other chronic non-communicable diseases.⁵
19 In elderly patients, the effects of late-stage CKD are likely to have a substantial influence on
20 physical and cognitive abilities, medication safety and cardiovascular prognosis.^{2 6 41} It is
21 therefore important that physicians do not underestimate the burden and effects of CKD in
22 elderly patients and initiate guideline-appropriate management in a timely manner. Existing
23 clinical tools (such as confirmatory cystatin C testing in suspected cases of CKD) can help
24 mitigate the risk of overdiagnosis, although these remain underutilised.⁶ CKD management in
25 elderly patients should be adapted taking into consideration factors such as their age, frailty,
26 comedications and comorbidities.

1
2
3 In line with previous studies that suggest CKD is more prevalent in women than in men,^{42 43}
4
5 the proportion of female patients with stage 3 CKD was higher than in male patients in all
6
7 countries except Japan. Despite the higher prevalence of CKD in female patients, after
8
9 adjusting for potential confounding factors, female patients had a higher likelihood of being
10
11 undiagnosed than male patients in all countries. It has been suggested that the rate of
12
13 progression of CKD is slower in women than in men,⁴⁴⁻⁴⁷ and physicians may therefore be
14
15 less likely to diagnose the condition at early stages in women. However, the inequality
16
17 demonstrated in this study is substantial, and suggests a need for elevated awareness to
18
19 minimise this gender disparity.
20
21
22
23

24
25 REVEAL-CKD used the internationally recognised CKD-EPI equation to calculate eGFR
26
27 values from available serum creatinine measurements.²³ Race was not included as a modifier
28
29 in line with recent trends among physicians^{24 25} and guidance from expert
30
31 recommendations.²⁶ In a sensitivity analysis performed on the US TriNetX database which
32
33 included data on race, a substantial proportion of Black patients (46.1%, corresponding to
34
35 9.2% of the overall TriNetX cohort) were reclassified as having CKD stage 2
36
37
38 **(Supplementary Table 6)** when the race modifier was included in the calculation of eGFR.
39
40 The inclusion of this modifier may therefore allow CKD to progress further in Black patients
41
42 before they receive appropriate diagnosis and intervention. The decision to use the CKD-EPI
43
44 equation without race was made in part to facilitate comparisons among countries and
45
46 databases in which race was not available, and also to ensure that the eGFR levels seen in
47
48 patients included in REVEAL-CKD were likely to be reflective of eGFR levels calculated
49
50 when the measurements were taken.
51
52
53

54
55 Some limitations must be kept in mind when interpreting these data. Results from the
56
57 included countries may not be generalisable to other countries, which could have
58
59
60

1
2
3 significantly different diagnostic coding practices, healthcare systems and screening policies;
4
5 conclusions regarding the observed differences between countries cannot be drawn for
6
7 similar reasons. The TriNetX and LCED databases contained a high proportion of
8
9 commercially insured patients, and therefore may not be representative of the overall US
10
11 population. Furthermore, data licensing issues prevented the pooling of data from multiple
12
13 databases to provide an overall estimate of the prevalence of undiagnosed CKD. Although
14
15 serum creatinine is typically included in standard laboratory blood tests, patients who did not
16
17 require blood tests will be missing from this analysis. As such, there may be a degree of
18
19 selection bias present in these results toward patients who are being routinely monitored for
20
21 other conditions, or who are actively seeking healthcare. Confirmatory UACR testing was not
22
23 necessary to meet the study definition of stage 3 CKD owing to the extremely low levels of
24
25 UACR testing in most of the cohorts. The proportion of inpatient versus outpatient
26
27 encounters was unavailable for many of the databases used, and therefore comparisons
28
29 between diagnoses in these two settings could not be made. Because many of the databases
30
31 used did not include data on race, variability in the prevalence of undiagnosed CKD
32
33 according to race could not be assessed. It is important to note that this study focused on
34
35 underdiagnosis for stage 3 CKD; low levels of UACR testing in all countries studied suggest
36
37 that the prevalence of undiagnosed stage 1 and 2 CKD may be even higher. Lastly, there is a
38
39 risk of misclassification if CKD diagnoses were made in clinical settings that do not
40
41 contribute to the databases, or if patients had CKD that was recognised by their healthcare
42
43 providers but was not recorded with an appropriate ICD-9/10 code in the databases. Although
44
45 a lack of such codes may not always indicate that a patient's CKD is undiagnosed, this
46
47 definition of CKD diagnosis has been validated by previous real-world studies,^{8 11 12 27} and
48
49 provides an appropriate surrogate measure for rates of diagnosis in large epidemiological
50
51 studies such as REVEAL-CKD.
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, this analysis of six large, secondary databases from five countries
4
5 demonstrates that most cases of stage 3 CKD are not diagnosed in a timely manner despite
6
7 clinical evidence of the disease. Furthermore, although patients with existing risk factors for,
8
9 or complications from, CKD were typically more likely to receive a CKD diagnosis, the
10
11 prevalence of undiagnosed CKD in these patients remained alarmingly high. Clear
12
13 opportunities exist for improved diagnosis of stage 3 CKD, particularly in female patients,
14
15 elderly patients and patients at high risk of CKD progression and complications. Future
16
17 research will help to quantify the impact of early diagnosis and initiation of effective
18
19 therapies on the risk of CKD progression, complications and long-term patient outcomes.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributors

EJP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MA, EJP and HC developed and conducted the statistical analysis plan. All authors agreed the general content of the manuscript and were involved in drafting and critical revision of the manuscript during its development. All authors approved the final version of the manuscript before its submission. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Data availability statement

Data used in this study were obtained from a third party and may not be publicly available. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at <https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>.

Acknowledgments

Medical writing support was provided by Bobby Thompson, MSc(Res), of Oxford PharmaGenesis, Oxford, United Kingdom, and was funded by AstraZeneca. Analysis of data from the IQVIA Longitudinal Patient Database was conducted by Claudio Ripellino and Franca Heiman of IQVIA Solutions S.r.l., Milan, Italy, and was funded by AstraZeneca.

Competing interests

SB, EJP, HC, KJ and EW are employees of AstraZeneca and hold stock options. MA is an employee of AstraZeneca. NT has received grants from AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd

1
2
3 and Tricida, Inc, has received honoraria from AstraZeneca, Boehringer Ingelheim/Eli Lilly
4 and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd and Tricida, Inc and
5
6 holds stock options from Mesentech, Inc, Réribus Therapeutics, Inc, pulseData and Tricida,
7
8 Inc. MPS has received advisory board fees and honoraria from AstraZeneca, Bayer AG, Vifor
9
10 Pharma Group and Boehringer Ingelheim/Eli Lilly and Company. LDN has received fees for
11
12 scientific consultation and/or lectures by Astellas Pharma Inc, AstraZeneca, Mundipharma
13
14 GmbH and Vifor Pharma Group. PK has received speaker's bureau and advisory board fees
15
16 from AstraZeneca, Eli Lilly and Company and Novo Nordisk A/S, speaker's fees from Bayer
17
18 AG and honoraria from AstraZeneca and Eli Lilly and Company. TM and JBV have no
19
20
21 conflicts of interest to disclose.
22
23
24
25
26

27 **Funding**

28
29 REVEAL-CKD is funded by AstraZeneca (grant number N/A). It is a non-interventional
30
31 observational study, and as such, no drugs are supplied or funded. AstraZeneca designed the
32
33 REVEAL-CKD study with input and guidance from the external authors. AstraZeneca
34
35 provided funding for data collection, management and analysis. An AstraZeneca team
36
37 reviewed this manuscript for scientific accuracy during its development and was allowed to
38
39 make suggestions. However, the final content, analysis and interpretation of the data was
40
41 determined by the authors. The decision to submit the data for publication was determined by
42
43 the authors.
44
45
46
47
48
49

50 **Ethics Approval**

51
52 This study does not involve human participants. REVEAL-CKD is an analysis of
53
54 commercially available anonymized electronic medical records and claims data and did not
55
56 require ethics committee approval.
57
58
59
60

REFERENCES

1. Levey AS, Atkins R, Coresh J, *et al.* Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. *Kidney Int.* 2007;72(3):247–59. doi: 10.1038/sj.ki.5002343
2. Bikbov B, Purcell CA, Levey AS, *et al.* Global, regional, and national burden of chronic kidney disease, 1990–2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2020;395(10225):709–33. doi: 10.1016/S0140-6736(20)30045-3
3. Xie Y, Bowe B, Mokdad AH, *et al.* Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney Int.* 2018;94(3):567–81. doi: 10.1016/j.kint.2018.04.011
4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, *et al.* Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet.* 2013;382(9889):339–52. doi: 10.1016/s0140-6736(13)60595-4
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3:1–150. doi: 10.1038/kisup.2012.73
6. Shlipak MG, Tummalaipalli SL, Boulware LE, *et al.* The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2021;99(1):34–47. doi: 10.1016/j.kint.2020.10.012
7. Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. *Pragmat Obs Res.* 2016;7:21–32. doi: 10.2147/POR.S97310
8. Ravera M, Noberasco G, Weiss U, *et al.* CKD awareness and blood pressure control in the primary care hypertensive population. *Am J Kidney Dis.* 2011;57(1):71–7. doi: 10.1053/j.ajkd.2010.08.022
9. Gasparini A, Evans M, Coresh J, *et al.* Prevalence and recognition of chronic kidney disease in Stockholm healthcare. *Nephrol Dial Transplant.* 2016;31(12):2086–94. doi: 10.1093/ndt/gfw354
10. Ryan TP, Sloan JA, Winters PC, Corsetti JP, Fisher SG. Chronic kidney disease prevalence and rate of diagnosis. *Am J Med.* 2007;120(11):981–6. doi: 10.1016/j.amjmed.2007.05.012
11. Diamantidis CJ, Hale SL, Wang V, Smith VA, Scholle SH, Maciejewski ML. Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance. *BMC Nephrology.* 2019;20(1):357. doi: 10.1186/s12882-019-1551-3
12. Bakris G. Prevalence and factors associated with undiagnosed chronic kidney disease in diabetes mellitus. National Kidney Foundation 2019 Spring Clinical Meetings.; 8–12 May, 2019; Boston, MA, USA.
13. Centers for Medicare and Medicaid Services. *Chronic kidney disease often undiagnosed in Medicare beneficiaries.* <https://www.cms.gov/files/document/ckd-data-highlight102020-2.pdf>. Published 2020. Accessed May 26, 2022.
14. Tuttle KR, Alicic RZ, Duru OK, *et al.* Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. *JAMA Network Open.* 2019;2(12):e1918169. doi: 10.1001/jamanetworkopen.2019.18169

15. Szczech LA, Stewart RC, Su H-L, *et al.* Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (Awareness, Detection and Drug therapy in type 2 diabetes and Chronic Kidney Disease). *PLOS ONE*. 2014;9(11):e110535. doi: 10.1371/journal.pone.0110535
16. Kushner P, Peach E, Wittbrodt E, *et al.* Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study. *Clinical Kidney Journal*. 2021;15(4):738–46. doi: 10.1093/ckj/sfab235
17. Cegedim Health Data. *THIN: The Health Improvement Network*. <https://www.cegedim-health-data.com/cegedim-health-data/thin-the-health-improvement-network/>. Published 2021. Accessed January 12, 2022.
18. Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database *Int J Clin Pharmacol Ther*. 2018;56(10):459–66. doi: 10.5414/cp203320
19. Health Search. *XIV Report HealthSearch [Italian]*. https://report.healthsearch.it/Report_XIV.pdf?anno=2022. Published 2021. Accessed 12 May, 2022.
20. Ono Y, Taneda Y, Takeshima T, Iwasaki K, Yasui A. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database. *Clin Epidemiol*. 2020;12:367–75. doi: 10.2147/CLEP.S245555
21. Alford SH, Piccone J, Sexton M, Gilder J, Pesanello M. Watson Health: a new approach to population health and research. *J Patient Cent Res Rev*. 2016;3(3):201. doi: 10.1001/jama.2020.22124
22. TriNetX. *TriNetX Real World Data*. <https://trinetx.com/real-world-data/linked/>. Published 2021. Accessed May 26, 2022.
23. Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
24. Duggal V, Thomas Ic, Montez-Rath ME, Chertow GM, Kurella Tamura M. National estimates of CKD prevalence and potential impact of estimating glomerular filtration rate without race. *J Am Soc Nephrol*. 2021;32(6):1454. doi: 10.1681/ASN.2020121780
25. Diao JA, Wu GJ, Taylor HA, *et al.* Clinical implications of removing race from estimates of kidney function. *JAMA*. 2021;325(2):184–6. doi: 10.1001/jama.2020.22124
26. Delgado C, Baweja M, Crews DC, *et al.* A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *Journal of the American Society of Nephrology*. 2021;32(12):2994–3015. doi: 10.1681/asn.2021070988
27. Winkelmayr WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis*. 2005;46(2):225–32. doi: 10.1053/j.ajkd.2005.04.029
28. Tangri N, Stevens LA, Griffith J, *et al.* A predictive model for progression of chronic kidney disease to kidney failure. *JAMA*. 2011;305(15):1553–9. doi: 10.1001/jama.2011.451
29. Astor BC, Matsushita K, Gansevoort RT, *et al.* Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int*. 2011;79(12):1331–40. doi: 10.1038/ki.2010.550

- 1
- 2
- 3
- 4 30. van der Velde M, Matsushita K, Coresh J, *et al.* Lower estimated glomerular filtration
- 5 rate and higher albuminuria are associated with all-cause and cardiovascular
- 6 mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int.*
- 7 2011;79(12):1341–52. doi: 10.1038/ki.2010.536
- 8 31. Matsushita K, Coresh J, Sang Y, *et al.* Estimated glomerular filtration rate and
- 9 albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis
- 10 of individual participant data. *Lancet Diabetes Endocrinol.* 2015;3(7):514–25. doi:
- 11 10.1016/s2213-8587(15)00040-6
- 12 32. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic
- 13 kidney disease: a systematic review. *Am J Med.* 2011;124(11):1073–80. doi:
- 14 10.1016/j.amjmed.2011.04.026
- 15 33. Gabriela Dieguez, Rebecca Smith. *The impact of earlier CKD detection and delayed*
- 16 *disease progression.* [https://www.milliman.com/-/media/milliman/pdfs/2021-](https://www.milliman.com/-/media/milliman/pdfs/2021-articles/7-13-21-the_impact_of_earlier_ckd_detection_and_delayed.ashx)
- 17 [articles/7-13-21-the_impact_of_earlier_ckd_detection_and_delayed.ashx](https://www.milliman.com/-/media/milliman/pdfs/2021-articles/7-13-21-the_impact_of_earlier_ckd_detection_and_delayed.ashx). Published
- 18 2021. Accessed 26 May, 2022.
- 19 34. Rahman M, Xie D, Feldman HI, *et al.* Association between chronic kidney disease
- 20 progression and cardiovascular disease: results from the CRIC Study. *Am J Nephrol.*
- 21 2014;40(5):399–407. doi: 10.1159/000368915
- 22 35. Cabrera CS, Lee AS, Olsson M, *et al.* Impact of CKD progression on cardiovascular
- 23 disease risk in a contemporary UK cohort of individuals with diabetes. *Kidney Int*
- 24 *Rep.* 2020;5(10):1651–60. doi: 10.1016/j.ekir.2020.07.029
- 25 36. Kovesdy CP, Isaman D, Petruski-Ivleva N, *et al.* Chronic kidney disease progression
- 26 among patients with type 2 diabetes identified in US administrative claims: a
- 27 population cohort study. *Clin Kidney J.* 2020;14(6):1657–64. doi:
- 28 10.1093/ckj/sfaa200
- 29 37. Fontes-Carvalho R, Santos-Ferreira D, Raz I, Marx N, Ruschitzka F, Cosentino F.
- 30 Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces
- 31 of the same coin. *European Journal of Preventive Cardiology.* 2021;29(9):1352–
- 32 1360. doi: 10.1093/eurjpc/zwab034
- 33 38. Rangaswami J, Bhalla V, Boer IHD, *et al.* Cardiorenal Protection With the Newer
- 34 Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A
- 35 Scientific Statement From the American Heart Association. *Circulation.*
- 36 2020;142(17):e265–e286. doi: doi:10.1161/CIR.0000000000000920
- 37 39. Glasscock RJ, Rule AD. Aging and the Kidneys: Anatomy, Physiology and
- 38 Consequences for Defining Chronic Kidney Disease. *Nephron.* 2016;134(1):25–9.
- 39 doi: 10.1159/000445450
- 40 40. Schmitt R, Melk A. Molecular mechanisms of renal aging. *Kidney Int.*
- 41 2017;92(3):569–79. doi: 10.1016/j.kint.2017.02.036
- 42 41. De Nicola L, Minutolo R, Chiodini P, *et al.* The effect of increasing age on the
- 43 prognosis of non-dialysis patients with chronic kidney disease receiving stable
- 44 nephrology care. *Kidney Int.* 2012;82(4):482–8. doi: 10.1038/ki.2012.174
- 45 42. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the
- 46 epidemiology and outcomes of chronic kidney disease. *Nat Rev Nephrol.*
- 47 2018;14(3):151–64. doi: 10.1038/nrneph.2017.181
- 48 43. Hill NR, Fatoba ST, Oke JL, *et al.* Global prevalence of chronic kidney disease - a
- 49 systematic review and meta-analysis. *PloS one.* 2016;11(7):e0158765. doi:
- 50 10.1371/journal.pone.0158765
- 51 44. Silbiger S, Neugarten J. Gender and human chronic renal disease. *Gen Med.* 2008;5
- 52 Suppl A:S3-s10. doi: 10.1016/j.genm.2008.03.002
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 45. Jafar TH, Schmid CH, Stark PC, *et al.* The rate of progression of renal disease may
4 not be slower in women compared with men: a patient-level meta-analysis. *Nephrol*
5 *Dial Transplant.* 2003;18(10):2047-53. doi: 10.1093/ndt/gfg317
6
7 46. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year
8 population-based study of the effects of gender and age. *Kidney Int.* 2006;69(2):375-
9 82. doi: 10.1038/sj.ki.5000058
10
11 47. Swartling O, Rydell H, Stendahl M, Segelmark M, Trolle Lagerros Y, Evans M. CKD
12 progression and mortality among men and women: a nationwide study in Sweden. *Am*
13 *J Kidney Dis.* 2021;78(2):190–199.e1. doi: 10.1053/j.ajkd.2020.11.026
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure Legends

Figure 1. Cohort selection

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LCED, Explorys Linked Claims and Electronic Medical Records Data; LPD, Longitudinal Patient Database; RWD, Real World Data; THIN, The Health Improvement Network.

Figure 2. Overall prevalence of undiagnosed stage 3 CKD according to country and database

Undiagnosed cases are those which lack a diagnosis code for CKD (any stage), any time before and up to 6 months after study index.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Figure 3. Prevalence of undiagnosed stage 3 CKD according to the presence of comorbidities at study index, by country and database

Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischaemic attack, coronary artery bypass graft and percutaneous coronary intervention. Study index is defined as the date of a patient's second qualifying eGFR measurement.

*Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

†Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Figure 4. Kaplan–Meier estimates of time to CKD diagnosis according to country and database in patients undiagnosed at index, overall and by CKD stage (3a/3b)

Shaded areas represent 95% confidence intervals.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Country:	France	Germany	Italy	Japan	USA	USA
Database:	THIN Cegedim	Disease Analyzer	LPD	Japan RWD	LCED 2019	TriNetX


Step 0
All patients in data source




Step 1
Patients with at least two consecutive eGFR measurements with values ≥ 30 and <60 mL/min/1.73 m² that are >90 and ≤ 730 days apart, with the second eGFR measurement taken in 2015 or later



Step 2
At least 12 months of continuous registration in the database prior to the index date (for data sources with information on enrollment), and patient age ≥ 18 years



Step 3
Exclude patients with any evidence of advanced CKD (stage 4, 5) or renal replacement therapy prior to study index



Exclusion steps 3 and 4 performed together at this stage for France

The LPD lacks granularity in ICD-9/10 codes to determine CKD stage and history of renal replacement therapy

Step 4
Exclude patients who underwent a solid organ transplant prior to study index





The German Disease Analyzer does not contain procedure data

All patients had at least 1 day of follow-up


Step 5
Exclude patients with no further follow-up data available after study index






1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


France




Germany




Italy




Japan



USA (LCED)




USA (TriNetX)



With comorbid condition
 Without comorbid condition

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SUPPLEMENTAL MATERIALS

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study

Navdeep Tangri,¹ Toshiki Moriyama,² Markus P Schneider,³ Jean Blaise J Virgitti,⁴ Luca De Nicola,⁵ Matthew Arnold,⁶ Salvatore Barone,⁷ Emily J Peach,⁸ Eric Wittbrodt,⁹ Hungta Chen,¹⁰ Krister Järbrink,¹¹ Pamela Kushner,¹²

¹ Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

² Osaka University, Suita, Osaka, Japan

³ Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen–Nuremberg, Erlangen, Germany

⁴ Cabinet Médical, Orry-La-Ville, France

⁵ Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit, University of Campania Luigi Vanvitelli, Naples, Italy

⁶ Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

⁷ Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA

⁸ Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

⁹ Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA

1
2
3 ¹⁰ Medical/Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca,
4
5 Gaithersburg, Maryland, USA
6
7

8 ¹¹ Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical,
9
10 AstraZeneca, Gothenburg, Sweden
11
12

13 ¹² Department of Family Medicine, University of California Irvine Medical Center, Orange,
14
15 California, USA
16
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary table 1. REVEAL-CKD study inclusion and exclusion criteria

Inclusion criteria:

- ≥ 2 consecutive eGFR laboratory measurements recorded in 2015 or later, with values ≥ 30 and < 60 mL/min/1.73 m² (stage 3a/3b CKD using the CKD-EPI¹ equation) that are > 90 and ≤ 730 days apart
 - ≥ 12 months of continuous presence in the database before the first qualifying eGFR measurement (look-back period)
 - Age ≥ 18 years at the index date (defined as the date of the second qualifying laboratory eGFR measurement indicative of stage 3a/3b CKD).
-

Exclusion criteria:

- Solid organ transplant recorded before the index date
 - Any evidence of advanced CKD (stages 4, 5, and end-stage renal disease) based on CKD diagnosis codes or renal replacement therapy before the index date.
-

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

Supplementary table 2. ICD-9/10 codes used to identify patients with diagnosed stage 3 CKD

Description	ICD-9*	ICD-10†
CKD, stage I	585.1‡	N18.1§
CKD, stage II	585.2	N18.2
CKD, stage III	585.3	N18.3
CKD, stage IV (severe)	585.4	N18.4
CKD, stage V	585.5	N18.5
End-stage renal disease	585.6	N18.6
CKD, unspecified	585.9	N18.9
Hypertensive CKD	403, 403.01, 403.1, 403.11, 403.9, 403.91, 404, 404.01, 404.02, 404.03, 404.1, 404.11, 404.12, 404.13, 404.9, 404.91, 404.92, 404.93	I12.0, I12.9, I13.0, I13.10, I13.11, I13.2
Diabetes with renal manifestation	250.4, 250.41, 250.42, 250.43	E10.2, E11.2, E11.21, E11.22, E11.29
Disorders from impaired renal function	588, 588.1, 588.81, 588.89, 588.9	N25.0, N25.1, N25.81, N25.89, N25.9

*ICD-9 codes were used to identify CKD in Italy and in the US LCED and TriNetX databases.

†ICD 10 codes were used to identify CKD in France, Germany, Japan and the US LCED and TriNetX databases.

‡The ICD-9 code 585 (CKD, unspecified) was included in the code list for Italy owing to the large proportion of non-specific CKD reporting in this database.

§The ICD-10 codes N18 and N18.0 (CKD, unspecified) were included in the code list for France owing to the large proportion of non-specific CKD reporting in this database.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; ICD, International Classification of Diseases.

Supplementary table 3. ICD-9/10 codes used to identify CKD in the sensitivity analysis using a broader definition for CKD adapted from Winkelmayr et al., 2005²

Description	ICD-9*	ICD-10 [†]
CKD, stage I	585.1 [‡]	N18.1 [§]
CKD, stage II	585.2	N18.2
CKD, stage III	585.3	N18.3
CKD, stage IV (severe)	585.4	N18.4
CKD, stage V	585.5	N18.5
End-stage renal disease	585.6	N18.6
CKD, unspecified	585.9	N18.9
Chronic renal insufficiency	582, 582.1, 582.2, 582.4, 582.81, 582.89, 582.9, 583, 583.1, 583.2, 583.4, 583.6, 583.7, 583.81, 583.89, 583.9	N03.0, N03.1, N03.2, N03.3, N03.4, N03.5, N03.6, N03.7, N03.8, N03.9, N05.0, N05.1, N05.2, N05.3, N05.4, N05.5, N05.6, N05.7, N05.8, N05.9, N19, N26.9
Hypertensive CKD	403, 403.01, 403.1, 403.11, 403.9, 403.91, 404, 404.01, 404.02, 404.03, 404.1, 404.11, 404.12, 404.13, 404.9, 404.91, 404.92, 404.93	I12.0, I12.9, I13.0, I13.10, I13.11, I13.2
Diabetes with renal manifestation	250.4, 250.41, 250.42, 250.43	E10.2, E11.2, E11.21, E11.22, E11.29
Disorders from impaired renal function	588, 588.1, 588.81, 588.89, 588.9	N25.0, N25.1, N25.81, N25.89, N25.9, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322, M10.329, M10.331, M10.332, M10.339, M10.341, M10.342, M10.349, M10.351, M10.352, M10.359,

Description	ICD-9*	ICD-10†
Acute renal failure	572.4, 580, 580.4, 580.81, 580.89, 580.9, 584.5, 584.6, 584.7, 584.8, 584.9, 791.2, 791.3	M10.361, M10.362, M10.369, M10.371, M10.372, M10.379, M10.38, M10.39 K76.7, N00.3, N00.8, N00.9, N01.3, N17.0, N17.1, N17.2, N17.8, N17.9, R82.1, R82.3
Miscellaneous	274.1, 440.1, 442.1, 453.3, 581, 581.1, 581.2, 581.3, 581.81, 581.89, 581.9, 586, 587, 593, 593.1, 593.2, 593.3, 593.4, 593.5, 593.6, 593.7, 593.71, 593.72, 593.73, 593.81, 593.82, 593.89, 593.9, 753, 753.3, 866, 866.01, 866.1, 866.11, 866.12, 866.13	I70.1, I72.2, I82.3, N02.2, N04.0, N04.1, N04.2, N04.3, N04.4, N04.5, N04.6, N04.7, N04.8, N04.9, N08, N13.4, N13.5, N13.70, N13.71, N13.721, N13.722, N13.729, N13.731, N13.732, N13.739, N13.8, N28.1, N28.81, N28.82, N28.83, N28.89, N28.9, Q60.2, Q60.5, Q63.0, Q63.1, Q63.2, Q63.3, Q63.8, Q63.9, R80.2, S31.001, S37.009, S37.019, S37.029, S37.039, S37.049, S37.059, S37.069

*ICD-9 codes were used to identify CKD in Italy and in the US LCED and TriNetX databases.

†ICD-10 codes were used to identify CKD in France, Germany, Japan and the US LCED and TriNetX databases.

‡The ICD-9 code 585 (CKD, unspecified) was included in the code list for Italy owing to the large proportion of non-specific CKD reporting in this database.

§The ICD-10 codes N18 and N18.0 (CKD, unspecified) were included in the code list for France owing to the large proportion of non-specific CKD reporting in this database.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; ICD, International Classification of Diseases.

Supplementary table 4. Overall patient characteristics at study index (date of second eGFR measurement) according to country and database

Country Database	France	Germany	Italy	Japan	USA	
	THIN Cegecim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
CKD status*, n (%)						
Diagnosed	892 (4.5)	4210 (15.7)	15 129 (23.0)	7209 (7.9)	8625 (38.4)	89 625 (35.7)
Undiagnosed	19 120 (95.5)	22 557 (84.3)	50 547 (77.0)	83 693 (92.1)	13 845 (61.6)	161 254 (64.3)
Age, y, median (IQR)	80 (72–86)	79 (72–84)	80 (74–85)	76 (69–83)	74 (64–82)	71 (64–78)
Age groups, y						
<45	67 (0.3)	66 (0.2)	188 (0.3)	791 (0.9)	243 (1.1)	5523 (2.2)
45–64	1677 (8.4)	2431 (9.1)	3780 (5.8)	13 286 (14.6)	5991 (26.7)	63 726 (25.4)
65–74	4641 (23.2)	6032 (22.5)	14 264 (21.7)	25 627 (28.2)	5592 (24.9)	87 880 (35.0)
≥75	13 627 (68.1)	18 238 (68.1)	47 444 (72.2)	51 198 (56.3)	10 644 (47.4)	93 750 (37.4)
Male, n (%)	9091 (45.4)	11 216 (41.9)	27 728 (42.2)	48 123 (52.9)	10 051 (44.7)	105 112 (41.9)
eGFR, mL/min/1.73 m², median (IQR)	52 (45–56)	52 (44–56)	49 (42–55)	52 (46–56)	51 (44–56)	51 (44–56)
CKD stage, n (%)						
CKD stage 3a	15 101 (75.5)	19 492 (72.8)	43 937 (66.9)	70 668 (77.7)	16 320 (72.6)	183 618 (73.2)
CKD stage 3b	4911 (24.5)	7275 (27.2)	21 739 (33.1)	20 234 (22.3)	6150 (27.4)	67 261 (26.8)
Baseline UACR available, n (%)	450 (2.2)	0 (0.0) [†]	9 (<0.1) [‡]	4992 (5.5)	899 (4.0)	4604 (1.8)
HDL, mmol/L, median (IQR)	1.37 (1.11–1.65)	1.34 (1.10–1.63)	1.32 (1.09–1.58)	1.40 (1.14–1.71)	1.22 (0.98–1.50)	1.22 (0.98–1.50)
Missing, n	6514	8232	17 513	35 305	10 022	138 798
LDL, mmol/L, median (IQR)	2.89 (2.24–3.61)	2.84 (2.17–3.65)	2.69 (2.07–3.36)	2.74 (2.30–3.31)	2.38 (1.84–3.05)	2.38 (1.81–3.05)
Missing, n	6676	7087	19 475	33 589	8936	125 474
Comorbidities, n (%)						
Hypertension	12 412 (62.0)	13 679 (51.1)	51 324 (78.1)	53 022 (58.3)	20 061 (89.3)	203 155 (81.0)
Type 2 diabetes	3532 (17.6)	6935 (25.9)	21 300 (32.4) [§]	18 989 (20.9)	9288 (41.3)	95 441 (38.0)
Established CVD [¶]	1449 (7.2)	1904 (7.1)	6937 (10.6)	25 637 (28.2)	6292 (28.0)	49 744 (19.8)
Heart failure	986 (4.9)	4364 (16.3)	6378 (9.7)	30 063 (33.1)	5314 (23.6)	47 002 (18.7)
Atrial fibrillation	2161 (10.8)	4217 (15.8)	11 105 (16.9)	11 991 (13.2)	4627 (20.6)	41 214 (16.4)
Medication use, n (%)						
ACE inhibitor	4634 (23.2)	9635 (36.0)	25 098 (38.2)	4501 (5.0)	8783 (39.1)	57 806 (23.0)
ARB	6530 (32.6)	10 573 (39.5)	26 198 (39.9)	21 422 (23.6)	6302 (28.0)	37 946 (15.1)
SGLT2 inhibitor	0 (0.0)	0 (0.0)	353 (0.5)	1363 (1.5)	22 (0.1)	2149 (0.9)
GLD (any)	3489 (17.4)	8319 (31.1)	17 363 (26.4)	13 431 (14.8)	9400 (41.8)	60 259 (24.0)
Antiplatelets	5964 (29.8)	6597 (24.6)	31 151 (47.4)	18 796 (20.7)	2476 (11.0)	16 308 (6.5)
Loop diuretic	2924 (14.6)	10 508 (39.3)	22 160 (33.7)	11 979 (13.2)	5563 (24.8)	43 470 (17.3)
Anticoagulants	3018 (15.1)	8182 (30.6)	16 197 (24.7)	14 486 (15.9)	6347 (28.2)	54 986 (21.9)

1
2
3 Unless otherwise stated, percentages represent the proportion of patients in a specific group (eg, age) or with a specific variable (eg, medical history).

4 *Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort for each country/database.

5 †UACR testing data not available in the German Disease Analyzer database.

6 ‡Direct measurements of UACR were not available in the IQVIA Longitudinal Patient Database in Italy, however, UACR was calculated as urine albumin (mg/dL) divided
7 by urine creatinine (g/dL) if patients had records for both of these variables on the same day.

8 §Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

9 ¶Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous
10 coronary intervention.

11 ¶¶Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary
12 intervention in patients from Italy.

13 ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular
14 filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LCED, Explorys Linked
15 Claims and Electronic Medical Records Data; LDL, low-density lipoprotein; LPD, Longitudinal Patient Database; RWD, Real World Data; SGLT2, sodium-glucose
16 cotransporter-2; THIN, The Health Improvement Network; UACR, urinary albumin-creatinine ratio.

Supplementary table 5. Sensitivity analysis of undiagnosed stage 3 CKD using a broader CKD definition adapted from Winkelmayr et al., 2005² according to country and database

Country Database	France THIN Cegedim n=20 012	Germany Disease Analyzer n=26 767	Italy LPD n=65 676	Japan Japan RWD n=90 902	USA LCED n=22 470	USA TriNetX n=250 879
CKD status*, n (%)						
Diagnosed	2031 (10.1)	6165 (23.0)	21 146 (32.2)	12 113 (13.3)	10 421 (46.4)	109 735 (43.7)
Undiagnosed	17 981 (89.9)	20 602 (77.0)	44 530 (67.8)	78 789 (86.7)	12 049 (53.6)	141 144 (56.3)

*Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort for each country/database.
 CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; LPD, Longitudinal Patient Database; RWD, Real World Data; THIN, The Health Improvement Network.


peer review only

Supplementary table 6. Comparison of CKD stages in Black and non-Black patients from the US TriNetX database when calculating eGFR using two different equations: CKD-EPI (without adjusting for race) and CKD-EPI (with race modifier)¹

	CKD-EPI, no race modifier	CKD-EPI, with race modifier
Black (n=50 283)		
CKD stage 2, n (%)	0 (0.0)	23 156 (46.1)
CKD stage 3a, n (%)	36 005 (71.6)	20 455 (40.7)
CKD stage 3b, n (%)	14 278 (28.4)	6672 (13.3)
Non-Black (n=200 596)		
CKD stage 2, n (%)	0 (0.0)	0 (0.0)
CKD stage 3a, n (%)	147 613 (73.6)	147 613 (73.6)
CKD stage 3b, n (%)	52 983 (26.4)	52 983 (26.4)


CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

Supplementary figure 1. Prevalence of undiagnosed stage 3 CKD according to calendar year of study index according to country and database



CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.


Supplementary figure 2. Prevalence of undiagnosed stage 3 CKD according to age group at study index according to country and database



CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Only

Supplementary figure 3. Factors associated with a lack of CKD diagnosis any time before or up to 6 months after index date according to country and database



Whiskers represent 95% confidence intervals.

*Odds ratios adjusted for covariates at index: sex, age, CKD stage, family history of CKD (not available in France, Germany and Japan), number of clinical visits in year before index, medical history (heart failure, established CVD, diabetes [any type], hypertension, other kidney disease) and medication use (diuretics, β -blockers, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, lipid-lowering drugs, antithrombotic drugs, metformin, glucagon-like peptide receptor-1 inhibitors or sodium-glucose cotransporter-2 inhibitors, and other glucose-lowering drugs).


†Upper 95% confidence interval extends beyond the boundary of the graph.

‡Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

§Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 4. Factors associated with time to CKD diagnosis in patients undiagnosed at index according to country and database



Whiskers represent 95% confidence intervals.

^aHazard ratios adjusted for covariates at index: sex, age, CKD stage, family history of CKD (not available in France, Germany and Japan), number of clinical visits in year before index, medical history (heart failure, established CVD, diabetes [any type], hypertension, other kidney disease) and medication use (diuretics, β-blockers, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, lipid-lowering drugs, antithrombotic drugs, metformin, glucagon-like peptide receptor-1 inhibitors or sodium-glucose cotransporter-2 inhibitors and other glucose-lowering drugs).

^bEstablished CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

^cOwing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; HR, hazard ratio; LCED, Explorys Linked Claims and Electronic Medical Records Data.

References

1. Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
2. Winkelmayr WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis.* 2005;46(2):225–32. doi: 10.1053/j.ajkd.2005.04.029

For peer review only

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	a) Title, page 1, and abstract, page 3 [Design section] b) Abstract, page 3	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	1.1) Abstract, page 3 (Setting section) 1.2) Abstract, page 3 (Setting and Participants sections) 1.3) N/A
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, page 5		
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, page 5		
Methods					
Study Design	4	Present key elements of study design early in the paper	Materials and Methods, page 6 (Study Design)		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Materials and Methods, page 6 (Study Design)		

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30</p> <p>Participants</p>	<p>6</p>	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	<p>A) Eligibility criteria, follow-up duration and data sources described in Materials and Methods, page 6 and 7 (Study Design)</p>	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>6.1) Materials and Methods, page 7 (Study Design) with full lists of ICD9/10 codes used to identify diagnosed/undiagnosed cases given in Supplementary Materials 6.2) N/A (eligible patients were identified based on eGFR which was calculated from serum creatinine as described in Materials and Methods and according to internationally-recognized equations for eGFR calculations) 6.3) N/A</p>
<p>31 32 33 34 35 36 37</p> <p>Variables</p>	<p>7</p>	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.</p>	<p>Materials and Methods, page 7 (Study Design section)</p>	<p>RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.</p>	<p>7.1) Full list of ICD9/10 codes used in Supplementary Tables 2 and 3</p>
<p>38 39 40 41 42</p> <p>Data sources/ measurement</p>	<p>8</p>	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement).</p>	<p>Materials and Methods, page 6 (Study Design section)</p>		

		Describe comparability of assessment methods if there is more than one group			
Bias	9	Describe any efforts to address potential sources of bias	Materials and Methods, page 7 (Study Design section); potential bias addressed in Discussion, pages 16 and 17		
Study size	10	Explain how the study size was arrived at	N/A (all eligible patients within specified time frame were included)		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	N/A (quantitative variables collected from existing EMR/claims databases; CKD stage groupings based on existing KDIGO guidelines referenced in the manuscript)		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how	Materials and Methods, pages 7 and 8 (Study Design and Statistical Analysis sections)		

		<p>matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>			
Data access and cleaning methods	..			<p>RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.</p> <p>RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.</p>	<p>12.1) Author Contributions section, page 19</p> <p>12.2) N/A</p>
Linkage	..			<p>RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.</p>	12.3) N/A
Results					
Participants	13	<p>(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)</p> <p>(b) Give reasons for non-participation at each stage.</p> <p>(c) Consider use of a flow diagram</p>	<p>a) Results, page 8</p> <p>b) N/A</p> <p>c) Figure 1 (cohort selection)</p>	<p>RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i>, study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.</p>	<p>13.1) Figure 1 (cohort selection); Results, page 8</p>
Descriptive data	14	<p>(a) Give characteristics of study participants (<i>e.g.</i>, demographic,</p>	<p>a) Results, pages 9 and 12</p>		

		clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (e.g., average and total amount)	(Demographics and Clinical Characteristics of Patients with Diagnosed and Undiagnosed CKD section); Table 1 b) Table 1 c) Results, page 12 (Time to CKD Diagnosis section)		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures	Results, pages 8 and 9		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	a) Results, page 13; confounders for multivariate analyses given in footnotes of supplementary Figure 3 and 4 b) N/A c) N/A		
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and	Results, pages 12 and 13		

		interactions, and sensitivity analyses			
Discussion					
Key results	18	Summarise key results with reference to study objectives	Discussion, page 14		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion, pages 16 and 17 (Strengths and Limitations)	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion, page 17 (Strengths and Limitations)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, page 18 (Conclusions)		
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion, page 17 (Strengths and Limitations)		
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding, page 20		
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Data Availability Statement, page 19; Supplementary Appendix

1 *Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working
2 Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015;
3 in press.

4 *Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

BMJ Open

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-067386.R1
Article Type:	Original research
Date Submitted by the Author:	01-Dec-2022
Complete List of Authors:	Tangri, Navdeep; University of Manitoba, Medicine Moriyama, Toshiki; Osaka University Schneider, Markus P.; Erlangen University Hospital Department of Medicine 4 Nephrology and Hypertension Virgitti, Jean Blaise; Cabinet Médical De Nicola, Luca ; Università degli Studi della Campania Luigi Vanvitelli, Arnold, Matt; AstraZeneca PLC, Real World Evidence Data & Analytics, BioPharmaceuticals Medical Barone, Salvatore; AstraZeneca US, Global Medical Affairs, BioPharmaceuticals Medical Peach, Emily; AstraZeneca PLC, Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical Wittbrodt, Eric; AstraZeneca US, Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical Chen, Hungta; AstraZeneca US, Medical/Payer Evidence Statistics, BioPharmaceuticals Medical Järbrink, Krister; AstraZeneca Sweden, Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical Kushner, Pamela; University of California Irvine Medical Center, Department of Family Medicine
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Epidemiology
Keywords:	NEPHROLOGY, EPIDEMIOLOGY, Chronic renal failure < NEPHROLOGY, Adult nephrology < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Prevalence of undiagnosed stage 3 chronic kidney disease in**
4
5
6 **France, Germany, Italy, Japan and the USA: results from the**
7
8
9 **multinational observational REVEAL-CKD study**
10
11

12 Navdeep Tangri,¹ Toshiki Moriyama,² Markus P Schneider,³ Jean Blaise J Virgitti,⁴ Luca De
13 Nicola,⁵ Matthew Arnold,⁶ Salvatore Barone,⁷ Emily J Peach,⁸ Eric Wittbrodt,⁹ Hungta
14 Chen,¹⁰ Krister Järbrink,¹¹ Pamela Kushner¹²
15
16
17
18
19

20
21
22 ¹Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;
23

24 ²Osaka University, Suita, Osaka, Japan; ³Department of Nephrology and Hypertension,
25 University Hospital Erlangen, University of Erlangen–Nuremberg, Erlangen, Germany;
26
27

28 ⁴Cabinet Médical, Orry-La-Ville, France; ⁵Department of Advanced Medical and Surgical
29 Sciences, Nephrology and Dialysis Unit, University of Campania Luigi Vanvitelli, Naples,
30 Italy; ⁶Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca,
31
32
33

34 Cambridge, UK; ⁷Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca,
35 Gaithersburg, Maryland, USA; ⁸Cardiovascular, Renal and Metabolism Epidemiology,
36
37

38 BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; ⁹Cardiovascular, Renal and
39 Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg,
40
41
42

43 Maryland, USA; ¹⁰Medical/Payer Evidence Statistics, BioPharmaceuticals Medical,
44 AstraZeneca, Gaithersburg, Maryland, USA; ¹¹Cardiovascular, Renal and Metabolism
45
46
47

48 Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden; ¹²Department of
49 Family Medicine, University of California Irvine Medical Center, Orange, California, USA
50
51
52

53
54
55
56 **Corresponding author:** Navdeep Tangri, MD, PhD, Seven Oaks General Hospital, 2LB19-
57 2300 McPhillips Street, Winnipeg, Manitoba, R2V 3M3, Canada (ntangri@sogh.mb.ca)
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Target journal: *BMJ Open*

Word count: 3117/4000

For peer review only

ABSTRACT (298/300 words)

Objectives: REVEAL-CKD aims to estimate the prevalence of, and factors associated with, undiagnosed stage 3 chronic kidney disease (CKD).

Design: Multinational, observational study.

Setting: Data from six country-specific electronic medical records and/or insurance claims databases from five countries (France, Germany, Italy, Japan and the USA [two databases]).

Participants: Eligible participants (≥ 18 years old) had ≥ 2 consecutive estimated glomerular filtration rate (eGFR) measurements (calculated from serum creatinine values, sex and age) taken from 2015 onwards that were indicative of stage 3 CKD (≥ 30 and < 60 mL/min/1.73 m²). Undiagnosed cases lacked an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before, and up to 6 months after, the second qualifying eGFR measurement (study index).

Main outcome measures: The primary outcome was point prevalence of undiagnosed stage 3 CKD. Time to diagnosis was assessed using the Kaplan–Meier approach. Factors associated with lacking a CKD diagnosis and risk of diagnostic delay were assessed using logistic regression adjusted for baseline covariates.

Results: The prevalence of undiagnosed stage 3 CKD was 95.5% (19,120/20,012 patients) in France, 84.3% (22,557/26,767) in Germany, 77.0% (50,547/65,676) in Italy, 92.1% (83,693/90,902) in Japan, 61.6% (13,845/22,470) in the US Explorys LCED database and 64.3% (161,254/250,879) in the US TriNetX database. The prevalence of undiagnosed CKD increased with age. Factors associated with undiagnosed CKD were female sex (vs male, range of odds ratio across countries: 1.29–1.77), stage 3a CKD (vs 3b, 1.81–3.66), no medical history (vs a history) of diabetes (1.26–2.77) or hypertension (1.35–1.78).

Conclusions: There are substantial opportunities to improve stage 3 CKD diagnosis, particularly in female patients and older patients. The low diagnosis rates in patients with

1
2
3 comorbidities that put them at risk of disease progression and complications requires
4
5 attention.
6

7
8 **Trial registration:** NCT04847531
9

10 11 12 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 13
14
15 • REVEAL-CKD uses large, contemporary, country-specific databases to provide
16
17 robust estimates of the prevalence of undiagnosed stage 3 CKD.
- 18
19
20 • The study uses a strict, consistent and internationally recognised definition of stage 3
21
22 CKD to ensure accuracy when calculating the prevalence of diagnosed/undiagnosed
23
24 CKD.
- 25
26
27 • Data from the countries and databases examined may not be representative of other
28
29 countries with substantially different healthcare systems or CKD screening policies.
- 30
31
32 • There is a risk of misclassification of undiagnosed CKD if diagnoses were made in
33
34 environments that did not contribute to the databases used or if diagnosing physicians
35
36 did not use ICD-9/10 codes appropriately.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic kidney disease (CKD) is an established global public health concern.¹ CKD has a significant effect on patients, attributable to direct mortality and morbidity, as well as elevated risk of cardiovascular diseases.² The global prevalence of CKD is rising,³ owing to aging populations and increased prevalence of CKD-associated risk factors including type 2 diabetes (T2D) and hypertension.⁴

Early intervention and appropriate management of CKD is recommended in the internationally recognised Kidney Disease: Improving Global Outcomes (KDIGO) guidelines⁵ to help delay disease progression and reduce the incidence of complications. Furthermore, in 2019, KDIGO held a controversies conference on the topic of early identification and intervention in CKD. The consensus statement from this conference urged action, including the implementation of screening programs and interventions for high-risk individuals.⁶ Early-stage CKD is primarily asymptomatic,⁷ therefore CKD is primarily diagnosed at later disease stages and the initiation of effective interventions is delayed or missed.⁵ Previous studies have demonstrated low levels of diagnosis of early-stage CKD in Italy,⁸ Sweden⁹ and the USA.¹⁰⁻¹⁵ However, these previous studies have been limited to single countries or databases, or at-risk groups such as patients with T2D, and did not assess the prevalence of CKD diagnosis across various subgroups (eg, patients with or without comorbidities). There is a need for contemporary information on the prevalence of, and factors associated with, undiagnosed stage 3 CKD, as well as a need to understand factors associated with diagnostic delay in these patients.

REVEAL-CKD (NCT04847531) is a multinational, observational study designed to fill this evidence gap. REVEAL-CKD aims to quantify the prevalence of, and factors associated with, undiagnosed stage 3 CKD in large populations across several countries.¹⁶ Here, we present

1
2
3 data on the prevalence of, and factors associated with, undiagnosed stage 3 CKD in France,
4
5 Germany, Italy, Japan and the USA.
6
7

8 9 **METHODS**

10 11 12 **Study design**

13
14
15 The study design for REVEAL-CKD has been reported in detail elsewhere,¹⁶ and is
16
17 summarised below.
18
19

20
21 Existing secondary data were extracted from established, verified relevant databases
22
23 containing electronic medical records and/or insurance claims in the countries of interest.
24
25 Data for France were extracted from The Health Improvement Network, a large database of
26
27 anonymised electronic medical records.¹⁷ Data for Germany were extracted from the German
28
29 Disease Analyzer, a database of anonymised longitudinal data on drug prescriptions,
30
31 diagnoses and medical and demographic data contributed by a panel of more than 2500
32
33 physicians in Germany.¹⁸ Data for Italy were extracted from the IQVIA Longitudinal Patient
34
35 Database, a computerised network of over 900 family physicians, which includes anonymised
36
37 data on patient consultations and treatments.¹⁹ Data for Japan were extracted from Japan Real
38
39 World Data, an integrated database of medical information including both electronic medical
40
41 records and claims data.²⁰ Data for the USA were extracted from two separate databases:
42
43 Explorys Linked Claims and Electronic Medical Records Data (LCED), a database of
44
45 inpatient and outpatient medical records and claims data from commercially insured
46
47 individuals,²¹ and TriNetX, a database of integrated electronic medical records and claims
48
49 data from 35 healthcare organisations, which provides clinical patient data from both
50
51 inpatient and outpatient encounters.²² The coverage of each database used is described in
52
53
54
55
56
57

58 **Supplementary table 1.**

59
60

1
2
3 Patients aged ≥ 18 years were included in the analyses if they had at least two consecutive
4
5 estimated glomerular filtration rate (eGFR) measurements that fell within the range indicative
6
7 of stage 3 CKD (≥ 30 and < 60 mL/min/1.73 m²) and were recorded > 90 and ≤ 730 days apart,
8
9 taken on or after 1 January 2015. The decision to require at least two eGFR measurements
10
11 with a gap of at least 90 days between each measurement was made to ensure that patients
12
13 met the KDIGO definition for CKD,⁵ and to avoid potential misclassification of patients
14
15 based on single spurious eGFR measurements < 60 mL/min/1.73 m². All patients had at least
16
17 12 months of continuous presence in the database before the first qualifying eGFR
18
19 measurement. Full inclusion and exclusion criteria are shown in **Supplementary table 2**.
20
21 eGFR was calculated from serum creatinine values, sex and age, using the CKD
22
23 Epidemiology Collaboration (CKD-EPI) equation.²³ In line with current trends among
24
25 physicians^{24 25} and guidance from expert recommendations,²⁶ race modifiers were not used in
26
27 the calculation of eGFR.
28
29
30
31
32
33

34 To account for potential delays in recording of diagnostic codes, undiagnosed CKD was
35
36 defined as lacking an International Classification of Diseases (ICD) 9/10 diagnosis code
37
38 corresponding to CKD (any stage), any time before and up to 6 months after index (date of
39
40 second qualifying eGFR measurement). The ICD coding system varied by country depending
41
42 on what was available in each database; the full list of ICD-9/10 codes used to determine
43
44 diagnosed cases can be found in **Supplementary table 3**. A sensitivity analysis was
45
46 performed to calculate the overall prevalence of undiagnosed stage 3 CKD using a broader
47
48 definition of CKD adapted from Winkelmayr et al.²⁷ This sensitivity analysis included
49
50 diagnostic codes for several additional manifestations of renal disease (**Supplementary**
51
52 **table 4**).
53
54
55
56
57
58
59
60

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Statistical analysis

Overall prevalence of undiagnosed stage 3 CKD and patient demographic and clinical characteristics at index are presented descriptively. Odds ratios for factors associated with being undiagnosed any time before and up to 6 months after index were calculated using logistic regression analysis, adjusted for covariates at index. Hazard ratios for diagnostic delay among patients undiagnosed at index were calculated using Cox regression analysis, adjusted for covariates at index. The Kaplan–Meier method was used to estimate the time to diagnosis among patients undiagnosed at index. Statistical analysis was performed using Python 3.7 and R 4.0.2.

RESULTS

This analysis of patients with stage 3 CKD included 20 012 patients from France, 90 902 patients from Germany, 65 676 patients from Italy, 26 767 patients from Japan, 22 470 patients from the LCED database in the USA, and 250 879 patients from the TriNetX database in the USA (**Figure 1**). Characteristics of these patients at index are shown in **Supplementary Table 5**. At index, median age was 71–80 years, median eGFR was 49–52 mL/min/1.73 m², 66.9%–77.7% of patients had CKD stage 3a (eGFR \geq 45 and $<$ 60 mL/min/1.73 m²) and 22.3%–33.1% of patients had CKD stage 3b (eGFR \geq 30 and $<$ 45 mL/min/1.73 m²). The overall prevalence of urinary albumin-creatinine ratio (UACR) testing was very low and ranged from 1.8% (US, TriNetX) to 5.5% (Japan).

Overall prevalence of undiagnosed stage 3 CKD

The proportion of patients with stage 3 CKD without a diagnosis at or within 6 months after index varied by database, and was 95.5% in France, 84.3% in Germany, 77.0% in Italy, 92.1% in Japan, 61.6% in the US LCED database and 64.3% in the US TriNetX database (**Figure 2A**). In the sensitivity analysis using a broader set of ICD-9/10 codes to identify CKD diagnoses, the prevalence of undiagnosed CKD was 53.6%–89.9% (**Supplementary Table 6**). The proportion of patients with undiagnosed CKD per calendar year at index is shown in **Supplementary Figure 1**. Overall, there were no prevailing trends in the proportion of patients with undiagnosed CKD per calendar year, except in Italy, where the proportion of undiagnosed CKD tended to increase over time (68.2% undiagnosed in 2015 to 83.1% in 2020).

1
2
3 **Demographics and clinical characteristics of patients with diagnosed and undiagnosed**
4 **stage 3 CKD**
5
6

7
8
9 Characteristics for patients with diagnosed and undiagnosed stage 3 CKD at index are
10
11 presented in **Table 1**.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Overall patient characteristics at study index according to country, by CKD diagnosis status 6 months after index

Country	France		Germany		Italy		Japan		USA			
Database	THIN CegeDim		Disease Analyzer		LPD		Japan RWD		LCED		TriNetX	
	Undiagnosed n=19 120	Diagnosed* n=892	Undiagnosed n=22 557	Diagnosed* n=4210	Undiagnosed n=50 547	Diagnosed* n=15 129	Undiagnosed n=83 693	Diagnosed* n=7209	Undiagnosed n=13 845	Diagnosed* n=8625	Undiagnosed n=161 254	Diagnosed* n=89 625
Age, y, median (IQR)	80 (72–86)	77 (69–84)	79 (72–84)	79 (71–84)	80 (74–85)	80 (73–85)	76 (69–83)	77 (68–83)	74 (64–82)	74 (64–82)	71 (64–79)	70 (62–78)
Age groups, y												
<45	58 (0.3)	9 (1.0)	46 (0.2)	20 (0.5)	95 (0.2)	93 (0.6)	652 (0.8)	139 (1.9)	109 (0.8)	134 (1.6)	2426 (1.5)	3097 (3.5)
45–64	1551 (8.1)	126 (14.1)	1957 (8.7)	474 (11.3)	2724 (5.4)	1056 (7.0)	12 260 (14.6)	1026 (14.2)	3754 (27.1)	2237 (25.9)	38 302 (23.8)	25 424 (28.4)
65–74	4421 (23.1)	220 (24.7)	5088 (22.6)	944 (22.4)	10 976 (21.7)	3288 (21.7)	23 696 (28.3)	1931 (26.8)	3415 (24.7)	2177 (25.2)	57 891 (35.9)	29 989 (33.5)
≥75	13 090 (68.5)	537 (60.2)	15 466 (68.6)	2772 (65.8)	36 752 (72.7)	10 692 (70.7)	47 085 (56.3)	4113 (57.1)	6567 (47.4)	4077 (47.3)	62 635 (38.8)	31 115 (34.7)
Male, n (%)	8599 (45.0)	492 (55.2)	9173 (40.7)	2043 (48.5)	19 820 (39.2)	7908 (52.3)	43 658 (52.2)	4465 (61.9)	5438 (39.3)	4613 (53.5)	57 989 (36.0)	47 123 (52.6)
eGFR, mL/min/1.73 m², median (IQR)	52 (46–56)	45 (38–52)	52 (45–56)	49 (40–55)	51 (44–55)	45 (38–52)	53 (47–56)	45 (37–53)	53 (47–57)	47 (40–53)	53 (47–57)	47 (40–53)
CKD stage, n (%)												
CKD stage 3a	14 661 (76.7)	440 (49.3)	16 871 (74.8)	2621 (62.3)	36 460 (72.1)	7477 (49.4)	66 955 (80.0)	3713 (51.5)	11 348 (82.0)	4972 (57.6)	131 385 (81.5)	52 233 (58.3)
CKD stage 3b	4459 (23.3)	452 (50.7)	5686 (25.2)	1589 (37.7)	14 087 (27.9)	7652 (50.6)	16 738 (20.0)	3496 (48.5)	2497 (18.0)	3653 (42.4)	29 869 (18.5)	37 392 (41.7)
Baseline UACR available, n (%)	424 (2.2)	26 (2.9)	0 (0.0) [†]	0 (0.0) [†]	4 (<0.1) [‡]	5 (<0.1) [‡]	3851 (4.6)	1141 (15.8)	474 (3.4)	425 (4.9)	2455 (1.5)	2149 (2.4)
HDL, mmol/L, median (IQR)	1.37 (1.11–1.65)	1.32 (1.08–1.65)	1.34 (1.11–1.63)	1.29 (1.06–1.55)	1.32 (1.11–1.59)	1.27 (1.06–1.53)	1.40 (1.16–1.71)	1.32 (1.09–1.60)	1.24 (1.03–1.53)	1.16 (0.96–1.45)	1.24 (1.03–1.55)	1.14 (0.93–1.42)
Missing, n	6172	342	6904	1328	13 379	4134	33 243	2062	5673	4349	88 031	50 767
LDL, mmol/L, median (IQR)	2.89 (2.24–3.61)	2.81 (2.18–3.53)	2.87 (2.20–3.70)	2.70 (2.07–3.49)	2.74 (2.12–3.39)	2.53 (1.97–3.21)	2.77 (2.22–3.34)	2.53 (2.04–3.10)	2.46 (1.89–3.13)	2.25 (1.71–2.95)	2.43 (1.87–3.13)	2.22 (1.68–2.92)
Missing, n	6331	345	6026	1061	14 915	4560	31 643	1946	4988	3948	78 408	47 066
Comorbidities, n (%)												
Hypertension	11 737 (61.4)	675 (75.7)	10 969 (48.6)	2710 (64.4)	38 849 (76.9)	12 475 (82.5)	47 311 (56.5)	5711 (79.2)	11 863 (85.7)	8198 (95.0)	123 002 (76.3)	80 153 (89.4)
Type 2 diabetes	3311 (17.3)	221 (24.8)	5145 (22.8)	1790 (42.5)	15 785 (31.2) [§]	5515 (36.5) [§]	15 655 (18.7)	3334 (46.2)	4667 (33.7)	4621 (53.6)	49 299 (30.6)	46 142 (51.5)
Established CVD [¶]	1368 (7.2)	81 (9.1)	1467 (6.5)	437 (10.4)	5153 (10.2)	1784 (11.8)	23 248 (27.8)	2389 (33.1)	3337 (24.1)	2955 (34.3)	26 666 (16.5)	23 078 (25.7)
Heart failure	922 (4.8)	64 (7.2)	3318 (14.7)	1046 (24.8)	4248 (8.4)	2130 (14.1)	26 077 (31.2)	3986 (55.3)	2523 (18.2)	2791 (32.4)	22 422 (13.9)	24 580 (27.4)
Atrial fibrillation	2057 (10.8)	104 (11.7)	3351 (14.9)	866 (20.6)	8293 (16.4)	2812 (18.6)	10 765 (12.9)	1226 (17.0)	2409 (17.4)	2218 (25.7)	23 224 (14.4)	17 990 (20.1)
Medication use, n (%)												
ACE inhibitor	4363 (22.8)	271 (30.4)	8023 (35.6)	1612 (38.3)	19 141 (37.9)	5957 (39.4)	4027 (4.8)	474 (6.6)	5058 (36.5)	3725 (43.2)	33 532 (20.8)	24 274 (27.1)
ARB	6181 (32.3)	349 (39.1)	8855 (39.3)	1718 (40.8)	19 770 (39.1)	6428 (42.5)	18 959 (22.7)	2463 (34.2)	3605 (26.0)	2697 (31.3)	22 656 (14.0)	15 290 (17.1)
SGLT2 inhibitor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	287 (0.6)	66 (0.4)	1082 (1.3)	281 (3.9)	11 (0.1)	11 (0.1)	1171 (0.7)	978 (1.1)
GLD (any)	3300 (17.3)	189 (21.2)	6742 (29.9)	1577 (37.5)	13 108 (25.9)	4255 (28.1)	11 303 (13.5)	2128 (29.5)	5012 (36.2)	4388 (50.9)	29 690 (18.4)	30 569 (34.1)
Antiplatelets	5636 (29.5)	328 (36.8)	5451 (24.2)	1146 (27.2)	23 245 (46.0)	7906 (52.3)	16 690 (19.9)	2106 (29.2)	1274 (9.2)	1202 (13.9)	8256 (5.1)	8052 (9.0)
Loop diuretic	2747 (14.4)	177 (19.8)	8564 (38.0)	1944 (46.2)	15 719 (31.1)	6441 (42.6)	10 346 (12.4)	1633 (22.7)	2720 (19.6)	2843 (33.0)	21 136 (13.1)	22 334 (24.9)
Anticoagulants	2885 (15.1)	133 (14.9)	6838 (30.3)	1344 (31.9)	12 214 (24.2)	3983 (26.3)	12 886 (15.4)	1600 (22.2)	3434 (24.8)	2913 (33.8)	28 521 (17.7)	26 465 (29.5)

Percentages represent the proportion of diagnosed/undiagnosed patients in a specific group (eg, age) or with a specific variable (eg, medical history).

*Diagnosed cases include patients with a corresponding ICD-9/10 diagnosis code for CKD at or within 6 months of study index (date of second qualifying eGFR measurement).

[†]UACR testing data not available in the German Disease Analyzer database.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

‡Direct measurements of UACR were not available in the IQVIA Longitudinal Patient Database in Italy, however, UACR was calculated as urine albumin (mg/dL) divided by urine creatinine (g/dL) if patients had records for both of these variables on the same day.

§Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

¶Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischaemic attack, coronary artery bypass graft and percutaneous coronary intervention.

*Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LCED, Explorys Linked Claims and Electronic Medical Records Data; LDL, low-density lipoprotein; LPD, Longitudinal Patient Database; RWD, Real World Data; SGLT2, sodium-glucose cotransporter-2; THIN, The Health Improvement Network; UACR, urinary albumin-creatinine ratio

For peer review only

1
2
3 Patients with undiagnosed CKD tended to have slightly higher eGFR values than those with
4 diagnosed CKD. A greater proportion of patients with stage 3a CKD were undiagnosed than
5 patients with stage 3b CKD. There were fewer comorbidities such as hypertension, T2D and
6 established cardiovascular disease in patients who were undiagnosed than in those who were
7 diagnosed. Similarly, the proportion of patients taking medicines such as glucose-lowering
8 drugs, loop diuretics, angiotensin-II converting enzyme inhibitors and angiotensin receptor
9 blockers tended to be lower in undiagnosed patients than in those who were diagnosed. In all
10 databases, a greater proportion of stage 3 CKD cases were undiagnosed in female patients
11 than in male patients (**Figure 2B**). Additionally, in all databases, patients aged less than 45
12 years had the lowest proportion of undiagnosed CKD; the prevalence of undiagnosed CKD
13 increased in older age groups in France, Germany, Italy and in the US TriNetX database
14 (**Supplementary Figure 2**).

31 **Factors associated with undiagnosed CKD**

32
33 The proportion of undiagnosed CKD tended to be higher in those without comorbidities at
34 study index versus those with such comorbidities (**Figure 3**). When adjusting for baseline
35 covariates, female patients (vs male patients), patients with CKD stage 3a (vs 3b) and patients
36 without a diagnosis of diabetes or hypertension (vs those with a diagnosis) were consistently
37 more likely to lack a CKD diagnosis before and up to 6 months after index (**Supplementary**
38 **Figure 3**).

49 **Time to CKD diagnosis**

50
51 Among patients who lacked a diagnosis for stage 3 CKD at or before study index, the median
52 (interquartile range [IQR]) follow-up duration was 2.22 (1.18–3.64) years in France, 0.61
53 (0.27–1.03) years in Germany, 3.64 (2.08–4.88) years in Italy, 1.96 (0.84–3.41) years in
54 Japan, 1.28 (0.53–2.34) years in the US LCED database and 1.19 (0.44–2.32) years in the US
55
56
57
58
59
60

1
2
3 TriNetX database. In patients undiagnosed at index, only a small proportion received a
4 diagnosis during follow-up: 686/19 293 patients (3.6%) in France, 1157/23 302 patients
5 (5.0%) in Germany, 8152/52 533 patients (15.5%) in Italy, 3855/84 603 patients (4.6%) in
6 Japan, 3987/15 376 patients (25.9%) in the US LCED database and 44 007/178 410 patients
7 (24.7%) in the US TriNetX database.
8
9
10
11
12
13
14

15
16 Among patients undiagnosed at index, diagnoses tended to accrue slowly over the whole
17 duration of follow-up (**Figure 4**). The proportion of patients with initial eGFR values
18 indicative of stage 3b CKD (≥ 30 and < 45 mL/min/1.73 m²) who received a diagnosis during
19 follow-up was consistently higher than patients with initial eGFR values indicative of stage
20 3a CKD (≥ 45 and < 60 mL/min/1.73 m²; **Figure 4**).
21
22
23
24
25
26
27

28
29 Among all patients undiagnosed at index (regardless of whether they received a diagnosis
30 during follow-up), median time to diagnosis was only calculable using the Kaplan–Meier
31 method for the US TriNetX database, because more than half of the patients in the other
32 databases remained undiagnosed at the end of the study period. In this database, the overall
33 median (IQR) time to diagnosis was 4.75 (4.68–4.82) years.
34
35
36
37
38
39

40
41 After adjusting for selected baseline covariates, in all countries, female patients (vs male
42 patients) and patients with stage 3a CKD at index (vs 3b) were more likely to be diagnosed
43 later during follow-up (**Supplementary Figure 4**). Although less pronounced, patients
44 without a history of comorbidities such as diabetes, heart failure or hypertension had a
45 slightly elevated likelihood of delayed diagnosis (vs patients with a history of these
46 conditions). Older patients also typically had a greater likelihood of delayed diagnosis than
47 patients aged less than 45 years.
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

REVEAL-CKD is a large, multinational, observational study that uses a consistent, strict definition for undiagnosed CKD based on internationally recognised guidelines. By extracting data from contemporary, country-specific databases, the study provides a robust estimate of the prevalence of undiagnosed CKD in countries across the globe. The results from this analysis of six databases from five countries (France, Germany, Italy, Japan and the USA) demonstrate severe shortcomings in the diagnosis of stage 3 CKD. Although there was some variability among countries, the consistently high proportions of undiagnosed stage 3 CKD despite clinical evidence of the disease are highly concerning, as are the low levels of UACR testing. Of note, except in Japan, the prevalence of UACR testing did not appear to be substantially higher even in patients with a diagnosis of stage 3 CKD. UACR testing, however, is necessary for assessing the risk of future progression to kidney failure.²⁸ Missing opportunities for early diagnosis, prognostic assessment and management leaves patients at greater risk of further disease progression and complications, including end-stage renal disease and cardiovascular events.^{6 29-31} Early interventions in CKD have been shown to improve outcomes by slowing CKD progression and reducing cardiovascular risk,^{6 32} and healthcare costs associated with the disease increase substantially as CKD stage advances.³³ It is therefore vital for clinicians to seize the opportunity to diagnose and manage the condition as early as possible to minimise the impact of the disease, both in terms of financial burden and effects on health-related quality of life.

It is reassuring that the patients who have comorbidities that are established risk factors for CKD, such as hypertension and T2D, had higher rates of diagnosis and tended to be diagnosed sooner than patients without these conditions. However, even in patients with these comorbidities, the prevalence of undiagnosed CKD remained high. In the US databases,

1
2
3 which had the lowest rates of undiagnosed CKD, approximately 50% of patients with
4 comorbidities in addition to CKD still lacked a CKD diagnosis. Alarming, this was the case
5 for patients with hypertension, T2D and established cardiovascular disease: groups in which
6 KDIGO recommends screening for CKD,⁶ owing to their elevated risks of CKD progression
7 and associated complications.³⁴⁻³⁶ Without an appropriate CKD diagnosis, opportunities may
8 also be missed to prescribe newer therapies such as sodium-glucose cotransporter-2 inhibitors
9 which have been shown to improve cardiorenal outcomes in patients with CKD.^{37 38}

10
11 We observed that the prevalence of undiagnosed CKD tended to rise with age, and older
12 patients tended to have a higher risk of increased diagnostic delay than younger patients. In
13 elderly patients, physicians may assume that eGFR values indicative of stage 3 CKD are
14 caused by age-related decline of kidney function.^{39 40} However, large population-based
15 studies indicate that even in older adults at lower risk for kidney failure, stage 3 CKD is
16 associated with an elevated risk of mortality, cardiovascular events and acute kidney injury.⁴¹
17 Accordingly, KDIGO guidelines support the use of a single threshold value to define CKD
18 across age subgroups consistent with criteria for other chronic non-communicable diseases.⁵
19 In elderly patients, the effects of late-stage CKD are likely to have a substantial influence on
20 physical and cognitive abilities, medication safety and cardiovascular prognosis.^{2 6 41} It is
21 therefore important that physicians do not underestimate the burden and effects of CKD in
22 elderly patients and initiate guideline-appropriate management in a timely manner. Existing
23 clinical tools (such as confirmatory cystatin C testing in suspected cases of CKD) can help
24 mitigate the risk of overdiagnosis, although these remain underutilised.⁶ CKD management in
25 elderly patients should be adapted taking into consideration factors such as their age, frailty,
26 comedications and comorbidities.

1
2
3 In line with previous studies that suggest CKD is more prevalent in women than in men,^{42 43}
4 the proportion of female patients with stage 3 CKD was higher than in male patients in all
5 countries except Japan. Despite the higher prevalence of CKD in female patients, after
6 adjusting for potential confounding factors, female patients had a higher likelihood of being
7 undiagnosed than male patients in all countries. It has been suggested that the rate of
8 progression of CKD is slower in women than in men,⁴⁴⁻⁴⁷ and physicians may therefore be
9 less likely to diagnose the condition at early stages in women. However, the inequality
10 demonstrated in this study is substantial, and suggests a need for elevated awareness to
11 minimise this gender disparity.

12
13 REVEAL-CKD used the internationally recognised CKD-EPI equation to calculate eGFR
14 values from available serum creatinine measurements.²³ Multiple consecutive eGFR
15 measurements indicative of stage 3 CKD were required to confirm the presence of chronic
16 kidney disease, in line with KDIGO recommendations suggesting a threshold of >90 days to
17 consider the condition to be chronic.⁵ Estimates of the prevalence of undiagnosed stage 3
18 CKD based on a single measurement are likely to be higher, owing to the potential for the
19 inclusion of patients with isolated eGFR measurements within the threshold for stage 3 CKD
20 (as a result of, for example, transient dehydration or acute kidney injury). When calculating
21 eGFR, race was not included as a modifier in line with recent trends among physicians^{24 25}
22 and guidance from expert recommendations.²⁶ Inclusion of the race modifier may have been
23 expected to inflate eGFR in Black patients. Indeed, in a sensitivity analysis performed on the
24 US TriNetX database which included data on race (**Supplementary Table 7**), we saw that a
25 substantial proportion of Black patients (46.1%, corresponding to 9.2% of the overall
26 TriNetX cohort) were reclassified as having stage 2 CKD (eGFR between 60–
27 89 mL/min/1.73 m²) when the race modifier was included in the calculation of eGFR. The
28 inclusion of this modifier may therefore allow CKD to progress further in Black patients

1
2
3 before they receive appropriate diagnosis and intervention. The decision to use the CKD-EPI
4 equation without race was made in part to facilitate comparisons among countries and
5 databases in which race was not available, and also to provide a consistent method of
6 calculating eGFR for measurements taken across a time period where the inclusion of the
7 race modifier was being actively debated.⁴⁸⁻⁵²

15 Some limitations must be kept in mind when interpreting these data. Results from the
16 included countries may not be generalisable to other countries, which could have
17 significantly different diagnostic coding practices, healthcare systems and screening policies;
18 conclusions regarding the observed differences between countries cannot be drawn for
19 similar reasons. The TriNetX and LCED databases contained a high proportion of
20 commercially insured patients, and therefore may not be representative of the overall US
21 population. Furthermore, data licensing issues prevented the pooling of data from multiple
22 databases to provide an overall estimate of the prevalence of undiagnosed CKD. Although
23 serum creatinine is typically included in standard laboratory blood tests, patients who did not
24 require blood tests will be missing from this analysis. As such, there may be a degree of
25 selection bias present in these results toward patients who are being routinely monitored for
26 other conditions, or who are actively seeking healthcare. Confirmatory UACR testing was not
27 necessary to meet the study definition of stage 3 CKD owing to the extremely low levels of
28 UACR testing in most of the cohorts. For the same reason, UACR testing was not included in
29 the multivariate analyses which assessed factors associated with a lack of CKD diagnosis and
30 factors associated with time to CKD diagnosis. The proportion of inpatient versus outpatient
31 encounters was unavailable for many of the databases used, and therefore comparisons
32 between diagnoses in these two settings could not be made. Because many of the databases
33 used did not include data on race, variability in the prevalence of undiagnosed CKD
34 according to race could not be assessed. Because data were collected from between 2015 and
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 2020, physicians may have still been using the race modifier for Black patients. Therefore,
4
5 some Black patients may have been classified as having stage 2 CKD and have been less
6
7 likely to receive a diagnosis as a result. It is important to note that this study focused on
8
9 underdiagnosis for stage 3 CKD; low levels of UACR testing in all countries studied suggest
10
11 that the prevalence of undiagnosed stage 1 and 2 CKD may be even higher. Lastly, there is a
12
13 risk of misclassification if CKD diagnoses were made in clinical settings that do not
14
15 contribute to the databases, or if patients had CKD that was recognised by their healthcare
16
17 providers but was not recorded with an appropriate ICD-9/10 code in the databases. Although
18
19 a lack of such codes may not always indicate that a patient's CKD is undiagnosed, this
20
21 definition of CKD diagnosis has been validated by previous real-world studies,^{8 11 12 27} and
22
23 provides an appropriate surrogate measure for rates of diagnosis in large epidemiological
24
25 studies such as REVEAL-CKD.
26
27
28
29

30
31 In conclusion, this analysis of six large, secondary databases from five countries
32
33 demonstrates that most cases of stage 3 CKD are not diagnosed in a timely manner despite
34
35 clinical evidence of the disease. Furthermore, although patients with existing risk factors for,
36
37 or complications from, CKD were typically more likely to receive a CKD diagnosis, the
38
39 prevalence of undiagnosed CKD in these patients remained alarmingly high. Clear
40
41 opportunities exist for improved diagnosis of stage 3 CKD, particularly in female patients,
42
43 elderly patients and patients at high risk of CKD progression and complications. Future
44
45 research will help to quantify the impact of early diagnosis and initiation of effective
46
47 therapies on the risk of CKD progression, complications and long-term patient outcomes.
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributors

NT, SB, EJP, EW, HC, KJ and PK were responsible for the study concept and design. EJP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MA, EJP and HC developed and conducted the statistical analysis plan. NT, TM, MPS, JBJV, LDN, MA, SB, EJP, EW, HC, KJ and PK were involved in review and editing of manuscript drafts, as well as critical revision of the content during its development. All authors approved the final version of the manuscript before its submission. The corresponding author (NT) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Data availability statement

Data used in this study were obtained from a third party and may not be publicly available. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at <https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>.

Acknowledgments

Medical writing support was provided by Bobby Thompson, MSc(Res), of Oxford PharmaGenesis, Oxford, United Kingdom, and was funded by AstraZeneca. Analysis of data from the IQVIA Longitudinal Patient Database was conducted by Claudio Ripellino and Franca Heiman of IQVIA Solutions S.r.l., Milan, Italy, and was funded by AstraZeneca.

Competing interests

SB, EJP, HC, KJ and EW are employees of AstraZeneca and hold stock options. MA is an employee of AstraZeneca. NT has received grants from AstraZeneca, Boehringer

1
2
3 Ingelheim/Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd
4 and Tricida, Inc, has received honoraria from AstraZeneca, Boehringer Ingelheim/Eli Lilly
5 and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd and Tricida, Inc and
6 holds stock options from Mesentech, Inc, Réribus Therapeutics, Inc, pulseData and Tricida,
7 Inc. MPS has received advisory board fees and honoraria from AstraZeneca, Bayer AG, Vifor
8 Pharma Group and Boehringer Ingelheim/Eli Lilly and Company. LDN has received fees for
9 scientific consultation and/or lectures by Astellas Pharma Inc, AstraZeneca, Mundipharma
10 GmbH and Vifor Pharma Group. PK has received speaker's bureau and advisory board fees
11 from AstraZeneca, Eli Lilly and Company and Novo Nordisk A/S, speaker's fees from Bayer
12 AG and honoraria from AstraZeneca and Eli Lilly and Company. TM and JBV have no
13 conflicts of interest to disclose.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Funding**

31
32 REVEAL-CKD is funded by AstraZeneca (grant number N/A). It is a non-interventional
33 observational study, and as such, no drugs are supplied or funded. AstraZeneca designed the
34 REVEAL-CKD study with input and guidance from the external authors. AstraZeneca
35 provided funding for data collection, management and analysis. An AstraZeneca team
36 reviewed this manuscript for scientific accuracy during its development and was allowed to
37 make suggestions. However, the final content, analysis and interpretation of the data was
38 determined by the authors. The decision to submit the data for publication was determined by
39 the authors.
40
41
42
43
44
45
46
47
48
49
50

51 **Ethics Approval**

52 REVEAL-CKD used de-identified data from existing databases and did not require data
53 collection beyond that of routine clinical care. No identifiable information was collected or
54 examined as part of the study. All externally conducted analyses were completed in line with
55
56
57
58
59
60

1
2
3 local ethics regulations/legislation. De-identified, internally licensed databases were shared
4
5 with AstraZeneca by the licensee; therefore, ethics review and approval was not required for
6
7 the use of these databases for this study.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. *Kidney Int* 2007;72(3):247–59. doi: <https://doi.org/10.1038/sj.ki.5002343>
2. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020;395(10225):709–33. doi: 10.1016/S0140-6736(20)30045-3
3. Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney Int* 2018;94(3):567–81. doi: 10.1016/j.kint.2018.04.011
4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013;382(9889):339–52. doi: 10.1016/s0140-6736(13)60595-4
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013;3:1–150.
6. Shlipak MG, Tummalaipalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2021;99(1):34–47. doi: 10.1016/j.kint.2020.10.012
7. Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. *Pragmat Obs Res* 2016;7:21–32. doi: 10.2147/POR.S97310
8. Ravera M, Noberasco G, Weiss U, et al. CKD awareness and blood pressure control in the primary care hypertensive population. *Am J Kidney Dis* 2011;57(1):71–77. doi: 10.1053/j.ajkd.2010.08.022
9. Gasparini A, Evans M, Coresh J, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. *Nephrol Dial Transplant* 2016;31(12):2086–94. doi: 10.1093/ndt/gfw354
10. Ryan TP, Sloand JA, Winters PC, et al. Chronic kidney disease prevalence and rate of diagnosis. *Am J Med* 2007;120(11):981–86. doi: 10.1016/j.amjmed.2007.05.012
11. Diamantidis CJ, Hale SL, Wang V, et al. Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance. *BMC Nephrol* 2019;20(1):357. doi: 10.1186/s12882-019-1551-3
12. Bakris G. Prevalence and factors associated with undiagnosed chronic kidney disease in diabetes mellitus. National Kidney Foundation 2019 Spring Clinical Meetings. Boston, MA, USA, 2019.
13. Centers for Medicare and Medicaid Services. *Chronic kidney disease often undiagnosed in Medicare beneficiaries*. <https://www.cms.gov/files/document/ckd-data-highlight102020-2.pdf>. Published 2020. Accessed November 22, 2022.
14. Tuttle KR, Alicic RZ, Duru OK, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. *JAMA Network Open* 2019;2(12):e1918169. doi: 10.1001/jamanetworkopen.2019.18169
15. Szczech LA, Stewart RC, Su H-L, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (Awareness, Detection and Drug

- therapy in type 2 diabetes and Chronic Kidney Disease). *PLOS ONE* 2014;9(11):e110535. doi: 10.1371/journal.pone.0110535
16. Kushner P, Peach E, Wittbrodt E, et al. Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study. *Clin Kidney J* 2021;15(4):738–46. doi: 10.1093/ckj/sfab235
17. Cegedim Health Data. *THIN: The Health Improvement Network*. <https://www.cegedim-health-data.com/cegedim-health-data/thin-the-health-improvement-network/>. Published 2021. Accessed November 22, 2022.
18. Rathmann W, Bongaerts B, Carius HJ, et al. Basic characteristics and representativeness of the German Disease Analyzer database *Int J Clin Pharmacol Ther* 2018;56(10):459–66. doi: 10.5414/cp203320
19. Health Search. *XIV Report HealthSearch [Italian]*. https://report.healthsearch.it/Report_XIV.pdf?anno=2022. Published 2021. Accessed November 22, 2022.
20. Ono Y, Taneda Y, Takeshima T, et al. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database. *Clin Epidemiol* 2020;12:367–75. doi: 10.2147/CLEP.S245555
21. Alford SH, Piccone J, Sexton M, et al. Watson Health: a new approach to population health and research. *J Patient Cent Res Rev* 2016;3(3):201.
22. TriNetX. *TriNetX Research*. <https://trinetx.com/trinetx-research/>. Published 2021. Accessed March 12, 2021.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
24. Duggal V, Thomas Ic, Montez-Rath ME, et al. National estimates of CKD prevalence and potential impact of estimating glomerular filtration rate without race. *J Am Soc Nephrol* 2021;32(6):1454. doi: 10.1681/ASN.2020121780
25. Diao JA, Wu GJ, Taylor HA, et al. Clinical implications of removing race from estimates of kidney function. *JAMA* 2021;325(2):184–86. doi: 10.1001/jama.2020.22124
26. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol* 2021;32(12):2994–3015. doi: 10.1681/asn.2021070988
27. Winkelmayr WC, Schneeweiss S, Mogun H, et al. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis* 2005;46(2):225–32. doi: 10.1053/j.ajkd.2005.04.029
28. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. *JAMA* 2011;305(15):1553–59. doi: 10.1001/jama.2011.451
29. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* 2011;79(12):1331–40. doi: 10.1038/ki.2010.550
30. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011;79(12):1341–52. doi: 10.1038/ki.2010.536
31. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis

- of individual participant data. *Lancet Diabetes Endocrinol* 2015;3(7):514–25. doi: 10.1016/s2213-8587(15)00040-6
32. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. *Am J Med* 2011;124(11):1073–80. doi: 10.1016/j.amjmed.2011.04.026
33. Dieguez G, Smith R. *The impact of earlier CKD detection and delayed disease progression*. https://www.milliman.com/-/media/milliman/pdfs/2021-articles/7-13-21-the_impact_of_earlier_ckd_detection_and_delayed.ashx. Published 2021. Accessed November 22, 2022.
34. Rahman M, Xie D, Feldman HI, et al. Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study. *Am J Nephrol* 2014;40(5):399–407. doi: 10.1159/000368915
35. Cabrera CS, Lee AS, Olsson M, et al. Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. *Kidney Int Rep* 2020;5(10):1651–60. doi: 10.1016/j.ekir.2020.07.029
36. Kovesdy CP, Isaman D, Petruski-Ivleva N, et al. Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. *Clin Kidney J* 2020;14(6):1657–64. doi: 10.1093/ckj/sfaa200
37. Fontes-Carvalho R, Santos-Ferreira D, Raz I, et al. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. *Eur J Prev Cardiol* 2021;29(9):1352–60. doi: 10.1093/eurjpc/zwab034
38. Rangaswami J, Bhalla V, Boer IH, et al. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. *Circulation* 2020;142(17):e265–e86. doi: 10.1161/CIR.0000000000000920
39. Glassock RJ, Rule AD. Aging and the Kidneys: Anatomy, Physiology and Consequences for Defining Chronic Kidney Disease. *Nephron* 2016;134(1):25–9. doi: 10.1159/000445450
40. Schmitt R, Melk A. Molecular mechanisms of renal aging. *Kidney Int* 2017;92(3):569–79. doi: 10.1016/j.kint.2017.02.036
41. De Nicola L, Minutolo R, Chiodini P, et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. *Kidney Int* 2012;82(4):482–8. doi: 10.1038/ki.2012.174
42. Carrero JJ, Hecking M, Chesnaye NC, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nat Rev Nephrol* 2018;14(3):151–64. doi: 10.1038/nrneph.2017.181
43. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. *PLoS one* 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765
44. Silbiger S, Neugarten J. Gender and human chronic renal disease. *Gen Med* 2008;5 Suppl A:S3-s10. doi: 10.1016/j.genm.2008.03.002
45. Jafar TH, Schmid CH, Stark PC, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. *Nephrol Dial Transplant* 2003;18(10):2047-53. doi: 10.1093/ndt/gfg317
46. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. *Kidney Int* 2006;69(2):375-82. doi: 10.1038/sj.ki.5000058
47. Swartling O, Rydell H, Stendahl M, et al. CKD progression and mortality among men and women: a nationwide study in Sweden. *Am J Kidney Dis* 2021;78(2):190–99.e1. doi: 10.1053/j.ajkd.2020.11.026

- 1
2
3 48. Diao JA, Inker LA, Levey AS, et al. In search of a better equation — Performance and
4 equity in estimates of kidney function. *New Engl J Med* 2021;384(5):396-99. doi:
5 10.1056/NEJMp2028243
6
7 49. Eneanya ND, Yang W, Reese PP. Reconsidering the consequences of using race to
8 estimate kidney function. *JAMA* 2019;322(2):113-14. doi: 10.1001/jama.2019.5774
9
10 50. Norris KC, Eneanya ND, Boulware LE. Removal of race from estimates of kidney
11 function: first, do no harm. *Jama* 2021;325(2):135-37. doi: 10.1001/jama.2020.23373
12
13 51. Powe NR. Black kidney function matters: use or misuse of race? *JAMA*
14 2020;324(8):737-38. doi: 10.1001/jama.2020.13378
15
16 52. Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight — Reconsidering the use of
17 race correction in clinical algorithms. *New Engl J Med* 2020;383(9):874-82. doi:
18 10.1056/NEJMms2004740
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure Legends

Figure 1. Cohort selection

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LCED, Explorys Linked Claims and Electronic Medical Records Data; LPD, Longitudinal Patient Database; RWD, Real World Data; THIN, The Health Improvement Network.

Figure 2. Overall prevalence of undiagnosed stage 3 CKD according to country and database

Undiagnosed cases are those which lack a diagnosis code for CKD (any stage), any time before and up to 6 months after study index.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Figure 3. Prevalence of undiagnosed stage 3 CKD according to the presence of comorbidities at study index, by country and database

Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischaemic attack, coronary artery bypass graft and percutaneous coronary intervention. Study index is defined as the date of a patient's second qualifying eGFR measurement.

*Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

†Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Figure 4. Kaplan–Meier estimates of time to CKD diagnosis according to country and database in patients undiagnosed at index, overall and by CKD stage (3a/3b)

Shaded areas represent 95% confidence intervals.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Country:	France	Germany	Italy	Japan	USA	USA
Database:	THIN Cegedim	Disease Analyzer	LPD	Japan RWD	LCED 2019	TriNetX

Step 0
All patients in data source




Step 1
Patients with at least two consecutive eGFR measurements with values ≥ 30 and < 60 mL/min/1.73 m² that are > 90 and ≤ 730 days apart, with the second eGFR measurement taken in 2015 or later



Step 2
At least 12 months of continuous registration in the database prior to the index date (for data sources with information on enrollment), and patient age ≥ 18 years



Step 3
Exclude patients with any evidence of advanced CKD (stage 4, 5) or renal replacement therapy prior to study index



Exclusion steps 3 and 4 performed together at this stage for France

The LPD lacks granularity in ICD-9/10 codes to determine CKD stage and history of renal replacement therapy

Step 4
Exclude patients who underwent a solid organ transplant prior to study index





The German Disease Analyzer does not contain procedure data

All patients had at least 1 day of follow-up


Step 5
Exclude patients with no further follow-up data available after study index






1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


France




Germany




Italy




Japan



USA (LCED)




USA (TriNetX)



With comorbid condition
 Without comorbid condition

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SUPPLEMENTARY MATERIALS

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study

Navdeep Tangri,¹ Toshiki Moriyama,² Markus P Schneider,³ Jean Blaise J Virgitti,⁴ Luca De Nicola,⁵ Matthew Arnold,⁶ Salvatore Barone,⁷ Emily J Peach,⁸ Eric Wittbrodt,⁹ Hungta Chen,¹⁰ Krister Järbrink,¹¹ Pamela Kushner¹²

¹ Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

² Osaka University, Suita, Osaka, Japan

³ Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen–Nuremberg, Erlangen, Germany

⁴ Cabinet Médical, Orry-La-Ville, France

⁵ Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit, University of Campania Luigi Vanvitelli, Naples, Italy

⁶ Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

⁷ Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA

⁸ Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

⁹ Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA

1
2
3 ¹⁰ Medical/Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca,
4
5 Gaithersburg, Maryland, USA
6
7

8 ¹¹ Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical,
9
10 AstraZeneca, Gothenburg, Sweden
11
12

13 ¹² Department of Family Medicine, University of California Irvine Medical Center, Orange,
14
15 California, USA
16
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Table 1. Data sources used in the REVEAL-CKD study.

Country	Data source(s)	Database type (EMR/claims)	Coverage
France	THIN: The Health Improvement Network/Cegedim Health Data	EMR	Primary care
Germany	IQVIA Disease Analyzer	EMR	Primary care/endocrinology
Japan	Japan RWD	EMR and claims	Inpatient/outpatient
USA	TriNetX	EMR and claims	Inpatient/outpatient
	LCED	EMR and claims	Inpatient/outpatient
Italy	The Health Search Database/IQVIA Health Solutions Italy	EMR	Primary care

EMR, electronic medical records; LCED, Explorys Linked Claims and Electronic Medical Records Data; RWD, Real World Data.

Supplementary table 2. REVEAL-CKD study inclusion and exclusion criteria**Inclusion criteria:**

- ≥ 2 consecutive eGFR laboratory measurements recorded in 2015 or later, with values ≥ 30 and < 60 mL/min/1.73 m² (stage 3a/3b CKD using the CKD-EPI¹ equation) that are > 90 and ≤ 730 days apart
- ≥ 12 months of continuous presence in the database before the first qualifying eGFR measurement (look-back period)
- Age ≥ 18 years at the index date (defined as the date of the second qualifying laboratory eGFR measurement indicative of stage 3a/3b CKD).

Exclusion criteria:

- Solid organ transplant recorded before the index date
- Any evidence of advanced CKD (stages 4, 5, and end-stage renal disease) based on CKD diagnosis codes or renal replacement therapy before the index date.

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

Supplementary table 3. ICD-9/10 codes used to identify patients with diagnosed stage 3 CKD

Description	ICD-9*	ICD-10†
CKD, stage I	585.1‡	N18.1§
CKD, stage II	585.2	N18.2
CKD, stage III	585.3	N18.3
CKD, stage IV (severe)	585.4	N18.4
CKD, stage V	585.5	N18.5
End-stage renal disease	585.6	N18.6
CKD, unspecified	585.9	N18.9
Hypertensive CKD	403, 403.01, 403.1, 403.11, 403.9, 403.91, 404, 404.01, 404.02, 404.03, 404.1, 404.11, 404.12, 404.13, 404.9, 404.91, 404.92, 404.93	I12.0, I12.9, I13.0, I13.10, I13.11, I13.2
Diabetes with renal manifestation	250.4, 250.41, 250.42, 250.43	E10.2, E11.2, E11.21, E11.22, E11.29
Disorders from impaired renal function	588, 588.1, 588.81, 588.89, 588.9	N25.0, N25.1, N25.81, N25.89, N25.9

*ICD-9 codes were used to identify CKD in Italy and in the US LCED and TriNetX databases.

†ICD 10 codes were used to identify CKD in France, Germany, Japan and the US LCED and TriNetX databases.

‡The ICD-9 code 585 (CKD, unspecified) was included in the code list for Italy owing to the large proportion of non-specific CKD reporting in this database.

§The ICD-10 codes N18 and N18.0 (CKD, unspecified) were included in the code list for France owing to the large proportion of non-specific CKD reporting in this database.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; ICD, International Classification of Diseases.

Supplementary table 4. ICD-9/10 codes used to identify CKD in the sensitivity analysis using a broader definition for CKD adapted from Winkelmayr et al., 2005²

Description	ICD-9*	ICD-10†
CKD, stage I	585.1‡	N18.1§
CKD, stage II	585.2	N18.2
CKD, stage III	585.3	N18.3
CKD, stage IV (severe)	585.4	N18.4
CKD, stage V	585.5	N18.5
End-stage renal disease	585.6	N18.6
CKD, unspecified	585.9	N18.9
Chronic renal insufficiency	582, 582.1, 582.2, 582.4, 582.81, 582.89, 582.9, 583, 583.1, 583.2, 583.4, 583.6, 583.7, 583.81, 583.89, 583.9	N03.0, N03.1, N03.2, N03.3, N03.4, N03.5, N03.6, N03.7, N03.8, N03.9, N05.0, N05.1, N05.2, N05.3, N05.4, N05.5, N05.6, N05.7, N05.8, N05.9, N19, N26.9
Hypertensive CKD	403, 403.01, 403.1, 403.11, 403.9, 403.91, 404, 404.01, 404.02, 404.03, 404.1, 404.11, 404.12, 404.13, 404.9, 404.91, 404.92, 404.93	I12.0, I12.9, I13.0, I13.10, I13.11, I13.2
Diabetes with renal manifestation	250.4, 250.41, 250.42, 250.43	E10.2, E11.2, E11.21, E11.22, E11.29
Disorders from impaired renal function	588, 588.1, 588.81, 588.89, 588.9	N25.0, N25.1, N25.81, N25.89, N25.9, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322, M10.329, M10.331, M10.332, M10.339, M10.341, M10.342, M10.349, M10.351, M10.352, M10.359,

Description	ICD-9*	ICD-10†
Acute renal failure	572.4, 580, 580.4, 580.81, 580.89, 580.9, 584.5, 584.6, 584.7, 584.8, 584.9, 791.2, 791.3	M10.361, M10.362, M10.369, M10.371, M10.372, M10.379, M10.38, M10.39 K76.7, N00.3, N00.8, N00.9, N01.3, N17.0, N17.1, N17.2, N17.8, N17.9, R82.1, R82.3
Miscellaneous	274.1, 440.1, 442.1, 453.3, 581, 581.1, 581.2, 581.3, 581.81, 581.89, 581.9, 586, 587, 593, 593.1, 593.2, 593.3, 593.4, 593.5, 593.6, 593.7, 593.71, 593.72, 593.73, 593.81, 593.82, 593.89, 593.9, 753, 753.3, 866, 866.01, 866.1, 866.11, 866.12, 866.13	I70.1, I72.2, I82.3, N02.2, N04.0, N04.1, N04.2, N04.3, N04.4, N04.5, N04.6, N04.7, N04.8, N04.9, N08, N13.4, N13.5, N13.70, N13.71, N13.721, N13.722, N13.729, N13.731, N13.732, N13.739, N13.8, N28.1, N28.81, N28.82, N28.83, N28.89, N28.9, Q60.2, Q60.5, Q63.0, Q63.1, Q63.2, Q63.3, Q63.8, Q63.9, R80.2, S31.001, S37.009, S37.019, S37.029, S37.039, S37.049, S37.059, S37.069

*ICD-9 codes were used to identify CKD in Italy and in the US LCED and TriNetX databases.

†ICD-10 codes were used to identify CKD in France, Germany, Japan and the US LCED and TriNetX databases.

‡The ICD-9 code 585 (CKD, unspecified) was included in the code list for Italy owing to the large proportion of non-specific CKD reporting in this database.

§The ICD-10 codes N18 and N18.0 (CKD, unspecified) were included in the code list for France owing to the large proportion of non-specific CKD reporting in this database.

CKD, chronic kidney disease; LCED, Explorays Linked Claims and Electronic Medical Records Data; ICD, International Classification of Diseases.

Supplementary table 5. Overall patient characteristics at study index (date of second eGFR measurement) according to country and database

Country	France	Germany	Italy	Japan	USA	
Database	THIN CegeDim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
CKD status*, n (%)						
Diagnosed	892 (4.5)	4210 (15.7)	15 129 (23.0)	7209 (7.9)	8625 (38.4)	89 625 (35.7)
Undiagnosed	19 120 (95.5)	22 557 (84.3)	50 547 (77.0)	83 693 (92.1)	13 845 (61.6)	161 254 (64.3)
Age, y, median (IQR)	80 (72–86)	79 (72–84)	80 (74–85)	76 (69–83)	74 (64–82)	71 (64–78)
Age groups, y						
<45	67 (0.3)	66 (0.2)	188 (0.3)	791 (0.9)	243 (1.1)	5523 (2.2)
45–64	1677 (8.4)	2431 (9.1)	3780 (5.8)	13 286 (14.6)	5991 (26.7)	63 726 (25.4)
65–74	4641 (23.2)	6032 (22.5)	14 264 (21.7)	25 627 (28.2)	5592 (24.9)	87 880 (35.0)
≥75	13 627 (68.1)	18 238 (68.1)	47 444 (72.2)	51 198 (56.3)	10 644 (47.4)	93 750 (37.4)
Male, n (%)	9091 (45.4)	11 216 (41.9)	27 728 (42.2)	48 123 (52.9)	10 051 (44.7)	105 112 (41.9)
eGFR, mL/min/1.73 m², median (IQR)	52 (45–56)	52 (44–56)	49 (42–55)	52 (46–56)	51 (44–56)	51 (44–56)
CKD stage, n (%)						
CKD stage 3a	15 101 (75.5)	19 492 (72.8)	43 937 (66.9)	70 668 (77.7)	16 320 (72.6)	183 618 (73.2)
CKD stage 3b	4911 (24.5)	7275 (27.2)	21 739 (33.1)	20 234 (22.3)	6150 (27.4)	67 261 (26.8)
Baseline UACR available, n (%)	450 (2.2)	0 (0.0) [†]	9 (<0.1) [*]	4992 (5.5)	899 (4.0)	4604 (1.8)
HDL, mmol/L, median (IQR)	1.37 (1.11–1.65)	1.34 (1.10–1.63)	1.32 (1.09–1.58)	1.40 (1.14–1.71)	1.22 (0.98–1.50)	1.22 (0.98–1.50)
Missing, n	6514	8232	17 513	35 305	10 022	138 798
LDL, mmol/L, median (IQR)	2.89 (2.24–3.61)	2.84 (2.17–3.65)	2.69 (2.07–3.36)	2.74 (2.30–3.31)	2.38 (1.84–3.05)	2.38 (1.81–3.05)
Missing, n	6676	7087	19 475	33 589	8936	125 474
Comorbidities, n (%)						
Hypertension	12 412 (62.0)	13 679 (51.1)	51 324 (78.1)	53 022 (58.3)	20 061 (89.3)	203 155 (81.0)
Type 2 diabetes	3532 (17.6)	6935 (25.9)	21 300 (32.4) [§]	18 989 (20.9)	9288 (41.3)	95 441 (38.0)
Established CVD [¶]	1449 (7.2)	1904 (7.1)	6937 (10.6)	25 637 (28.2)	6292 (28.0)	49 744 (19.8)
Heart failure	986 (4.9)	4364 (16.3)	6378 (9.7)	30 063 (33.1)	5314 (23.6)	47 002 (18.7)
Atrial fibrillation	2161 (10.8)	4217 (15.8)	11 105 (16.9)	11 991 (13.2)	4627 (20.6)	41 214 (16.4)
Medication use, n (%)						
ACE inhibitor	4634 (23.2)	9635 (36.0)	25 098 (38.2)	4501 (5.0)	8783 (39.1)	57 806 (23.0)
ARB	6530 (32.6)	10 573 (39.5)	26 198 (39.9)	21 422 (23.6)	6302 (28.0)	37 946 (15.1)
SGLT2 inhibitor	0 (0.0)	0 (0.0)	353 (0.5)	1363 (1.5)	22 (0.1)	2149 (0.9)
GLD (any)	3489 (17.4)	8319 (31.1)	17 363 (26.4)	13 431 (14.8)	9400 (41.8)	60 259 (24.0)
Antiplatelets	5964 (29.8)	6597 (24.6)	31 151 (47.4)	18 796 (20.7)	2476 (11.0)	16 308 (6.5)
Loop diuretic	2924 (14.6)	10 508 (39.3)	22 160 (33.7)	11 979 (13.2)	5563 (24.8)	43 470 (17.3)

Country	France	Germany	Italy	Japan	USA	
Database	THIN Cegedim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
Anticoagulants	3018 (15.1)	8182 (30.6)	16 197 (24.7)	14 486 (15.9)	6347 (28.2)	54 986 (21.9)

Unless otherwise stated, percentages represent the proportion of patients in a specific group (eg, age) or with a specific variable (eg, medical history).

*Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort for each country/database.

†UACR testing data not available in the German Disease Analyzer database.

‡Direct measurements of UACR were not available in the IQVIA Longitudinal Patient Database in Italy, however, UACR was calculated as urine albumin (mg/dL) divided by urine creatinine (g/dL) if patients had records for both of these variables on the same day.

§Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

¶Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

¶¶Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LCED, Explorays Linked Claims and Electronic Medical Records Data; LDL, low-density lipoprotein; LPD, Longitudinal Patient Database; RWD, Real World Data; SGLT2, sodium-glucose cotransporter-2; THIN, The Health Improvement Network; UACR, urinary albumin-creatinine ratio.

For peer review only

Supplementary table 6. Sensitivity analysis of undiagnosed stage 3 CKD using a broader CKD definition adapted from Winkelmayr et al., 2005² according to country and database

Country	France	Germany	Italy	Japan	USA	
Database	THIN Cegedim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
CKD status*, n (%)						
Diagnosed	2031 (10.1)	6165 (23.0)	21 146 (32.2)	12 113 (13.3)	10 421 (46.4)	109 735 (43.7)
Undiagnosed	17 981 (89.9)	20 602 (77.0)	44 530 (67.8)	78 789 (86.7)	12 049 (53.6)	141 144 (56.3)

*Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort for each country/database.


CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; LPD, Longitudinal Patient Database; RWD, Real World Data; THIN, The Health Improvement Network.

Supplementary table 7. Comparison of CKD stages in Black and non-Black patients from the US TriNetX database when calculating eGFR using two different equations: CKD-EPI (without adjusting for race) and CKD-EPI (with race modifier)¹

	CKD-EPI, no race modifier	CKD-EPI, with race modifier
Black (n=50 283)		
Stage 2 CKD, n (%)	0 (0.0)	23 156 (46.1)
Stage 3a CKD, n (%)	36 005 (71.6)	20 455 (40.7)
Stage 3b CKD, n (%)	14 278 (28.4)	6672 (13.3)
Non-Black (n=200 596)		
Stage 2 CKD, n (%)	0 (0.0)	0 (0.0)
Stage 3a CKD, n (%)	147 613 (73.6)	147 613 (73.6)
Stage 3b CKD, n (%)	52 983 (26.4)	52 983 (26.4)


CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

Supplementary figure 1. Prevalence of undiagnosed stage 3 CKD according to calendar year of study index according to country and database




CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 2. Prevalence of undiagnosed stage 3 CKD according to age group at study index according to country and database



CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 3. Factors associated with a lack of CKD diagnosis any time before or up to 6 months after index date according to country and database



Whiskers represent 95% confidence intervals.

*Odds ratios adjusted for covariates at index: sex, age, CKD stage, family history of CKD (not available in France, Germany and Japan), number of clinical visits in year before index, medical history (heart failure, established CVD, diabetes [any type], hypertension, other kidney disease) and medication use (diuretics, β-blockers, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, lipid-lowering drugs, antithrombotic drugs, metformin, glucagon-like peptide receptor-1 inhibitors or sodium-glucose cotransporter-2 inhibitors, and other glucose-lowering drugs).


†Upper 95% confidence interval extends beyond the boundary of the graph.

‡Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

§Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 4. Factors associated with time to CKD diagnosis in patients undiagnosed at index according to country and database



Whiskers represent 95% confidence intervals.

^aHazard ratios adjusted for covariates at index: sex, age, CKD stage, family history of CKD (not available in France, Germany and Japan), number of clinical visits in year before index, medical history (heart failure, established CVD, diabetes [any type], hypertension, other kidney disease) and medication use (diuretics, β -blockers, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, lipid-lowering drugs, antithrombotic drugs, metformin, glucagon-like peptide receptor-1 inhibitors or sodium-glucose cotransporter-2 inhibitors and other glucose-lowering drugs).

^bEstablished CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

^cOwing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; HR, hazard ratio; LCED, Explorys Linked Claims and Electronic Medical Records Data.

References

1. Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
2. Winkelmayr WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis.* 2005;46(2):225–32. doi: 10.1053/j.ajkd.2005.04.029

For peer review only

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	a) Title, page 1, and abstract, page 3 [Design section] b) Abstract, page 3	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	1.1) Abstract, page 3 (Setting section) 1.2) Abstract, page 3 (Setting and Participants sections) 1.3) N/A
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, page 5		
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, page 5		
Methods					
Study Design	4	Present key elements of study design early in the paper	Materials and Methods, page 6 (Study Design)		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Materials and Methods, page 6 (Study Design)		

Participants	6	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	A) Eligibility criteria, follow-up duration and data sources described in Materials and Methods, page 6 and 7 (Study Design)	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>6.1) Materials and Methods, page 7 (Study Design) with full lists of ICD9/10 codes used to identify diagnosed/undiagnosed cases given in Supplementary Materials</p> <p>6.2) N/A (eligible patients were identified based on eGFR which was calculated from serum creatinine as described in Materials and Methods and according to internationally-recognized equations for eGFR calculations)</p> <p>6.3) N/A</p>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Materials and Methods, page 7 (Study Design section)	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	7.1) Full list of ICD9/10 codes used in Supplementary Tables 2 and 3
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).	Materials and Methods, page 6 (Study Design section)		

		Describe comparability of assessment methods if there is more than one group			
Bias	9	Describe any efforts to address potential sources of bias	Materials and Methods, page 7 (Study Design section); potential bias addressed in Discussion, pages 16 and 17		
Study size	10	Explain how the study size was arrived at	N/A (all eligible patients within specified time frame were included)		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	N/A (quantitative variables collected from existing EMR/claims databases; CKD stage groupings based on existing KDIGO guidelines referenced in the manuscript)		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how	Materials and Methods, pages 7 and 8 (Study Design and Statistical Analysis sections)		

		<p>matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>			
Data access and cleaning methods	..			<p>RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.</p> <p>RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.</p>	<p>12.1) Author Contributions section, page 19</p> <p>12.2) N/A</p>
Linkage	..			<p>RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.</p>	12.3) N/A
Results					
Participants	13	<p>(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)</p> <p>(b) Give reasons for non-participation at each stage.</p> <p>(c) Consider use of a flow diagram</p>	<p>a) Results, page 8</p> <p>b) N/A</p> <p>c) Figure 1 (cohort selection)</p>	<p>RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i>, study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.</p>	<p>13.1) Figure 1 (cohort selection); Results, page 8</p>
Descriptive data	14	<p>(a) Give characteristics of study participants (<i>e.g.</i>, demographic,</p>	<p>a) Results, pages 9 and 12</p>		

		<p>clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (e.g., average and total amount)</p>	<p>(Demographics and Clinical Characteristics of Patients with Diagnosed and Undiagnosed CKD section); Table 1 b) Table 1 c) Results, page 12 (Time to CKD Diagnosis section)</p>		
Outcome data	15	<p><i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures</p>	Results, pages 8 and 9		
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p>	<p>a) Results, page 13; confounders for multivariate analyses given in footnotes of supplementary Figure 3 and 4 b) N/A c) N/A</p>		
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and	Results, pages 12 and 13		

		interactions, and sensitivity analyses			
Discussion					
Key results	18	Summarise key results with reference to study objectives	Discussion, page 14		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion, pages 16 and 17 (Strengths and Limitations)	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion, page 17 (Strengths and Limitations)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, page 18 (Conclusions)		
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion, page 17 (Strengths and Limitations)		
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding, page 20		
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Data Availability Statement, page 19; Supplementary Appendix

1 *Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working
2 Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015;
3 in press.

4 *Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

BMJ Open

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-067386.R2
Article Type:	Original research
Date Submitted by the Author:	31-Mar-2023
Complete List of Authors:	Tangri, Navdeep; University of Manitoba, Medicine Moriyama, Toshiki; Osaka University Schneider, Markus P.; Erlangen University Hospital Department of Medicine 4 Nephrology and Hypertension Virgitti, Jean Blaise; Cabinet Médical De Nicola, Luca ; Università degli Studi della Campania Luigi Vanvitelli, Arnold, Matt; AstraZeneca PLC, Real World Evidence Data & Analytics, BioPharmaceuticals Medical Barone, Salvatore; AstraZeneca US, Global Medical Affairs, BioPharmaceuticals Medical Peach, Emily; AstraZeneca PLC, Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical Wittbrodt, Eric; AstraZeneca US, Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical Chen, Hungta; AstraZeneca US, Medical/Payer Evidence Statistics, BioPharmaceuticals Medical Järbrink, Krister; AstraZeneca Sweden, Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical Kushner, Pamela; University of California Irvine Medical Center, Department of Family Medicine
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Epidemiology
Keywords:	NEPHROLOGY, EPIDEMIOLOGY, Chronic renal failure < NEPHROLOGY, Adult nephrology < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Prevalence of undiagnosed stage 3 chronic kidney disease in**
4
5
6 **France, Germany, Italy, Japan and the USA: results from the**
7
8
9 **multinational observational REVEAL-CKD study**
10
11

12 Navdeep Tangri,¹ Toshiki Moriyama,² Markus P Schneider,³ Jean Blaise J Virgitti,⁴ Luca De
13 Nicola,⁵ Matthew Arnold,⁶ Salvatore Barone,⁷ Emily J Peach,⁸ Eric Wittbrodt,⁹ Hungta
14 Chen,¹⁰ Krister Järbrink,¹¹ Pamela Kushner¹²
15
16
17
18
19

20
21
22 ¹Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;
23

24 ²Osaka University, Suita, Osaka, Japan; ³Department of Nephrology and Hypertension,
25 University Hospital Erlangen, University of Erlangen–Nuremberg, Erlangen, Germany;
26
27

28 ⁴Cabinet Médical, Orry-La-Ville, France; ⁵Department of Advanced Medical and Surgical
29 Sciences, Nephrology and Dialysis Unit, University of Campania Luigi Vanvitelli, Naples,
30 Italy; ⁶Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca,
31
32
33

34 Cambridge, UK; ⁷Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca,
35 Gaithersburg, Maryland, USA; ⁸Cardiovascular, Renal and Metabolism Epidemiology,
36
37

38 BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; ⁹Cardiovascular, Renal and
39 Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg,
40
41
42

43 Maryland, USA; ¹⁰Medical/Payer Evidence Statistics, BioPharmaceuticals Medical,
44 AstraZeneca, Gaithersburg, Maryland, USA; ¹¹Cardiovascular, Renal and Metabolism
45
46
47

48 Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden; ¹²Department of
49 Family Medicine, University of California Irvine Medical Center, Orange, California, USA
50
51
52

53
54
55
56 **Corresponding author:** Navdeep Tangri, MD, PhD, Seven Oaks General Hospital, 2LB19-
57 2300 McPhillips Street, Winnipeg, Manitoba, R2V 3M3, Canada (ntangri@sogh.mb.ca)
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Target journal: *BMJ Open*

Word count: 3620/4000

For peer review only

ABSTRACT (298/300 words)

Objectives: REVEAL-CKD aims to estimate the prevalence of, and factors associated with, undiagnosed stage 3 chronic kidney disease (CKD).

Design: Multinational, observational study.

Setting: Data from six country-specific electronic medical records and/or insurance claims databases from five countries (France, Germany, Italy, Japan and the USA [two databases]).

Participants: Eligible participants (≥ 18 years old) had ≥ 2 consecutive estimated glomerular filtration rate (eGFR) measurements (calculated from serum creatinine values, sex and age) taken from 2015 onwards that were indicative of stage 3 CKD (≥ 30 and < 60 mL/min/1.73 m²). Undiagnosed cases lacked an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before, and up to 6 months after, the second qualifying eGFR measurement (study index).

Main outcome measures: The primary outcome was point prevalence of undiagnosed stage 3 CKD. Time to diagnosis was assessed using the Kaplan–Meier approach. Factors associated with lacking a CKD diagnosis and risk of diagnostic delay were assessed using logistic regression adjusted for baseline covariates.

Results: The prevalence of undiagnosed stage 3 CKD was 95.5% (19,120/20,012 patients) in France, 84.3% (22,557/26,767) in Germany, 77.0% (50,547/65,676) in Italy, 92.1% (83,693/90,902) in Japan, 61.6% (13,845/22,470) in the US Explorys LCED database and 64.3% (161,254/250,879) in the US TriNetX database. The prevalence of undiagnosed CKD increased with age. Factors associated with undiagnosed CKD were female sex (vs male, range of odds ratio across countries: 1.29–1.77), stage 3a CKD (vs 3b, 1.81–3.66), no medical history (vs a history) of diabetes (1.26–2.77) or hypertension (1.35–1.78).

Conclusions: There are substantial opportunities to improve stage 3 CKD diagnosis, particularly in female patients and older patients. The low diagnosis rates in patients with

1
2
3 comorbidities that put them at risk of disease progression and complications requires
4
5 attention.
6

7
8 **Trial registration:** NCT04847531
9

10 11 12 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 13
14
15 • REVEAL-CKD uses large, contemporary, country-specific databases to provide
16
17 robust estimates of the prevalence of undiagnosed stage 3 CKD.
- 18
19
20 • The study uses a strict, consistent and internationally recognised definition of stage 3
21
22 CKD to ensure accuracy when calculating the prevalence of diagnosed/undiagnosed
23
24 CKD.
- 25
26
27 • Data from the countries and databases examined may not be representative of other
28
29 countries with substantially different healthcare systems or CKD screening policies.
- 30
31
32 • There is a risk of misclassification of undiagnosed CKD if diagnoses were made in
33
34 environments that did not contribute to the databases used or if diagnosing physicians
35
36 did not use ICD-9/10 codes appropriately.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic kidney disease (CKD) is an established global public health concern.¹ CKD has a significant effect on patients, attributable to direct mortality and morbidity, as well as elevated risk of cardiovascular diseases.² The global prevalence of CKD is rising,³ owing to aging populations and increased prevalence of CKD-associated risk factors including type 2 diabetes (T2D) and hypertension.⁴

Early intervention and appropriate management of CKD is recommended in the internationally recognised Kidney Disease: Improving Global Outcomes (KDIGO) guidelines⁵ to help delay disease progression and reduce the incidence of complications. Furthermore, in 2019, KDIGO held a controversies conference on the topic of early identification and intervention in CKD. The consensus statement from this conference urged action, including the implementation of screening programs and interventions for high-risk individuals.⁶ Early-stage CKD is primarily asymptomatic,⁷ therefore CKD is primarily diagnosed at later disease stages and the initiation of effective interventions is delayed or missed.⁵ Previous studies have demonstrated low levels of diagnosis of early-stage CKD in Italy,⁸ Sweden⁹ and the USA.¹⁰⁻¹⁵ However, these previous studies have been limited to single countries or databases, or at-risk groups such as patients with T2D, and did not assess the prevalence of CKD diagnosis across various subgroups (eg, patients with or without comorbidities). There is a need for contemporary information on the prevalence of, and factors associated with, undiagnosed stage 3 CKD, as well as a need to understand factors associated with diagnostic delay in these patients.

REVEAL-CKD (NCT04847531) is a multinational, observational study designed to fill this evidence gap. REVEAL-CKD aims to quantify the prevalence of, and factors associated with, undiagnosed stage 3 CKD in large populations across several countries.¹⁶ Here, we present

1
2
3 data on the prevalence of, and factors associated with, undiagnosed stage 3 CKD in France,
4
5 Germany, Italy, Japan and the USA.
6
7

8 9 **METHODS**

10 11 12 **Study design**

13
14
15 The study design for REVEAL-CKD has been reported in detail elsewhere,¹⁶ and is
16
17 summarised below.
18
19

20
21 Existing secondary data were extracted from established, verified relevant databases
22
23 containing electronic medical records and/or insurance claims in the countries of interest.
24
25 Data for France were extracted from The Health Improvement Network, a large database of
26
27 anonymised electronic medical records.¹⁷ Data for Germany were extracted from the German
28
29 Disease Analyzer, a database of anonymised longitudinal data on drug prescriptions,
30
31 diagnoses and medical and demographic data contributed by a panel of more than 2500
32
33 physicians in Germany.¹⁸ Data for Italy were extracted from the IQVIA Longitudinal Patient
34
35 Database, a computerised network of over 900 family physicians, which includes anonymised
36
37 data on patient consultations and treatments.¹⁹ Data for Japan were extracted from Japan Real
38
39 World Data, an integrated database of medical information including both electronic medical
40
41 records and claims data.²⁰ Data for the USA were extracted from two separate databases:
42
43 Explorys Linked Claims and Electronic Medical Records Data (LCED), a database of
44
45 inpatient and outpatient medical records and claims data from commercially insured
46
47 individuals,²¹ and TriNetX, a database of integrated electronic medical records and claims
48
49 data from 35 healthcare organisations, which provides clinical patient data from both
50
51 inpatient and outpatient encounters.²² The coverage of each database used is described in
52
53
54
55
56
57

58 **Supplementary table 1.**

59
60

1
2
3 Patients aged ≥ 18 years were included in the analyses if they had at least two consecutive
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patients aged ≥ 18 years were included in the analyses if they had at least two consecutive estimated glomerular filtration rate (eGFR) measurements that fell within the range indicative of stage 3 CKD (≥ 30 and < 60 mL/min/1.73 m²) and were recorded > 90 and ≤ 730 days apart, taken on or after 1 January 2015. The decision to require at least two eGFR measurements with a gap of at least 90 days between each measurement was made to ensure that patients met the requirements for the KDIGO definition of CKD.⁵ In order to investigate the potential impact of requiring two eGFR measurements to classify patients, a sensitivity analysis was performed on data from the TriNetX database that included all patients with at least one eGFR measurement within the range of stage 3 CKD, taken within the same date range used for the main analysis. All patients had at least 12 months of continuous presence in the database before the first qualifying eGFR measurement. Full inclusion and exclusion criteria are shown in **Supplementary table 2**. eGFR was calculated from serum creatinine values, sex and age, using the CKD Epidemiology Collaboration (CKD-EPI) equation.²³ In line with current trends among physicians^{24 25} and guidance from expert recommendations,²⁶ race modifiers were not used in the calculation of eGFR.

To account for potential delays in recording of diagnostic codes, undiagnosed CKD was defined as lacking an International Classification of Diseases (ICD) 9/10 diagnosis code corresponding to CKD (any stage), any time before and up to 6 months after index (date of second qualifying eGFR measurement). The ICD coding system varied by country depending on what was available in each database; the full list of ICD-9/10 codes used to determine diagnosed cases can be found in **Supplementary table 3**. A sensitivity analysis was performed to calculate the overall prevalence of undiagnosed stage 3 CKD using a broader definition of CKD adapted from Winkelmayr et al.²⁷ This sensitivity analysis included diagnostic codes for several additional manifestations of renal disease (**Supplementary table 4**).

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Statistical analysis

Overall prevalence of undiagnosed stage 3 CKD and patient demographic and clinical characteristics at index are presented descriptively. Comorbidities at index were identified using ICD-9/10 codes. Medication use at index was identified by the presence of at least one prescription for a given medication at or in the 12 months before index. Odds ratios for factors associated with being undiagnosed any time before and up to 6 months after index were calculated using logistic regression analysis, adjusted for covariates at index. Hazard ratios for diagnostic delay among patients undiagnosed at index were calculated using Cox regression analysis, adjusted for covariates at index. The Kaplan–Meier method was used to estimate the time to diagnosis among patients undiagnosed at index. Statistical analysis was performed using Python 3.7 and R 4.0.2.

RESULTS

This analysis of patients with stage 3 CKD included 20 012 patients from France, 90 902 patients from Germany, 65 676 patients from Italy, 26 767 patients from Japan, 22 470 patients from the LCED database in the USA, and 250 879 patients from the TriNetX database in the USA (**Figure 1**). Characteristics of these patients at index are shown in **Table 1**.

Table 1. Overall patient characteristics at study index (date of second eGFR measurement) according to country and database

Country	France	Germany	Italy	Japan	USA	
Database	THIN Cegedim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
CKD status*, n (%)						
Diagnosed	892 (4.5)	4210 (15.7)	15 129 (23.0)	7209 (7.9)	8625 (38.4)	89 625 (35.7)
Undiagnosed	19 120 (95.5)	22 557 (84.3)	50 547 (77.0)	83 693 (92.1)	13 845 (61.6)	161 254 (64.3)
Age, y, median (IQR)	80 (72–86)	79 (72–84)	80 (74–85)	76 (69–83)	74 (64–82)	71 (64–78)
Age groups, y						
<45	67 (0.3)	66 (0.2)	188 (0.3)	791 (0.9)	243 (1.1)	5523 (2.2)
45–64	1677 (8.4)	2431 (9.1)	3780 (5.8)	13 286 (14.6)	5991 (26.7)	63 726 (25.4)
65–74	4641 (23.2)	6032 (22.5)	14 264 (21.7)	25 627 (28.2)	5592 (24.9)	87 880 (35.0)
≥75	13 627 (68.1)	18 238 (68.1)	47 444 (72.2)	51 198 (56.3)	10 644 (47.4)	93 750 (37.4)
Male, n (%)	9091 (45.4)	11 216 (41.9)	27 728 (42.2)	48 123 (52.9)	10 051 (44.7)	105 112 (41.9)
eGFR, mL/min/1.73 m², median (IQR)	52 (45–56)	52 (44–56)	49 (42–55)	52 (46–56)	51 (44–56)	51 (44–56)
CKD stage, n (%)						
CKD stage 3a	15 101 (75.5)	19 492 (72.8)	43 937 (66.9)	70 668 (77.7)	16 320 (72.6)	183 618 (73.2)
CKD stage 3b	4911 (24.5)	7275 (27.2)	21 739 (33.1)	20 234 (22.3)	6150 (27.4)	67 261 (26.8)
Baseline UACR available, n (%)	450 (2.2)	0 (0.0) [†]	9 (<0.1) [‡]	4992 (5.5)	899 (4.0)	4604 (1.8)
HDL, mmol/L, median (IQR)	1.37 (1.11–1.65)	1.34 (1.10–1.63)	1.32 (1.09–1.58)	1.40 (1.14–1.71)	1.22 (0.98–1.50)	1.22 (0.98–1.50)
Missing, n	6514	8232	17 513	35 305	10 022	138 798
LDL, mmol/L, median (IQR)	2.89 (2.24–3.61)	2.84 (2.17–3.65)	2.69 (2.07–3.36)	2.74 (2.30–3.31)	2.38 (1.84–3.05)	2.38 (1.81–3.05)
Missing, n	6676	7087	19 475	33 589	8936	125 474
Comorbidities, n (%)						
Hypertension	12 412 (62.0)	13 679 (51.1)	51 324 (78.1)	53 022 (58.3)	20 061 (89.3)	203 155 (81.0)
Type 2 diabetes	3532 (17.6)	6935 (25.9)	21 300 (32.4) [§]	18 989 (20.9)	9288 (41.3)	95 441 (38.0)
Established CVD [¶]	1449 (7.2)	1904 (7.1)	6937 (10.6)	25 637 (28.2)	6292 (28.0)	49 744 (19.8)
Heart failure	986 (4.9)	4364 (16.3)	6378 (9.7)	30 063 (33.1)	5314 (23.6)	47 002 (18.7)
Atrial fibrillation	2161 (10.8)	4217 (15.8)	11 105 (16.9)	11 991 (13.2)	4627 (20.6)	41 214 (16.4)
Medication use, n (%)						
ACE inhibitor	4634 (23.2)	9635 (36.0)	25 098 (38.2)	4501 (5.0)	8783 (39.1)	57 806 (23.0)
ARB	6530 (32.6)	10 573 (39.5)	26 198 (39.9)	21 422 (23.6)	6302 (28.0)	37 946 (15.1)
SGLT2 inhibitor	0 (0.0)	0 (0.0)	353 (0.5)	1363 (1.5)	22 (0.1)	2149 (0.9)
GLD (any)	3489 (17.4)	8319 (31.1)	17 363 (26.4)	13 431 (14.8)	9400 (41.8)	60 259 (24.0)
Antiplatelets	5964 (29.8)	6597 (24.6)	31 151 (47.4)	18 796 (20.7)	2476 (11.0)	16 308 (6.5)
Loop diuretic	2924 (14.6)	10 508 (39.3)	22 160 (33.7)	11 979 (13.2)	5563 (24.8)	43 470 (17.3)

Country	France	Germany	Italy	Japan	USA	
Database	THIN Cegedim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
Anticoagulants	3018 (15.1)	8182 (30.6)	16 197 (24.7)	14 486 (15.9)	6347 (28.2)	54 986 (21.9)

Unless otherwise stated, percentages represent the proportion of patients in a specific group (eg, age) or with a specific variable (eg, medical history).

*Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort for each country/database.

†UACR testing data not available in the German Disease Analyzer database.

‡Direct measurements of UACR were not available in the IQVIA Longitudinal Patient Database in Italy, however, UACR was calculated as urine albumin (mg/dL) divided by urine creatinine (g/dL) if patients had records for both of these variables on the same day.

§Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

¶Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

*Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LCED, Explorys Linked Claims and Electronic Medical Records Data; LDL, low-density lipoprotein; LPD, Longitudinal Patient Database; RWD, Real World Data; SGLT2, sodium-glucose cotransporter-2; THIN, The Health Improvement Network; UACR, urinary albumin-creatinine ratio.

Preprint
Review only

1
2
3 At index, median age was 71–80 years, median eGFR was 49–52 mL/min/1.73 m², 66.9%–
4
5 77.7% of patients had CKD stage 3a (eGFR \geq 45 and <60 mL/min/1.73 m²) and 22.3%–
6
7 33.1% of patients had CKD stage 3b (eGFR \geq 30 and <45 mL/min/1.73 m²). The overall
8
9 prevalence of urinary albumin-creatinine ratio (UACR) testing was very low and ranged from
10
11 1.8% (US, TriNetX) to 5.5% (Japan).
12
13

14 15 **Overall prevalence of undiagnosed stage 3 CKD**

16
17
18 The proportion of patients with stage 3 CKD without a diagnosis at or within 6 months after
19
20 index varied by database, and was 95.5% in France, 84.3% in Germany, 77.0% in Italy,
21
22 92.1% in Japan, 61.6% in the US LCED database and 64.3% in the US TriNetX database
23
24 (Figure 2A). In the sensitivity analysis using a broader set of ICD-9/10 codes to identify
25
26 CKD diagnoses, the prevalence of undiagnosed CKD was 53.6%–89.9% (Supplementary
27
28 table 5). In the sensitivity analysis of 532 921 patients in the TriNetX database who had at
29
30 least one qualifying eGFR measurement, the prevalence of undiagnosed stage 3 CKD was
31
32 82.2% (Supplementary table 6).
33
34
35
36
37

38
39 The proportion of patients with undiagnosed CKD per calendar year at index is shown in
40
41 Supplementary Figure 1. Overall, there were no prevailing trends in the proportion of
42
43 patients with undiagnosed CKD per calendar year, except in Italy, where the proportion of
44
45 undiagnosed CKD tended to increase over time (68.2% undiagnosed in 2015 to 83.1% in
46
47 2020).
48
49

50 51 **Demographics and clinical characteristics of patients with diagnosed and undiagnosed** 52 53 **stage 3 CKD**

54
55
56 Characteristics for patients with diagnosed and undiagnosed stage 3 CKD at index are
57
58 presented in Supplementary Table 7.
59
60

1
2
3 Patients with undiagnosed CKD tended to have slightly higher eGFR values than those with
4 diagnosed CKD. A greater proportion of patients with stage 3a CKD were undiagnosed than
5 patients with stage 3b CKD. There were fewer comorbidities such as hypertension, T2D and
6 established cardiovascular disease in patients who were undiagnosed than in those who were
7 diagnosed. Similarly, the proportion of patients taking medicines such as glucose-lowering
8 drugs, loop diuretics, angiotensin-II converting enzyme inhibitors and angiotensin receptor
9 blockers tended to be lower in undiagnosed patients than in those who were diagnosed. In the
10 sensitivity analysis of 532 921 patients in the US TriNetX database who had at least one
11 qualifying eGFR measurement, the prevalence of comorbidities was lower than in the main
12 cohort (**Supplementary table 6**). In all databases, a greater proportion of stage 3 CKD cases
13 were undiagnosed in female patients than in male patients (**Figure 2B**). Additionally, in all
14 databases, patients aged less than 45 years had the lowest proportion of undiagnosed CKD;
15 the prevalence of undiagnosed CKD increased in older age groups in France, Germany, Italy
16 and in the US TriNetX database (**Supplementary Figure 2**).

36 **Factors associated with undiagnosed CKD**

37
38
39 The proportion of undiagnosed CKD tended to be higher in those without comorbidities at
40 study index versus those with such comorbidities (**Figure 3**). When adjusting for baseline
41 covariates, female patients (vs male patients), patients with CKD stage 3a (vs 3b) and patients
42 without a diagnosis of diabetes or hypertension (vs those with a diagnosis) were consistently
43 more likely to lack a CKD diagnosis before and up to 6 months after index (**Supplementary**
44 **Figure 3**).

54 **Time to CKD diagnosis**

55
56
57 Among patients who lacked a diagnosis for stage 3 CKD at or before study index, the median
58 (interquartile range [IQR]) follow-up duration was 2.22 (1.18–3.64) years in France, 0.61
59
60

1
2
3 (0.27–1.03) years in Germany, 3.64 (2.08–4.88) years in Italy, 1.96 (0.84–3.41) years in
4
5 Japan, 1.28 (0.53–2.34) years in the US LCED database and 1.19 (0.44–2.32) years in the US
6
7 TriNetX database. In patients undiagnosed at index, only a small proportion received a
8
9 diagnosis during follow-up: 686/19 293 patients (3.6%) in France, 1157/23 302 patients
10
11 (5.0%) in Germany, 8152/52 533 patients (15.5%) in Italy, 3855/84 603 patients (4.6%) in
12
13 Japan, 3987/15 376 patients (25.9%) in the US LCED database and 44 007/178 410 patients
14
15 (24.7%) in the US TriNetX database.
16
17
18
19

20
21 Among patients undiagnosed at index, diagnoses tended to accrue slowly over the whole
22
23 duration of follow-up (**Figure 4**). The proportion of patients with initial eGFR values
24
25 indicative of stage 3b CKD (≥ 30 and < 45 mL/min/1.73 m²) who received a diagnosis during
26
27 follow-up was consistently higher than patients with initial eGFR values indicative of stage
28
29 3a CKD (≥ 45 and < 60 mL/min/1.73 m²; **Figure 4**).
30
31

32
33 Among all patients undiagnosed at index (regardless of whether they received a diagnosis
34
35 during follow-up), median time to diagnosis was only calculable using the Kaplan–Meier
36
37 method for the US TriNetX database, because more than half of the patients in the other
38
39 databases remained undiagnosed at the end of the study period. In this database, the overall
40
41 median (IQR) time to diagnosis was 4.75 (4.68–4.82) years.
42
43
44

45
46 After adjusting for selected baseline covariates, in all countries, female patients (vs male
47
48 patients) and patients with stage 3a CKD at index (vs 3b) were more likely to be diagnosed
49
50 later during follow-up (**Supplementary Figure 4**). Although less pronounced, patients
51
52 without a history of comorbidities such as diabetes, heart failure or hypertension had a
53
54 slightly elevated likelihood of delayed diagnosis (vs patients with a history of these
55
56 conditions). Older patients also typically had a greater likelihood of delayed diagnosis than
57
58 patients aged less than 45 years.
59
60

DISCUSSION

REVEAL-CKD is a large, multinational, observational study that uses a consistent, strict definition for undiagnosed CKD based on internationally recognised guidelines. By extracting data from contemporary, country-specific databases, the study provides a robust estimate of the prevalence of undiagnosed CKD in countries across the globe. The results from this analysis of six databases from five countries (France, Germany, Italy, Japan and the USA) demonstrate severe shortcomings in the diagnosis of stage 3 CKD. Although there was some variability among countries, the consistently high proportions of undiagnosed stage 3 CKD despite clinical evidence of the disease are highly concerning, as are the low levels of UACR testing. Of note, except in Japan, the prevalence of UACR testing did not appear to be substantially higher even in patients with a diagnosis of stage 3 CKD. UACR testing, however, is necessary for assessing the risk of future progression to kidney failure.²⁸ Missing opportunities for early diagnosis, prognostic assessment and management leaves patients at greater risk of further disease progression and complications, including end-stage renal disease and cardiovascular events.^{6 29-31} Early interventions in CKD have been shown to improve outcomes by slowing CKD progression and reducing cardiovascular risk,^{6 32} and healthcare costs associated with the disease increase substantially as CKD stage advances.³³ It is therefore vital for clinicians to seize the opportunity to diagnose and manage the condition as early as possible to minimise the impact of the disease, both in terms of financial burden and effects on health-related quality of life.

It is reassuring that the patients who have comorbidities that are established risk factors for CKD, such as hypertension and T2D, had higher rates of diagnosis and tended to be diagnosed sooner than patients without these conditions. However, even in patients with these comorbidities, the prevalence of undiagnosed CKD remained high. In the US databases,

1
2
3 which had the lowest rates of undiagnosed CKD, approximately 50% of patients with
4 comorbidities in addition to CKD still lacked a CKD diagnosis. Alarming, this was the case
5 for patients with hypertension, T2D and established cardiovascular disease: groups in which
6 KDIGO recommends screening for CKD,⁶ owing to their elevated risks of CKD progression
7 and associated complications.³⁴⁻³⁶ Without an appropriate CKD diagnosis, opportunities may
8 also be missed to prescribe newer therapies such as sodium-glucose cotransporter-2 inhibitors
9 which have been shown to improve cardiorenal outcomes in patients with CKD.^{37 38}

10
11 We observed that the prevalence of undiagnosed CKD tended to rise with age, and older
12 patients tended to have a higher risk of increased diagnostic delay than younger patients. In
13 elderly patients, physicians may assume that eGFR values indicative of stage 3 CKD are
14 caused by age-related decline of kidney function.^{39 40} However, large population-based
15 studies indicate that even in older adults at lower risk for kidney failure, stage 3 CKD is
16 associated with an elevated risk of mortality, cardiovascular events and acute kidney injury.⁴¹
17 Accordingly, KDIGO guidelines support the use of a single threshold value to define CKD
18 across age subgroups consistent with criteria for other chronic non-communicable diseases.⁵
19 In elderly patients, the effects of late-stage CKD are likely to have a substantial influence on
20 physical and cognitive abilities, medication safety and cardiovascular prognosis.^{2 6 41} It is
21 therefore important that physicians do not underestimate the burden and effects of CKD in
22 elderly patients and initiate guideline-appropriate management in a timely manner. Existing
23 clinical tools (such as confirmatory cystatin C testing in suspected cases of CKD) can help
24 mitigate the risk of overdiagnosis, although these remain underutilised.⁶ CKD management in
25 elderly patients should be adapted taking into consideration factors such as their age, frailty,
26 comedications and comorbidities.

1
2
3 In line with previous studies that suggest CKD is more prevalent in women than in men,^{42 43}
4 the proportion of female patients with stage 3 CKD was higher than in male patients in all
5 countries except Japan. Despite the higher prevalence of CKD in female patients, after
6 adjusting for potential confounding factors, female patients had a higher likelihood of being
7 undiagnosed than male patients in all countries. It has been suggested that the rate of
8 progression of CKD is slower in women than in men,⁴⁴⁻⁴⁷ and physicians may therefore be
9 less likely to diagnose the condition at early stages in women. However, the inequality
10 demonstrated in this study is substantial, and suggests a need for elevated awareness to
11 minimise this gender disparity.
12
13
14
15
16
17
18
19
20
21
22
23

24 REVEAL-CKD used the internationally recognised CKD-EPI equation to calculate eGFR
25 values from available serum creatinine measurements.²³ Multiple consecutive eGFR
26 measurements indicative of stage 3 CKD were required to confirm the presence of CKD, in
27 line with KDIGO recommendations suggesting a threshold of >90 days to consider the
28 condition to be chronic.⁵ This decision was made to conform to these widely used guidelines,
29 and to avoid overestimating the prevalence of undiagnosed stage 3 CKD by including
30 patients who had isolated eGFR measurements within the threshold of inclusion for stage 3
31 CKD (as a result of, for example, transient dehydration or acute kidney injury). To
32 investigate the potential impact of requiring two qualifying eGFR measurements for inclusion
33 in REVEAL-CKD, a sensitivity analysis was performed using the TriNetX database that
34 included patients with at least one eGFR measurement indicative of stage 3 CKD. Among
35 these patients, the prevalence of undiagnosed stage 3 CKD was higher than in the main
36 REVEAL-CKD cohort (82.2% versus 64.3%, respectively), whereas the prevalence of
37 comorbidities was lower. This suggests that the requirement of multiple eGFR measurements
38 may have biased the sample to select for patients with inherently poorer health status,
39 because they may have been receiving more frequent healthcare visits than those with a
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 single measurement, and therefore may have had more eGFR measurements taken. Although
4
5 it is difficult to confirm which patients in this sensitivity analysis truly had stage 3 CKD and
6
7 who were included as a result of transient eGFR dips, it should be noted that these findings
8
9 suggest that the true prevalence of undiagnosed stage 3 CKD may be even higher than
10
11 identified in the present study.
12
13
14

15
16 When calculating eGFR, race was not included as a modifier in line with recent trends among
17
18 physicians^{24 25} and guidance from expert recommendations.²⁶ Inclusion of the race modifier
19
20 may have been expected to inflate eGFR in Black patients. Indeed, in a sensitivity analysis
21
22 performed on the US TriNetX database which included data on race (**Supplementary Table**
23
24 **8**), we saw that a substantial proportion of Black patients (46.1%, corresponding to 9.2% of
25
26 the overall TriNetX cohort) were reclassified as having stage 2 CKD (eGFR between 60–
27
28 89 mL/min/1.73 m²) when the race modifier was included in the calculation of eGFR. The
29
30 inclusion of this modifier may therefore allow CKD to progress further in Black patients
31
32 before they receive appropriate diagnosis and intervention. The decision to use the CKD-EPI
33
34 equation without race was made in part to facilitate comparisons among countries and
35
36 databases in which race was not available, and also to provide a consistent method of
37
38 calculating eGFR for measurements taken across a time period where the inclusion of the
39
40 race modifier was being actively debated.⁴⁸⁻⁵²
41
42
43
44
45

46
47 Some limitations must be kept in mind when interpreting these data. Results from the
48
49 included countries may not be generalisable to other countries, which could have
50
51 significantly different diagnostic coding practices, healthcare systems and screening policies;
52
53 conclusions regarding the observed differences between countries cannot be drawn for
54
55 similar reasons. The TriNetX and LCED databases contained a high proportion of
56
57 commercially insured patients, and therefore may not be representative of the overall US
58
59
60

1
2
3 population. Furthermore, data licensing issues prevented the pooling of data from multiple
4
5 databases to provide an overall estimate of the prevalence of undiagnosed CKD.
6

7
8 Confirmatory UACR testing was not necessary to meet the study definition of stage 3 CKD
9

10 owing to the extremely low levels of UACR testing in most of the cohorts. For the same
11
12 reason, UACR testing was not included in the multivariate analyses which assessed factors
13
14 associated with a lack of CKD diagnosis and factors associated with time to CKD diagnosis.
15

16
17 The proportion of inpatient versus outpatient encounters was unavailable for many of the
18
19 databases used, and therefore comparisons between diagnoses in these two settings could not
20
21 be made. Because many of the databases used did not include data on race, variability in the
22
23 prevalence of undiagnosed CKD according to race could not be assessed. Because data were
24
25 collected from between 2015 and 2020, physicians may have still been using the race
26
27 modifier for Black patients. Therefore, some Black patients may have been classified as
28
29 having stage 2 CKD and have been less likely to receive a diagnosis as a result. It is
30
31 important to note that this study focused on underdiagnosis for stage 3 CKD; low levels of
32
33 UACR testing in all countries studied suggest that the prevalence of undiagnosed stage 1 and
34
35 2 CKD may be even higher. Lastly, there is a risk of misclassification if CKD diagnoses were
36
37 made in clinical settings that do not contribute to the databases, or if patients had CKD that
38
39 was recognised by their healthcare providers but was not recorded with an appropriate ICD-
40
41 9/10 code in the databases. Although a lack of such codes may not always indicate that a
42
43 patient's CKD is undiagnosed, this definition of CKD diagnosis has been validated by
44
45 previous real-world studies,^{8 11 12 27} and provides an appropriate surrogate measure for rates of
46
47 diagnosis in large epidemiological studies such as REVEAL-CKD.
48
49
50
51
52
53

54
55 In conclusion, this analysis of six large, secondary databases from five countries
56
57 demonstrates that most cases of stage 3 CKD are not diagnosed in a timely manner despite
58
59 clinical evidence of the disease. Furthermore, although patients with existing risk factors for,
60

1
2
3 or complications from, CKD were typically more likely to receive a CKD diagnosis, the
4 prevalence of undiagnosed CKD in these patients remained alarmingly high. Clear
5 opportunities exist for improved diagnosis of stage 3 CKD, particularly in female patients,
6 elderly patients and patients at high risk of CKD progression and complications. Future
7 research will help to quantify the impact of early diagnosis and initiation of effective
8 therapies on the risk of CKD progression, complications and long-term patient outcomes.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Contributors

NT, SB, EJP, EW, HC, KJ and PK were responsible for the study concept and design. EJP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MA, EJP and HC developed and conducted the statistical analysis plan. NT, TM, MPS, JBJV, LDN, MA, SB, EJP, EW, HC, KJ and PK were involved in review and editing of manuscript drafts, as well as critical revision of the content during its development. All authors approved the final version of the manuscript before its submission. The corresponding author (NT) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Data availability statement

Data used in this study were obtained from a third party and may not be publicly available. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at <https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>.

Acknowledgments

Medical writing support was provided by Bobby Thompson, MSc(Res), of Oxford PharmaGenesis, Oxford, United Kingdom, and was funded by AstraZeneca. Analysis of data from the IQVIA Longitudinal Patient Database was conducted by Claudio Ripellino and Franca Heiman of IQVIA Solutions S.r.l., Milan, Italy, and was funded by AstraZeneca.

Competing interests

SB, EJP, HC, KJ and EW are employees of AstraZeneca and hold stock options. MA is an employee of AstraZeneca. NT has received grants from AstraZeneca, Boehringer

1
2
3 Ingelheim/Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd
4 and Tricida, Inc, has received honoraria from AstraZeneca, Boehringer Ingelheim/Eli Lilly
5 and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co, Ltd and Tricida, Inc and
6 holds stock options from Mesentech, Inc, Réribus Therapeutics, Inc, pulseData and Tricida,
7 Inc. MPS has received advisory board fees and honoraria from AstraZeneca, Bayer AG, Vifor
8 Pharma Group and Boehringer Ingelheim/Eli Lilly and Company. LDN has received fees for
9 scientific consultation and/or lectures by Astellas Pharma Inc, AstraZeneca, Mundipharma
10 GmbH and Vifor Pharma Group. PK has received speaker's bureau and advisory board fees
11 from AstraZeneca, Eli Lilly and Company and Novo Nordisk A/S, speaker's fees from Bayer
12 AG and honoraria from AstraZeneca and Eli Lilly and Company. TM and JBV have no
13 conflicts of interest to disclose.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Funding**

31
32 REVEAL-CKD is funded by AstraZeneca (grant number N/A). It is a non-interventional
33 observational study, and as such, no drugs are supplied or funded. AstraZeneca designed the
34 REVEAL-CKD study with input and guidance from the external authors. AstraZeneca
35 provided funding for data collection, management and analysis. An AstraZeneca team
36 reviewed this manuscript for scientific accuracy during its development and was allowed to
37 make suggestions. However, the final content, analysis and interpretation of the data was
38 determined by the authors. The decision to submit the data for publication was determined by
39 the authors.
40
41
42
43
44
45
46
47
48
49
50

51 **Ethics Approval**

52 REVEAL-CKD used de-identified data from existing databases and did not require data
53 collection beyond that of routine clinical care. No identifiable information was collected or
54 examined as part of the study. All externally conducted analyses were completed in line with
55
56
57
58
59
60

1
2
3 local ethics regulations/legislation. De-identified, internally licensed databases were shared
4
5 with AstraZeneca by the licensee; therefore, ethics review and approval was not required for
6
7 the use of these databases for this study.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. *Kidney Int* 2007;72(3):247–59. doi: <https://doi.org/10.1038/sj.ki.5002343>
2. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020;395(10225):709–33. doi: 10.1016/S0140-6736(20)30045-3
3. Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney Int* 2018;94(3):567–81. doi: 10.1016/j.kint.2018.04.011
4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013;382(9889):339–52. doi: 10.1016/s0140-6736(13)60595-4
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013;3:1–150.
6. Shlipak MG, Tummalaipalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2021;99(1):34–47. doi: 10.1016/j.kint.2020.10.012
7. Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. *Pragmat Obs Res* 2016;7:21–32. doi: 10.2147/POR.S97310
8. Ravera M, Noberasco G, Weiss U, et al. CKD awareness and blood pressure control in the primary care hypertensive population. *Am J Kidney Dis* 2011;57(1):71–77. doi: 10.1053/j.ajkd.2010.08.022
9. Gasparini A, Evans M, Coresh J, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. *Nephrol Dial Transplant* 2016;31(12):2086–94. doi: 10.1093/ndt/gfw354
10. Ryan TP, Sloand JA, Winters PC, et al. Chronic kidney disease prevalence and rate of diagnosis. *Am J Med* 2007;120(11):981–86. doi: 10.1016/j.amjmed.2007.05.012
11. Diamantidis CJ, Hale SL, Wang V, et al. Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance. *BMC Nephrol* 2019;20(1):357. doi: 10.1186/s12882-019-1551-3
12. Bakris G. Prevalence and factors associated with undiagnosed chronic kidney disease in diabetes mellitus. National Kidney Foundation 2019 Spring Clinical Meetings. Boston, MA, USA, 2019.
13. Centers for Medicare and Medicaid Services. *Chronic kidney disease often undiagnosed in Medicare beneficiaries*. <https://www.cms.gov/files/document/ckd-data-highlight102020-2.pdf>. Published 2020. Accessed November 22, 2022.
14. Tuttle KR, Alicic RZ, Duru OK, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. *JAMA Network Open* 2019;2(12):e1918169. doi: 10.1001/jamanetworkopen.2019.18169
15. Szczech LA, Stewart RC, Su H-L, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (Awareness, Detection and Drug

- therapy in type 2 diabetes and Chronic Kidney Disease). *PLOS ONE* 2014;9(11):e110535. doi: 10.1371/journal.pone.0110535
16. Kushner P, Peach E, Wittbrodt E, et al. Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study. *Clin Kidney J* 2021;15(4):738–46. doi: 10.1093/ckj/sfab235
17. Cegedim Health Data. *THIN: The Health Improvement Network*. <https://www.cegedim-health-data.com/cegedim-health-data/thin-the-health-improvement-network/>. Published 2021. Accessed November 22, 2022.
18. Rathmann W, Bongaerts B, Carius HJ, et al. Basic characteristics and representativeness of the German Disease Analyzer database *Int J Clin Pharmacol Ther* 2018;56(10):459–66. doi: 10.5414/cp203320
19. Health Search. *XIV Report HealthSearch [Italian]*. https://report.healthsearch.it/Report_XIV.pdf?anno=2022. Published 2021. Accessed November 22, 2022.
20. Ono Y, Taneda Y, Takeshima T, et al. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database. *Clin Epidemiol* 2020;12:367–75. doi: 10.2147/CLEP.S245555
21. Alford SH, Piccone J, Sexton M, et al. Watson Health: a new approach to population health and research. *J Patient Cent Res Rev* 2016;3(3):201.
22. TriNetX. *TriNetX Research*. <https://trinetx.com/trinetx-research/>. Published 2021. Accessed March 12, 2021.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
24. Duggal V, Thomas Ic, Montez-Rath ME, et al. National estimates of CKD prevalence and potential impact of estimating glomerular filtration rate without race. *J Am Soc Nephrol* 2021;32(6):1454. doi: 10.1681/ASN.2020121780
25. Diao JA, Wu GJ, Taylor HA, et al. Clinical implications of removing race from estimates of kidney function. *JAMA* 2021;325(2):184–86. doi: 10.1001/jama.2020.22124
26. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol* 2021;32(12):2994–3015. doi: 10.1681/asn.2021070988
27. Winkelmayr WC, Schneeweiss S, Mogun H, et al. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis* 2005;46(2):225–32. doi: 10.1053/j.ajkd.2005.04.029
28. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. *JAMA* 2011;305(15):1553–59. doi: 10.1001/jama.2011.451
29. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* 2011;79(12):1331–40. doi: 10.1038/ki.2010.550
30. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011;79(12):1341–52. doi: 10.1038/ki.2010.536
31. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis

- of individual participant data. *Lancet Diabetes Endocrinol* 2015;3(7):514–25. doi: 10.1016/s2213-8587(15)00040-6
32. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. *Am J Med* 2011;124(11):1073–80. doi: 10.1016/j.amjmed.2011.04.026
33. Dieguez G, Smith R. *The impact of earlier CKD detection and delayed disease progression*. https://www.milliman.com/-/media/milliman/pdfs/2021-articles/7-13-21-the_impact_of_earlier_ckd_detection_and_delayed.ashx. Published 2021. Accessed November 22, 2022.
34. Rahman M, Xie D, Feldman HI, et al. Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study. *Am J Nephrol* 2014;40(5):399–407. doi: 10.1159/000368915
35. Cabrera CS, Lee AS, Olsson M, et al. Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. *Kidney Int Rep* 2020;5(10):1651–60. doi: 10.1016/j.ekir.2020.07.029
36. Kovesdy CP, Isaman D, Petruski-Ivleva N, et al. Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. *Clin Kidney J* 2020;14(6):1657–64. doi: 10.1093/ckj/sfaa200
37. Fontes-Carvalho R, Santos-Ferreira D, Raz I, et al. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. *Eur J Prev Cardiol* 2021;29(9):1352–60. doi: 10.1093/eurjpc/zwab034
38. Rangaswami J, Bhalla V, Boer IH, et al. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. *Circulation* 2020;142(17):e265–e86. doi: 10.1161/CIR.0000000000000920
39. Glassock RJ, Rule AD. Aging and the Kidneys: Anatomy, Physiology and Consequences for Defining Chronic Kidney Disease. *Nephron* 2016;134(1):25–9. doi: 10.1159/000445450
40. Schmitt R, Melk A. Molecular mechanisms of renal aging. *Kidney Int* 2017;92(3):569–79. doi: 10.1016/j.kint.2017.02.036
41. De Nicola L, Minutolo R, Chiodini P, et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. *Kidney Int* 2012;82(4):482–8. doi: 10.1038/ki.2012.174
42. Carrero JJ, Hecking M, Chesnaye NC, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nat Rev Nephrol* 2018;14(3):151–64. doi: 10.1038/nrneph.2017.181
43. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. *PLoS one* 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765
44. Silbiger S, Neugarten J. Gender and human chronic renal disease. *Gen Med* 2008;5 Suppl A:S3-s10. doi: 10.1016/j.genm.2008.03.002
45. Jafar TH, Schmid CH, Stark PC, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. *Nephrol Dial Transplant* 2003;18(10):2047-53. doi: 10.1093/ndt/gfg317
46. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. *Kidney Int* 2006;69(2):375-82. doi: 10.1038/sj.ki.5000058
47. Swartling O, Rydell H, Stendahl M, et al. CKD progression and mortality among men and women: a nationwide study in Sweden. *Am J Kidney Dis* 2021;78(2):190–99.e1. doi: 10.1053/j.ajkd.2020.11.026

- 1
2
3 48. Diao JA, Inker LA, Levey AS, et al. In search of a better equation — Performance and
4 equity in estimates of kidney function. *New Engl J Med* 2021;384(5):396-99. doi:
5 10.1056/NEJMp2028243
6
7 49. Eneanya ND, Yang W, Reese PP. Reconsidering the consequences of using race to
8 estimate kidney function. *JAMA* 2019;322(2):113-14. doi: 10.1001/jama.2019.5774
9
10 50. Norris KC, Eneanya ND, Boulware LE. Removal of race from estimates of kidney
11 function: first, do no harm. *Jama* 2021;325(2):135-37. doi: 10.1001/jama.2020.23373
12
13 51. Powe NR. Black kidney function matters: use or misuse of race? *JAMA*
14 2020;324(8):737-38. doi: 10.1001/jama.2020.13378
15
16 52. Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight — Reconsidering the use of
17 race correction in clinical algorithms. *New Engl J Med* 2020;383(9):874-82. doi:
18 10.1056/NEJMms2004740
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure Legends

Figure 1. Cohort selection

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LCED, Explorers Linked Claims and Electronic Medical Records Data; LPD, Longitudinal Patient Database; RWD, Real World Data; THIN, The Health Improvement Network.

Figure 2. Prevalence of undiagnosed stage 3 CKD according to country and database (A) overall and (B) by sex

Undiagnosed cases are those which lack a diagnosis code for CKD (any stage), any time before and up to 6 months after study index.

CKD, chronic kidney disease; LCED, Explorers Linked Claims and Electronic Medical Records Data.

Figure 3. Prevalence of undiagnosed stage 3 CKD according to the presence of comorbidities at study index, by country and database

Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischaemic attack, coronary artery bypass graft and percutaneous coronary intervention. Study index is defined as the date of a patient's second qualifying eGFR measurement.

*Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

†Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; LCED, Explorers Linked Claims and Electronic Medical Records Data.

Figure 4. Kaplan–Meier estimates of time to CKD diagnosis according to country and database in patients undiagnosed at index, overall and by CKD stage (3a/3b)

Shaded areas represent 95% confidence intervals.

CKD, chronic kidney disease; LCED, Explorers Linked Claims and Electronic Medical Records Data.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Country:	France	Germany	Italy	Japan	USA	USA
Database:	THIN Cegedim	Disease Analyzer	LPD	Japan RWD	LCED 2019	TriNetX

Step 0
All patients in data source




Step 1
Patients with at least two consecutive eGFR measurements with values ≥ 30 and < 60 mL/min/1.73 m² that are > 90 and ≤ 730 days apart, with the second eGFR measurement taken in 2015 or later



Step 2
At least 12 months of continuous registration in the database prior to the index date (for data sources with information on enrollment), and patient age ≥ 18 years



Step 3
Exclude patients with any evidence of advanced CKD (stage 4, 5) or renal replacement therapy prior to study index



Exclusion steps 3 and 4 performed together at this stage for France

The LPD lacks granularity in ICD-9/10 codes to determine CKD stage and history of renal replacement therapy

Step 4
Exclude patients who underwent a solid organ transplant prior to study index





The German Disease Analyzer does not contain procedure data

All patients had at least 1 day of follow-up


Step 5
Exclude patients with no further follow-up data available after study index






1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


France




Germany




Italy




Japan



USA (LCED)




USA (TriNetX)



With comorbid condition
 Without comorbid condition

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SUPPLEMENTARY MATERIALS

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study

Navdeep Tangri,¹ Toshiki Moriyama,² Markus P Schneider,³ Jean Blaise J Virgitti,⁴ Luca De Nicola,⁵ Matthew Arnold,⁶ Salvatore Barone,⁷ Emily J Peach,⁸ Eric Wittbrodt,⁹ Hungta Chen,¹⁰ Krister Järbrink,¹¹ Pamela Kushner¹²

¹ Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

² Osaka University, Suita, Osaka, Japan

³ Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen–Nuremberg, Erlangen, Germany

⁴ Cabinet Médical, Orry-La-Ville, France

⁵ Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit, University of Campania Luigi Vanvitelli, Naples, Italy

⁶ Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

⁷ Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA

⁸ Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

⁹ Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA

1
2
3 ¹⁰ Medical/Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca,
4
5 Gaithersburg, Maryland, USA
6
7

8 ¹¹ Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical,
9
10 AstraZeneca, Gothenburg, Sweden
11
12

13 ¹² Department of Family Medicine, University of California Irvine Medical Center, Orange,
14
15 California, USA
16
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary table 1. Data sources used in the REVEAL-CKD study.

Country	Data source(s)	Database type (EMR/claims)	Coverage
France	THIN: The Health Improvement Network/Cegedim Health Data	EMR	Primary care
Germany	IQVIA Disease Analyzer	EMR	Primary care/endocrinology
Japan	Japan RWD	EMR and claims	Inpatient/outpatient
USA	TriNetX	EMR and claims	Inpatient/outpatient
	LCED	EMR and claims	Inpatient/outpatient
Italy	The Health Search Database/IQVIA Health Solutions Italy	EMR	Primary care

EMR, electronic medical records; LCED, Explorys Linked Claims and Electronic Medical Records Data; RWD, Real World Data.

Supplementary table 2. REVEAL-CKD study inclusion and exclusion criteria**Inclusion criteria:**

- ≥ 2 consecutive eGFR laboratory measurements recorded in 2015 or later, with values ≥ 30 and < 60 mL/min/1.73 m² (stage 3a/3b CKD using the CKD-EPI¹ equation) that are > 90 and ≤ 730 days apart
- ≥ 12 months of continuous presence in the database before the first qualifying eGFR measurement (look-back period)
- Age ≥ 18 years at the index date (defined as the date of the second qualifying laboratory eGFR measurement indicative of stage 3a/3b CKD).

Exclusion criteria:

- Solid organ transplant recorded before the index date
- Any evidence of advanced CKD (stages 4, 5, and end-stage renal disease) based on CKD diagnosis codes or renal replacement therapy before the index date.

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

Supplementary table 3. ICD-9/10 codes used to identify patients with diagnosed stage 3 CKD

Description	ICD-9*	ICD-10†
CKD, stage I	585.1‡	N18.1§
CKD, stage II	585.2	N18.2
CKD, stage III	585.3	N18.3
CKD, stage IV (severe)	585.4	N18.4
CKD, stage V	585.5	N18.5
End-stage renal disease	585.6	N18.6
CKD, unspecified	585.9	N18.9
Hypertensive CKD	403, 403.01, 403.1, 403.11, 403.9, 403.91, 404, 404.01, 404.02, 404.03, 404.1, 404.11, 404.12, 404.13, 404.9, 404.91, 404.92, 404.93	I12.0, I12.9, I13.0, I13.10, I13.11, I13.2
Diabetes with renal manifestation	250.4, 250.41, 250.42, 250.43	E10.2, E11.2, E11.21, E11.22, E11.29
Disorders from impaired renal function	588, 588.1, 588.81, 588.89, 588.9	N25.0, N25.1, N25.81, N25.89, N25.9

*ICD-9 codes were used to identify CKD in Italy and in the US LCED and TriNetX databases.

†ICD 10 codes were used to identify CKD in France, Germany, Japan and the US LCED and TriNetX databases.

‡The ICD-9 code 585 (CKD, unspecified) was included in the code list for Italy owing to the large proportion of non-specific CKD reporting in this database.

§The ICD-10 codes N18 and N18.0 (CKD, unspecified) were included in the code list for France owing to the large proportion of non-specific CKD reporting in this database.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; ICD, International Classification of Diseases.

Supplementary table 4. ICD-9/10 codes used to identify CKD in the sensitivity analysis using a broader definition for CKD adapted from Winkelmayr et al., 2005²

Description	ICD-9*	ICD-10†
CKD, stage I	585.1‡	N18.1§
CKD, stage II	585.2	N18.2
CKD, stage III	585.3	N18.3
CKD, stage IV (severe)	585.4	N18.4
CKD, stage V	585.5	N18.5
End-stage renal disease	585.6	N18.6
CKD, unspecified	585.9	N18.9
Chronic renal insufficiency	582, 582.1, 582.2, 582.4, 582.81, 582.89, 582.9, 583, 583.1, 583.2, 583.4, 583.6, 583.7, 583.81, 583.89, 583.9	N03.0, N03.1, N03.2, N03.3, N03.4, N03.5, N03.6, N03.7, N03.8, N03.9, N05.0, N05.1, N05.2, N05.3, N05.4, N05.5, N05.6, N05.7, N05.8, N05.9, N19, N26.9
Hypertensive CKD	403, 403.01, 403.1, 403.11, 403.9, 403.91, 404, 404.01, 404.02, 404.03, 404.1, 404.11, 404.12, 404.13, 404.9, 404.91, 404.92, 404.93	I12.0, I12.9, I13.0, I13.10, I13.11, I13.2
Diabetes with renal manifestation	250.4, 250.41, 250.42, 250.43	E10.2, E11.2, E11.21, E11.22, E11.29
Disorders from impaired renal function	588, 588.1, 588.81, 588.89, 588.9	N25.0, N25.1, N25.81, N25.89, N25.9, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322, M10.329, M10.331, M10.332, M10.339, M10.341, M10.342, M10.349, M10.351, M10.352, M10.359,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Description	ICD-9*	ICD-10†
Acute renal failure	572.4, 580, 580.4, 580.81, 580.89, 580.9, 584.5, 584.6, 584.7, 584.8, 584.9, 791.2, 791.3	M10.361, M10.362, M10.369, M10.371, M10.372, M10.379, M10.38, M10.39 K76.7, N00.3, N00.8, N00.9, N01.3, N17.0, N17.1, N17.2, N17.8, N17.9, R82.1, R82.3
Miscellaneous	274.1, 440.1, 442.1, 453.3, 581, 581.1, 581.2, 581.3, 581.81, 581.89, 581.9, 586, 587, 593, 593.1, 593.2, 593.3, 593.4, 593.5, 593.6, 593.7, 593.71, 593.72, 593.73, 593.81, 593.82, 593.89, 593.9, 753, 753.3, 866, 866.01, 866.1, 866.11, 866.12, 866.13	I70.1, I72.2, I82.3, N02.2, N04.0, N04.1, N04.2, N04.3, N04.4, N04.5, N04.6, N04.7, N04.8, N04.9, N08, N13.4, N13.5, N13.70, N13.71, N13.721, N13.722, N13.729, N13.731, N13.732, N13.739, N13.8, N28.1, N28.81, N28.82, N28.83, N28.89, N28.9, Q60.2, Q60.5, Q63.0, Q63.1, Q63.2, Q63.3, Q63.8, Q63.9, R80.2, S31.001, S37.009, S37.019, S37.029, S37.039, S37.049, S37.059, S37.069

*ICD-9 codes were used to identify CKD in Italy and in the US LCED and TriNetX databases.
†ICD-10 codes were used to identify CKD in France, Germany, Japan and the US LCED and TriNetX databases.
‡The ICD-9 code 585 (CKD, unspecified) was included in the code list for Italy owing to the large proportion of non-specific CKD reporting in this database.
§The ICD-10 codes N18 and N18.0 (CKD, unspecified) were included in the code list for France owing to the large proportion of non-specific CKD reporting in this database.
CKD, chronic kidney disease; LCED, Explorays Linked Claims and Electronic Medical Records Data; ICD, International Classification of Diseases.

Supplementary table 5. Sensitivity analysis of undiagnosed stage 3 CKD using a broader CKD definition adapted from Winkelmayr et al., 2005² according to country and database

Country	France	Germany	Italy	Japan	USA	
Database	THIN Cegedim n=20 012	Disease Analyzer n=26 767	LPD n=65 676	Japan RWD n=90 902	LCED n=22 470	TriNetX n=250 879
CKD status*, n (%)						
Diagnosed	2031 (10.1)	6165 (23.0)	21 146 (32.2)	12 113 (13.3)	10 421 (46.4)	109 735 (43.7)
Undiagnosed	17 981 (89.9)	20 602 (77.0)	44 530 (67.8)	78 789 (86.7)	12 049 (53.6)	141 144 (56.3)

*Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort for each country/database.

CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data; LPD, Longitudinal Patient Database; RWD, Real World Data; THIN, The Health Improvement Network.

Supplementary table 6. Sensitivity analysis of undiagnosed CKD in patients in the TriNetX database with one eGFR measurement indicative of stage 3 CKD

Country	USA
Database	TriNetX n=532 921
CKD status*, n (%)	
Diagnosed	94 780 (17.8)
Undiagnosed	438 141 (82.2)
Age, y, median (IQR)	67 (59–75)
Age groups, y	
<45	28 888 (5.4)
45–64	187 109 (35.1)
65–74	174 126 (32.7)
≥75	142 798 (26.8)
Male, n (%)	232 069 (43.5)
eGFR, mL/min/1.73 m², median (IQR)	54 (48–58)
CKD stage, n (%)	
CKD stage 3a	439 183 (82.4)
CKD stage 3b	93 738 (17.6)
Baseline UACR available, n (%)	5495 (1.0)
HDL, mmol/L, median (IQR)	1.24 (1.01–1.53)
Missing, n	349 531
LDL, mmol/L, median (IQR)	2.51 (1.91–3.21)
Missing, n	322 358
Comorbidities, n (%)	
Hypertension	371 933 (69.8)
Type 2 diabetes	160 129 (30.0)
Established CVD [†]	81 883 (15.4)
Heart failure	66 522 (12.5)
Atrial fibrillation	64 232 (12.1)
Medication use, n (%)	
ACE inhibitor	100 723 (18.9)
ARB	58 812 (11.0)
SGLT2 inhibitor	3777 (0.7)
GLD (any)	100 714 (18.9)
Antiplatelets	25 371 (4.8)
Loop diuretic	64 161 (12.0)
Anticoagulants	107 616 (20.2)

Unless otherwise stated, percentages represent the proportion of patients in a specific group (eg, age) or with a specific variable (eg, medical history).

*Percentages represent the proportion of diagnosed/undiagnosed cases in the overall cohort.

[†]Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LDL, low-density lipoprotein; SGLT2, sodium-glucose cotransporter-2; UACR, urinary albumin-creatinine ratio.

Supplementary table 7. Overall patient characteristics at study index according to country, by CKD diagnosis status 6 months after index

Country	France		Germany		Italy		Japan		USA			
Database	THIN CegeDim		Disease Analyzer		LPD		Japan RWD		LCED		TriNetX	
	Undiagnosed n=19 120	Diagnosed* n=892	Undiagnosed n=22 557	Diagnosed* n=4210	Undiagnosed n=50 547	Diagnosed* n=15 129	Undiagnosed n=83 693	Diagnosed* n=7209	Undiagnosed n=13 845	Diagnosed* n=8625	Undiagnosed n=161 254	Diagnosed* n=89 625
Age, y, median (IQR)	80 (72–86)	77 (69–84)	79 (72–84)	79 (71–84)	80 (74–85)	80 (73–85)	76 (69–83)	77 (68–83)	74 (64–82)	74 (64–82)	71 (64–79)	70 (62–78)
Age groups, y												
<45	58 (0.3)	9 (1.0)	46 (0.2)	20 (0.5)	95 (0.2)	93 (0.6)	652 (0.8)	139 (1.9)	109 (0.8)	134 (1.6)	2426 (1.5)	3097 (3.5)
45–64	1551 (8.1)	126 (14.1)	1957 (8.7)	474 (11.3)	2724 (5.4)	1056 (7.0)	12 260 (14.6)	1026 (14.2)	3754 (27.1)	2237 (25.9)	38 302 (23.8)	25 424 (28.4)
65–74	4421 (23.1)	220 (24.7)	5088 (22.6)	944 (22.4)	10 976 (21.7)	3288 (21.7)	23 696 (28.3)	1931 (26.8)	3415 (24.7)	2177 (25.2)	57 891 (35.9)	29 989 (33.5)
≥75	13 090 (68.5)	537 (60.2)	15 466 (68.6)	2772 (65.8)	36 752 (72.7)	10 692 (70.7)	47 085 (56.3)	4113 (57.1)	6567 (47.4)	4077 (47.3)	62 635 (38.8)	31 115 (34.7)
Male, n (%)	8599 (45.0)	492 (55.2)	9173 (40.7)	2043 (48.5)	19 820 (39.2)	7908 (52.3)	43 658 (52.2)	4465 (61.9)	5438 (39.3)	4613 (53.5)	57 989 (36.0)	47 123 (52.6)
eGFR, mL/min/1.73 m², median (IQR)	52 (46–56)	45 (38–52)	52 (45–56)	49 (40–55)	51 (44–55)	45 (38–52)	53 (47–56)	45 (37–53)	53 (47–57)	47 (40–53)	53 (47–57)	47 (40–53)
CKD stage, n (%)												
CKD stage 3a	14 661 (76.7)	440 (49.3)	16 871 (74.8)	2621 (62.3)	36 460 (72.1)	7477 (49.4)	66 955 (80.0)	3713 (51.5)	11 348 (82.0)	4972 (57.6)	131 385 (81.5)	52 233 (58.3)
CKD stage 3b	4459 (23.3)	452 (50.7)	5686 (25.2)	1589 (37.7)	14 087 (27.9)	7652 (50.6)	16 738 (20.0)	3496 (48.5)	2497 (18.0)	3653 (42.4)	29 869 (18.5)	37 392 (41.7)
Baseline UACR available, n (%)	424 (2.2)	26 (2.9)	0 (0.0) [†]	0 (0.0) [†]	4 (<0.1) [‡]	5 (<0.1) [‡]	3851 (4.6)	1141 (15.8)	474 (3.4)	425 (4.9)	2455 (1.5)	2149 (2.4)
HDL, mmol/L, median (IQR)	1.37 (1.11–1.65)	1.32 (1.08–1.65)	1.34 (1.11–1.63)	1.29 (1.06–1.55)	1.32 (1.11–1.59)	1.27 (1.06–1.53)	1.40 (1.16–1.71)	1.32 (1.09–1.60)	1.24 (1.03–1.53)	1.16 (0.96–1.45)	1.24 (1.03–1.55)	1.14 (0.93–1.42)
Missing, n	6172	342	6904	1328	13 379	4134	33 243	2062	5673	4349	88 031	50 767
LDL, mmol/L, median (IQR)	2.89 (2.24–3.61)	2.81 (2.18–3.53)	2.87 (2.20–3.70)	2.70 (2.07–3.49)	2.74 (2.12–3.39)	2.53 (1.97–3.21)	2.77 (2.22–3.34)	2.53 (2.04–3.10)	2.46 (1.89–3.13)	2.25 (1.71–2.95)	2.43 (1.87–3.13)	2.22 (1.68–2.92)
Missing, n	6331	345	6026	1061	14 915	4560	31 643	1946	4988	3948	78 408	47 066
Comorbidities, n (%)												
Hypertension	11 737 (61.4)	675 (75.7)	10 969 (48.6)	2710 (64.4)	38 849 (76.9)	12 475 (82.5)	47 311 (56.5)	5711 (79.2)	11 863 (85.7)	8198 (95.0)	123 002 (76.3)	80 153 (89.4)
Type 2 diabetes	3311 (17.3)	221 (24.8)	5145 (22.8)	1790 (42.5)	15 785 (31.2) [§]	5515 (36.5) [§]	15 655 (18.7)	3334 (46.2)	4667 (33.7)	4621 (53.6)	49 299 (30.6)	46 142 (51.5)
Established CVD [¶]	1368 (7.2)	81 (9.1)	1467 (6.5)	437 (10.4)	5153 (10.2)	1784 (11.8)	23 248 (27.8)	2389 (33.1)	3337 (24.1)	2955 (34.3)	26 666 (16.5)	23 078 (25.7)
Heart failure	922 (4.8)	64 (7.2)	3318 (14.7)	1046 (24.8)	4248 (8.4)	2130 (14.1)	26 077 (31.2)	3986 (55.3)	2523 (18.2)	2791 (32.4)	22 422 (13.9)	24 580 (27.4)
Atrial fibrillation	2057 (10.8)	104 (11.7)	3351 (14.9)	866 (20.6)	8293 (16.4)	2812 (18.6)	10 765 (12.9)	1226 (17.0)	2409 (17.4)	2218 (25.7)	23 224 (14.4)	17 990 (20.1)
Medication use, n (%)												
ACE inhibitor	4363 (22.8)	271 (30.4)	8023 (35.6)	1612 (38.3)	19 141 (37.9)	5957 (39.4)	4027 (4.8)	474 (6.6)	5058 (36.5)	3725 (43.2)	33 532 (20.8)	24 274 (27.1)
ARB	6181 (32.3)	349 (39.1)	8855 (39.3)	1718 (40.8)	19 770 (39.1)	6428 (42.5)	18 959 (22.7)	2463 (34.2)	3605 (26.0)	2697 (31.3)	22 656 (14.0)	15 290 (17.1)
SGLT2 inhibitor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	287 (0.6)	66 (0.4)	1082 (1.3)	281 (3.9)	11 (0.1)	11 (0.1)	1171 (0.7)	978 (1.1)
GLD (any)	3300 (17.3)	189 (21.2)	6742 (29.9)	1577 (37.5)	13 108 (25.9)	4255 (28.1)	11 303 (13.5)	2128 (29.5)	5012 (36.2)	4388 (50.9)	29 690 (18.4)	30 569 (34.1)
Antiplatelets	5636 (29.5)	328 (36.8)	5451 (24.2)	1146 (27.2)	23 245 (46.0)	7906 (52.3)	16 690 (19.9)	2106 (29.2)	1274 (9.2)	1202 (13.9)	8256 (5.1)	8052 (9.0)
Loop diuretic	2747 (14.4)	177 (19.8)	8564 (38.0)	1944 (46.2)	15 719 (31.1)	6441 (42.6)	10 346 (12.4)	1633 (22.7)	2720 (19.6)	2843 (33.0)	21 136 (13.1)	22 334 (24.9)
Anticoagulants	2885 (15.1)	133 (14.9)	6838 (30.3)	1344 (31.9)	12 214 (24.2)	3983 (26.3)	12 886 (15.4)	1600 (22.2)	3434 (24.8)	2913 (33.8)	28 521 (17.7)	26 465 (29.5)

Percentages represent the proportion of diagnosed/undiagnosed patients in a specific group (eg, age) or with a specific variable (eg, medical history).

*Diagnosed cases include patients with a corresponding ICD-9/10 diagnosis code for CKD at or within 6 months of study index (date of second qualifying eGFR measurement).

[†]UACR testing data not available in the German Disease Analyzer database.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

‡Direct measurements of UACR were not available in the IQVIA Longitudinal Patient Database in Italy, however, UACR was calculated as urine albumin (mg/dL) divided by urine creatinine (g/dL) if patients had records for both of these variables on the same day.

§Owing to a lack of granularity for ICD-9 diagnostic codes in the database used, type of diabetes could not be determined in patients from Italy.

¶Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischaemic attack, coronary artery bypass graft and percutaneous coronary intervention.

*Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.


ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLD, glucose-lowering drug; HDL, high-density lipoprotein; ICD, International Classification of Diseases; IQR, interquartile range; LCED, Explorys Linked Claims and Electronic Medical Records Data; LDL, low-density lipoprotein; LPD, Longitudinal Patient Database; RWD, Real World Data; SGLT2, sodium-glucose cotransporter-2; THIN, The Health Improvement Network; UACR, urinary albumin-creatinine ratio

Supplementary table 8. Comparison of CKD stages in Black and non-Black patients from the US TriNetX database when calculating eGFR using two different equations: CKD-EPI (without adjusting for race) and CKD-EPI (with race modifier)¹

	CKD-EPI, no race modifier	CKD-EPI, with race modifier
Black (n=50 283)		
Stage 2 CKD, n (%)	0 (0.0)	23 156 (46.1)
Stage 3a CKD, n (%)	36 005 (71.6)	20 455 (40.7)
Stage 3b CKD, n (%)	14 278 (28.4)	6672 (13.3)
Non-Black (n=200 596)		
Stage 2 CKD, n (%)	0 (0.0)	0 (0.0)
Stage 3a CKD, n (%)	147 613 (73.6)	147 613 (73.6)
Stage 3b CKD, n (%)	52 983 (26.4)	52 983 (26.4)


CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

Supplementary figure 1. Prevalence of undiagnosed stage 3 CKD according to calendar year of study index according to country and database




CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 2. Prevalence of undiagnosed stage 3 CKD according to age group at study index according to country and database



CKD, chronic kidney disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 3. Factors associated with a lack of CKD diagnosis any time before or up to 6 months after index date according to country and database



Whiskers represent 95% confidence intervals.

*Odds ratios adjusted for covariates at index: sex, age, CKD stage, family history of CKD (not available in France, Germany and Japan), number of clinical visits in year before index, medical history (heart failure, established CVD, diabetes [any type], hypertension, other kidney disease) and medication use (diuretics, β -blockers, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, lipid-lowering drugs, antithrombotic drugs, metformin, glucagon-like peptide receptor-1 inhibitors or sodium-glucose cotransporter-2 inhibitors, and other glucose-lowering drugs).


†Upper 95% confidence interval extends beyond the boundary of the graph.

‡Established CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

§Owing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; LCED, Explorys Linked Claims and Electronic Medical Records Data.

Supplementary figure 4. Factors associated with time to CKD diagnosis in patients undiagnosed at index according to country and database



Whiskers represent 95% confidence intervals.

^aHazard ratios adjusted for covariates at index: sex, age, CKD stage, family history of CKD (not available in France, Germany and Japan), number of clinical visits in year before index, medical history (heart failure, established CVD, diabetes [any type], hypertension, other kidney disease) and medication use (diuretics, β-blockers, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, lipid-lowering drugs, antithrombotic drugs, metformin, glucagon-like peptide receptor-1 inhibitors or sodium-glucose cotransporter-2 inhibitors and other glucose-lowering drugs).

^bEstablished CVD includes patients with a history of myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary artery bypass graft and percutaneous coronary intervention.

^cOwing to a lack of granularity for ICD-9 codes in the database used, established CVD does not include coronary artery bypass graft and percutaneous coronary intervention in patients from Italy.

CKD, chronic kidney disease; CVD, cardiovascular disease; HR, hazard ratio; LCED, Explorys Linked Claims and Electronic Medical Records Data.

References

1. Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
2. Winkelmayr WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis.* 2005;46(2):225–32. doi: 10.1053/j.ajkd.2005.04.029

For peer review only

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	a) Title, page 1, and abstract, page 3 [Design section] b) Abstract, page 3	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	1.1) Abstract, page 3 (Setting section) 1.2) Abstract, page 3 (Setting and Participants sections) 1.3) N/A
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, page 5		
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, page 5		
Methods					
Study Design	4	Present key elements of study design early in the paper	Materials and Methods, page 6 (Study Design)		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Materials and Methods, page 6 (Study Design)		

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	Participants	6	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	A) Eligibility criteria, follow-up duration and data sources described in Materials and Methods, page 6 and 7 (Study Design)	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>6.1) Materials and Methods, page 7 (Study Design) with full lists of ICD9/10 codes used to identify diagnosed/undiagnosed cases given in Supplementary Materials</p> <p>6.2) N/A (eligible patients were identified based on eGFR which was calculated from serum creatinine as described in Materials and Methods and according to internationally-recognized equations for eGFR calculations)</p> <p>6.3) N/A</p>
31 32 33 34 35 36 37	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Materials and Methods, page 7 (Study Design section)	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	7.1) Full list of ICD9/10 codes used in Supplementary Tables 2 and 3
38 39 40 41 42	Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).	Materials and Methods, page 6 (Study Design section)		

		Describe comparability of assessment methods if there is more than one group			
Bias	9	Describe any efforts to address potential sources of bias	Materials and Methods, page 7 (Study Design section); potential bias addressed in Discussion, pages 16 and 17		
Study size	10	Explain how the study size was arrived at	N/A (all eligible patients within specified time frame were included)		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	N/A (quantitative variables collected from existing EMR/claims databases; CKD stage groupings based on existing KDIGO guidelines referenced in the manuscript)		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how	Materials and Methods, pages 7 and 8 (Study Design and Statistical Analysis sections)		

		<p>matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>			
Data access and cleaning methods	..			<p>RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.</p> <p>RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.</p>	<p>12.1) Author Contributions section, page 19</p> <p>12.2) N/A</p>
Linkage	..			<p>RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.</p>	12.3) N/A
Results					
Participants	13	<p>(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)</p> <p>(b) Give reasons for non-participation at each stage.</p> <p>(c) Consider use of a flow diagram</p>	<p>a) Results, page 8</p> <p>b) N/A</p> <p>c) Figure 1 (cohort selection)</p>	<p>RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i>, study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.</p>	<p>13.1) Figure 1 (cohort selection); Results, page 8</p>
Descriptive data	14	<p>(a) Give characteristics of study participants (<i>e.g.</i>, demographic,</p>	<p>a) Results, pages 9 and 12</p>		

		clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (e.g., average and total amount)	(Demographics and Clinical Characteristics of Patients with Diagnosed and Undiagnosed CKD section); Table 1 b) Table 1 c) Results, page 12 (Time to CKD Diagnosis section)		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures	Results, pages 8 and 9		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	a) Results, page 13; confounders for multivariate analyses given in footnotes of supplementary Figure 3 and 4 b) N/A c) N/A		
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and	Results, pages 12 and 13		

		interactions, and sensitivity analyses			
Discussion					
Key results	18	Summarise key results with reference to study objectives	Discussion, page 14		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion, pages 16 and 17 (Strengths and Limitations)	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion, page 17 (Strengths and Limitations)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, page 18 (Conclusions)		
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion, page 17 (Strengths and Limitations)		
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding, page 20		
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Data Availability Statement, page 19; Supplementary Appendix

1 *Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working
2 Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015;
3 in press.

4 *Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only